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Abstract 
GPCR are integral membrane receptor proteins that are characterized by heptahelical 
transmembrane (7TM) domains connected by intracellular and extracellular loops, an extracellular 
N-terminus, and an intracellular C-terminus. GPCRs recognize neurotransmitters, sensory molecules 
and chemotactic agents and are involved in the control of many aspects of metabolism. Thus, 
GPCRs play important roles in diverse processes such as pain perception, growth and blood 
pressure regulation etc.  Due to their physiological importance, GPCRs are considered a highly 
convenient class of proteins for drug discovery, with more than 50% of all drugs regulating GPCR 
function, and some 30% of these drugs directly target GPCRs. A significant percent of global 
pharmaceutical sales are realized from drugs targeted against only 40-50 well-characterized GPCRs 
out of > 1,000 genes encoded in the human genome. Thusly, it is very likely that many more GPCRs 
remain to be validated as drug targets.  
A number of GPCR crystal structures determined in recent years have provided 
researchers with unprecedented opportunities in investigating how GPCRs function through the 
conformational changes regulated by their ligands. Unfortunately this number is a small fraction of 
total number of GPCRs known. Homology modeling, whereby an atomic structure of a target GPCR 
is constructed from the known crystallographic structure of another GPCR (the template) have 
been have been used instead. While the general 7TM domain is preserved, what often hampers 
homology modeling is the low sequence similarity between targets and templates. 
To that end, the first study undertaken in this thesis was aimed at describing the effect of 
template selection. Using molecular dynamic simulations (MD), the primary was aim to develop 
and model increasingly accurate three-dimensional structures of a target GPCR. In order to test 
the methodology, a post factum comparison between the models with the available 
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crystallographic structure of the target GPCR. For this purpose several atomistic models of rat M3 
muscarinic receptor were constructed by using MOE software from human M2 muscarinic 
receptor, human histamine 1 receptor and bovine rhodopsin receptor as templates. All of 
homology models resulted were refined with ligand (Tiotropium) docked inside using GLIDE 
software. In order to determine the effect of ligand in the simulation system, an extra model of 
M2 receptor was refined with NMS bound inside and an extra model refined without ligand. The 
five models system were embedded in a lipid bilayer prior to refinement process using GROMACS. 
The resulting models were compared with the crystallographic structure of rat M3 muscarinic 
receptor. Results show the sampling time 500ns is adequate simulation time and molecular 
dynamics simulation of the protein embedded in a lipid bilayer as a refinement process improves 
on the homology models. Specifically, the refinement process can correct the length of the TM 
segment of the target receptor, the accuracy of the model greatly depends on the proximity of the 
template and the target in the phylogenetic tree and finally, although the presence of a ligand 
produces a faster equilibration of the system. 
With the methodology firmly established, the thesis studies involved an in-depth study of 
bradykinin receptors B1 and B2 (B1R and B2R respectively) was performed in order to get insight 
into the stereochemical requirements for binding of their antagonists. Specifically, the goal of the 
thesis chapters (chapter 4 for B1R and chapter 5 for B2R) was to carry out a structure-activity 
study of bradykinin antagonism, taking into account the stereochemical features of diverse non-
peptide antagonists and the way these features translate into ligand anchoring points to 
complementary regions of the receptor, through the analysis of the respective ligand-receptor 
complex. Both receptors are drug targets for several pathophysiological conditions and their 
antagonists are thoughts to be analgesic, anti-inflammatory agents, etc. Since there are no 
crystallographic structures for B1R and B2R, atomistic models of each receptor was constructed 
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and refined using MD. 
 For B1R was constructed by homology modelling using the chemokine CXC4 and bovine 
rhodopsin receptors as template. The model was further refined using molecular dynamics with 
the protein embedded in a POPC bilayer. Simulations were run for 600 ns. From the simulations an 
average structure was obtained and energy minimized then later used for docking studies using 
Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, 
Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study show the 
role of specific receptor residues in ligand binding. These results permitted the definition of a 
pharmacophore that describes the stereochemical requirements of antagonist binding, and were 
used in the development of new compounds with varied activity B1R inhibition profile depending 
on the number of pharmacophoric points fulfilled by the designed antagonistic molecules. 
For B2R, a homology model was constructed using the chemokine CXC4 as template and 
subsequently refined embedded in a lipid bilayer by means of a 600 ns molecular dynamics 
trajectory. The average structure from the last hundred nanoseconds of the molecular dynamics 
trajectory was energy minimized and used as model of the receptor for docking studies. For this 
purpose, a set of compounds with antagonistic profile, covering maximal diversity were selected 
from the literature. Specifically, the set of compounds include Fasitibant, FR173657, Anatibant, 
WIN64338, Bradyzide, CHEMBL442294, and JSM10292. Molecules were docked into the B2R 
model and the corresponding complexes analyzed to understand ligand-receptor interactions. The 
outcome of this study is summarized in a 3D pharmacophore that explains the observed structure-
activity results and provides insight into the design of novel molecules with antagonistic profile. 
 To prove the validity of the pharmacophoric hypothesis, a virtual screening process was 
also carried out. The proposed B1R and B2R pharmacophores were used as queries to identify new 
hits using diverse data bases of molecules. The results of these studies revealed a set of new hits 
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with structures not connected to the molecules used for pharmacophores development. A few of 
these structures were purchased and tested. The results of the binding studies show about a 33% 
success rate with a correlation between the number of pharmacophore points fulfilled and their 
antagonistic potency. Some of these structures are disclosed in this thesis. Moreover, the B1R and 
B2R pharmacophores developed were compared and the observed differences permitted to 
explain the stereochemical requirements for receptor-selective ligands. 
The final study explores protein-protein interactions. Protein-protein interactions are 
important due to the fact that many proteins do not act in isolation, and often an examination of 
the interaction proteins can reveal a lot about their biological function together. Therefore, GPCR 
oligomers are also known to be targets of drug discovery. Two class A GPCRs, the serotonin 
receptor 5-Hydroxytryptamine 1A receptor (5-HT1A) and Galanin receptor 1 (GALR1) have been 
described to heterodimerize triggering an atypical physiological state that would lead to 
depression. Furthermore, zinc supplementation has been widely reported to improve treatment 
against major depressive disorder. Hence the main objective of this thesis study was to establish a 
rational explanation for the role of zinc in the molecular processes associated with protein-protein 
interactions and its relationship with depression. By means of homology modeling, the atomic 
models of the receptors were constructed using as templates the crystallographic structures of 5-
HT1B for 5-HT1A and κ–opioid receptor, and refined using molecular dynamics simulation. Using 
MOE GRID program the 5-HT1A was probed for Zinc and the zinc binding sites were annotated. 
Afterwards, to create the heterodimer of the two receptors, a protein-protein molecular docking 
was performed using GRAMM software.  
The results showed three possible dimer interfaces: the first at TM4 and TM5, the second 
at TM6 and TM7, and the last at TM1 and TM2. Analysis of the 12 zinc binding sites and the 
heterodimer interfaces suggests that there is a coincidence between zinc binding sites and 
 ix 
Discovery of new selective antagonists of G-Protein coupled receptors of therapeutic interest 
heterodimerization interfaces. The results also establish a rational explanation for the role of zinc 
in the molecular processes associated with heterodimer interactions and its relationship with 
depression, in agreement with previously reported evidence for the positive effects of zinc in 
depression treatment, and the involvement of the dimer in the same disease. 
 x 
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Preface 
I have always been interested in diseases; what causes them, how to characterize them and 
the therapeutic intervention in treating them. From early age my academic journey has been in 
service to these interest. With my bachelor studies I was able to gain knowledge on the etiology of 
many types of diseases. Later in my post-graduation employment I worked in genetic 
characterization. Learning the role of protein and protein mutations in the development of diseases. 
Finally in my master’s education I was introduced to computer aided drug design, a rational 
methodology in designing better and selective (where appropriate) drugs.  While the subject of my 
master’s thesis involved a smaller class of protein with big therapeutic impact, it is only “rational” 
that my doctorate thesis subject is the largest class of protein and with even bigger therapeutic 
impact.  
Indeed, the membrane GPCR family contains the largest number of drug targets in the 
human body, with more than a quarter of the clinically used drugs targeting them. They account for 
the majority of best-selling drugs and about 40% of all prescription pharmaceuticals on the market 
and that is from a mere 40-50 well characterized GPCRs which is a fraction of the over 1000 genes 
encoding for GPCRs. Their importance is also highlighted by the award of the 2012 Nobel Prize in 
chemistry to Robert Lefkowitz and Brian Kobilka for “characterizing these getaways to the cells”. To 
date there have been at least seven other Nobel Prizes awarded for different aspects of GPCRs 
mediated signaling. 
As it is with most GPCR, the common setback one experience in researching them is the lack 
of the crystallographic structure of a GPCR of interest. You see, there are only 25 GPCRs 
crystallographic structures available, with 21 of them belonging to the class A. To put into clear 
context, there are over 700 class A GPCR and only less than 3% of class A have been crystallized. Due 
to this, scientists have been using homology modeling to study GPCR. While the general structural 
characteristics such as the heptahelical transmembrane domain is preserved, low sequence 
similarity between the target GPCR and template GPCR often hinders the homology modeling 
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process. Thus scientists have put considerable efforts on ways to improve accuracy of GPCR 
homology models. 
This thesis is aimed at contributing on those efforts. Furthermore, to use the methodology 
or procedure develop to construct atomistic models of GPCR that can be used in drug discovery 
process. Specifically for the non-opiate pain mediating receptors bradykinin B1 and B2. Moreover, 
since GPCRs also signals as oligomers, a procedure is described herein, to models oligomers and 
study their interfaces either to designs ligands or to get insight into their interfaces as it was used in 
this thesis. This thesis consists of six main chapters. Chapter 1 provides a general introduction to 
GPCR, their structures, signaling etc. Chapter 2 also provides general introduction, but here is to the 
theoretical methodologies used in drug discovery process and molecular dynamic simulation. 
Chapters 3-6 is deals with the objectives of the thesis. 
Specifically, the objectives of this study are 
1. To improve on the methodology for obtaining more accurate 3D homology models 
of the GPCR by molecular dynamic simulation (Chapter 3) 
2. To construct an accurate homology model of bradykinin receptor B1 and use it to 
study the structure-activity-relationship (SAR) of the receptor and the available non-
peptidic antagonists of the receptor for the purpose of identifying the 
stereochemical requirements of the antagonist binding; the pharmacophore 
(Chapter 4). 
3. To construct an accurate homology model of bradykinin receptor B2 and use it to 
study the SAR of the receptor and the available non-peptidic antagonists of the 
receptor for the purpose of identifying the pharmacophore for antagonist binding 
(Chapter 5). 
4. Using the pharmacophores developed to explain on the features required for the 
design of antagonists capable of discriminating between the B1 and B2 bradykinin 
receptors (Chapter 5) 
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5.  To construct the heterodimer of GALR1 and 5HT1A in order to study their dimeric 
nature and explain their proposed link to major depression disorder. 
 
What I do hope for the results of this thesis is to add to the continuing advances in our 
knowledge of the characteristics of the GPCRs. Specifically, I do hope the procedures developed 
here can be applied to the study of other GPCRs and further development of new and selective 
receptor antagonists. GPCR research is not an easy task, and the impact of such research especially 
in the rational design of drugs effective in the therapeutic manipulation GPCR mediated-diseases 
will continue to grow. Hence, approaches and tools offered by computer aided drug design can be 
used to reduce the complexity of this task and, combined with computational modeling, can serve 
to yield testable predictions for the structural properties of GPCR-ligand complexes and GPCR 
oligomers. 
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Introduction 
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1.1 Membrane proteins and the G protein-coupled receptors 
One of the main constituents of cell membranes are bilayers made of lipids that surround the cells 
and the cell organelles. Lipid bilayers are not smooth because they contain a variety of proteins 
attached to the surface and embedded in the membrane. These membrane proteins are among the 
most important proteins from the biological point of view since they allow the cells to communicate 
with their environment, determine whether the immune system recognizes the cell as foreign or not, 
control cell adhesion to form tissues, dictate development of plants and animals, and they control 
important metabolic processes, including salt balance, energy production and transmission, and 
photosynthesis [1-3]. 
Membrane proteins are interesting because of their key roles in controlling the processes of 
life and can be used as targets of drugs. When a membrane protein binds to a chemical such as drug 
outside of the cell and the binding process causes a chemical response on the inside of a cell it is called 
a receptor.  Most of these receptors exhibit a basal activity in the absence of stimuli, suggesting that 
part of the receptors on the cell surface are activated. Accordingly, ligands binding on these receptors 
can act as agonists, antagonists or inverse agonists. An analysis of the human genome indicates that 
there are about a thousand receptors in the human genome. Thus, these receptors are important and 
perform critical biological functions [1-2].  
There are two types of membrane proteins namely, the peripheral proteins 
and integral proteins. Peripheral proteins have weaker and temporary connections to the membrane. 
Some just sit on the surface, anchored with a few ionic bonds while others might have small sections 
that dip into the hydrophobic section of the bilayer. The integral proteins are permanently connected 
to the cell membrane. They are hard workers and have large sections embedded in 
the hydrophobic middle layer of the membrane [1].  
G-protein-coupled receptors are integral proteins that cross the membrane and can act as 
pathways for ions and molecule. GPCR constitute one of the largest families of integral proteins in 
eukaryotic organisms and are responsible for the primary mechanism for signal transduction from the 
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cell external environment to its cytoplasm. These receptors are activated by a plethora of different 
stimuli, including different kind of ligands, like protein hormones, lipids, peptides, biogenic amines, 
nucleotides or ions and other exogenous stimuli like light, odor or taste. The activation of the G-
protein results in inhibition or stimulation of the production of second messengers that eventually 
elicit the linked cellular response. Abnormalities of signaling by GPCRs are at the root of disorders that 
affect most tissues and organs in our body, such as color blindness, pain, different types of cancers, 
obesity, schizophrenia, depression hyper functioning thyroid adenoma, precocious puberty and 
diabetes [4-7]. The G-protein coupled receptors are also responsible for the control of enzyme activity, 
ion channels and vesicle transport. Specific ligand binding triggers a conformational change in the 
receptor that leads to its active state, allowing binding and activation of heterotrimeric G-protein [8-
9].  
Targeting GPCRs for therapeutic intervention has been fruitful, with ˃50% of drugs on the 
market acting as either surrogate activators or inhibitors of the GPCRs that have defined native 
ligands. However, the majority of GPCRs identified (˃ 75%) are orphan receptors, which presents a 
challenge for identifying their native ligands and defining their function [10]. Approximately 9% of 
global pharmaceutical sales are realized from drugs targeted against only 40-50 well-characterized 
GPCRs [11-12]. Taking the fact GPCRs are encoded by > 1,000 genes in the human genome [13], it is 
very likely that there are many more GPCRs that remains to be validated as drug targets. Furthermore, 
endogenous ligands have been identified for only 200 GPCRs even though the human genome 
contains many more GPCR genes. Therefore, there are enormous opportunities for further drug 
discovery in the field of GPCRs [10].  
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1.2 GPCR topology  
A generalized GPCR topology is characterized by seven membrane-spanning alpha helices (7-
Transmembrane receptors, 7TM), the receptor amino-terminus (N-terminus) in the extracellular side 
and consequently with the receptor carboxyl-terminus (C-terminus) in the intracellular side of the cell 
(Figure 1.1). Typically the 7TM are connected by loops on the intracellular and extracellular side of the 
cell. The loops are termed according to their occurrence, extracellular loop (ECL1 - ECL3) and 
intracellular loop (ICL1 - ICL3) [14-15].  
 
 
Figure 1.1: The GPCR nestled in a membrane bilayer, showing the transmembrane regions, intracellular side and the 
extracellular side. Modified from [16].  
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The 7TMs topology also includes additional similar conserved residues or motifs. Some of these 
conserved residues includes the conserved asparagine in TM1, aspartic, arginine and tyrosine (DRY 
motif) in TM3 which is shown in Figure 1.2 as ERY (as it is in rhodopsin receptor), conserved P in TM 4 
and 5, CWXP in TM6 and the NPXXY motif in TM7 [14-15]. 
 
 
Figure 1.2. A generalized two-dimensional representation of the sequences of the GPCR. Showing Sites of glycosylation (Y) 
exist on ectodomains, while sites of phosphorylation are present intracellularly (grey ‘P’ circles). There are two disulfide bonds 
(connecting the cysteines) within the N-terminal tail and linking the top of TM3 with ECL2. In the C-terminal which undergoes 
reversible phosphorylation, there is also a site of palmitoylation within (two cysteines anchored) [17].   
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1.3 Classification of the GPCRs  
Despite having a common 7TM motif and the few conserved residues, GPCRs have low overall 
sequence homology.  In fact, GPCRs show a great conservation in their three-dimensional structure 
but exhibit high functional and sequence diversity. This makes it difficult to develop a comprehensive 
classification system based on sequence. Previous methods for GPCR classification have included 
motif-based prediction [18-19], support vector machines [20], as well as machine learning techniques 
such as Hidden Markov Models [21].  Currently, the most commonly used system for the functional 
classification of GPCRs (as used by the PSI GPCR network)  is the data driven, top-down hierarchical 
classification GRAFS system which groups the GPCRs into five classes (Figure 1.3),  Glutamate, 
Rhodopsin, Adhesion, the Frizzled receptors and Secretin class [22-24]. 
 
Figure 1.3: A Phylogenetic tree of the GPCRs showing their classification according to GRAFS system. 
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1.3.1 Rhodopsin-like 
The group also known as class A or family I, comprises of about 84% of all GPCRs superfamily. 
It is the largest subgroup of GPCRs and some of the receptor class members includes receptors for 
odorants, neurotransmitters (dopamine, serotonin, endocannabinoids etc.) as well as neuropeptides, 
glycoprotein hormones and chemokines. Rhodopsin-like receptors are characterized by several highly 
conserved amino acids and a disulphide bridge that connects the first and second extracellular loops. 
 Most of these receptors also have a palmitoylation site made of cysteine in the C-terminal 
tail, which serves as an anchor to the membrane. Diversity among members of this group is not found 
in their N-terminals since most receptors have only a short stretch of amino acids, but within the TM 
regions. Most Rhodopsin-like receptors are primarily activated by interactions between the ligand 
and the TM regions and extracellular loops owing to their short N-terminal stretch of amino acids [22, 
25-26].  
 
1.3.2 Secretin-like  
Also known as Class B or family II, many secretin receptors are regulated by peptide 
hormones from the glucagon hormone family and are implicated in cAMP-mediated signaling 
pathways.  Members of this class are activated by ligands including secretin, parathyroid hormone, 
glucagon, calcitonin gene related peptide, adreno-medullin, calcitonin, etc. The binding profile of the 
Secretin-like receptors can be illustrated mainly by three binding domains consisting of the proximal 
region and the juxta-membrane region of the N terminus and the extracellular loops together with 
TM6. The ligand is thought to activate the receptor by bridging the characteristic-long extracellular 
N-terminal and the TM segments or extracellular loops thereby stabilizing the active conformation of 
the receptor [26]. While the secretin receptor family GPCRs exist in many animal species, it has not 
been found in plants, fungi or prokaryotes [21, 27].  
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1.3.3 Glutamate receptors 
Also known as class C or family III, members of this GPCR group are structurally composed of 
the N-terminal signal sequence whereby the ligand binds, a large hydrophilic extracellular agonist-
binding region containing several conserved cysteine residues which could be involved in disulphide 
bonds, a shorter region containing the 7TM, and a C-terminal cytoplasmic domain of variable length. 
Members includes metabotropic glutamate receptors, the extracellular calcium-sensing receptors, 
the gamma-amino-butyric acid (GABA) type B receptors, and the vomer nasal type-2 receptors [22, 
28].  
 
1.3.4 Adhesion  
   The adhesion GPCRs also known as Class D, family IV is comprised of 33 members in humans, 
including the brain angiogenesis inhibitor 3 (ADGRB3), calcium-independent alpha-latrotoxin receptor 
1 (ADGRL1) etc. Ligand profiles and in vitro studies indicate that the primary role for adhesion GPCRs 
relates to the proper positioning of cells in a variety of organ systems (cell adhesion and migration). T 
he characteristic defining feature of adhesion GPCRs that distinguishes them from other 
GPCRs is their hybrid molecular structure. The extracellular region of adhesion GPCRs which is linked 
to the 7TM region by a stalk motif containing a GPCR proteolytic site, can be exceptionally long and 
contain a variety of structural and functional domains that are known for the ability to facilitate cell 
and matrix interactions.  Most of these receptors have long and diverse N-terminal, which is thought 
to be highly glycosylated and form a rigid structure that protrudes from the cell surface. Unlike the 
secretin class, the adhesion class of GPCRs are also found in Fungi [22, 30]. 
 
1.3.5  Frizzled/Taste2 family 
The frizzled family of receptors includes receptors critically involved in embryogenesis, and 
there is substantial evidence that members of this family also regulates tissue homeostasis in many 
different organs in the adult. Some of the members group includes the human smoothened receptor, 
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the bitter taste receptors etc. Frizzled GPCRS serves as receptors in the wnt/β-catenin signaling 
pathway whose mutations have been demonstrated to lead to a variety of diseases, 
including breast and prostate cancer, glioblastoma and type II diabetes among others.  
Sequence comparisons between the frizzled receptor and secretin receptors revealed 
resemblance in the extracellular regions and the presence of the well-conserved cysteines in the first 
and second extracellular loops. The extracellular part of the frizzled GPCRs range from 200 to 320 
amino acids in length in which the differences mostly lie in the linker region between the TM part and 
the extracellular ligand binding domain [21, 31].  
 
 
1.4 GPCR signaling   
It is well known that the signals in and out of a cell are mostly perceived at the level of the 
membrane and therefore the GPCR TMs are the likely routes for signal generation and transduction 
between cells [32-34].  First step in the GPCR mediated signaling cascade is binding of an agonist or 
ligand to GPCRs. Experimental results show that different ligands induce either G-protein dependent 
or G-protein independent signaling of GPCR via β- arrestins, which might result in functional selectivity 
[35]. Agonist binding to the GPCR promotes a conformational change in the receptor, specifically in an 
ionic interchange between TM3 and TM4. This induces coupling of the GPCR to the G-protein, initiating 
signaling to the cell interior. β-arrestins are well known negative regulators of GPCR signaling. Upon 
GPCR activation, β-arrestins translocate to the cell membrane and bind to the agonist-occupied 
receptors. This uncouples these receptors from G-proteins and promotes their internalization, thus 
causing desensitization. Furthermore, evidences have also indicated that β -arrestins also function as 
scaffold proteins that interact with several cytoplasmic proteins and link GPCRs to intracellular 
signaling pathways, such as mitogen activated protein kinase (MAPK) cascades [35-36].  
GPCR signaling induces coupling of the ligand-bound receptor to a heteromeric G-protein. These 
composed of α-, β- and γ- subunits, are also a diverse group of proteins, comprising 17 Gα, 5 Gβ and 
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12 Gγ subunits at present [37]. When a ligand activates the GPCR, it induces a conformational change 
in the receptor that allows the receptor to act as a guanine nucleotide exchange factor for the alpha 
subunit of the G protein, whereby activated receptor promotes the exchange of bound guanine 
diphosphate (GDP) for guanine triphosphate (GTP) on the Gα subunit, which is the rate-limiting step 
in G protein activation. In the traditional view of heterotrimeric protein activation, this exchange 
triggers the dissociation of the Gα subunit, bound to GTP, from the Gβγ dimer and the receptor. The 
free α- or βγ-subunits 4 then interact with second messengers; the precise nature of which is 
dependent upon the GPCR type and the G-protein subunits mobilized [38-39].  
G-proteins are classified into four major classes namely as the Gs, Gi/o, Gq/11, and G12/13 [40-
42].  Stimulation of the Gs subfamily activates adenylyl cyclase, whereas stimulation of the Gi 
subfamily leads to its inhibition. Stimulation of the Gq subfamily activates phospholipase C, and the 
G12 family is implicated in the regulation of small GTP binding proteins. It has now become apparent 
that not only the α-subunits, but also the βγ -subunits can bind to a great variety of effector molecules 
and regulate their activity [43-45]. Gβγ-subunits mediate signal transduction by interacting with many 
proteins, including GPCRs, GTPases and various effector molecules. The effector molecules that have 
been reported to be regulated by Gβγ- subunits include adenylyl cyclase, PLC, inwardly rectifying G-
protein-gated potassium channels, voltage-sensitive calcium channels, phosphoinositide 3-kinases 
(PI3 kinase) and molecules in the MAPK pathway. Recent developments indicate novel levels of 
complexity in GPCRs functioning [46].  
The initial idea of linear signaling pathways, transferring information from the cell membrane to 
the nucleus, has recently evolved into a complicated network of signaling pathways. Firstly, cross-talk 
of the GPCRs on signaling pathways is increasingly more evident [37]. Secondly, some GPCRs may be 
constitutively active, i.e. active in the absence of its ligand. Particularly, the level of constitutive activity 
may vary in such a profound way between cells and tissues that this could offer new ways of achieving 
specificity of drug action [46-47]. Thirdly, increasing number of evidence showed that many GPCRs 
can form oligomeric ensembles [46, 48]. Therefore, regulation of GPCRs at multiple levels causes 
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emergence of specificity and complexity of GPCRs targeting. 
However, this is all a classical paradigm of GPCR signaling, which is rather linear and sequential. 
Emerging evidence reveals that this is only a part of the complex signaling mediated by GPCR. In the 
classical model of GPCR signaling, stimulation of the 7TM leads to the activation of heterotrimeric G-
proteins, which dissociate into α- and βγ-subunits. These subunits activate effector molecules, which 
include second messenger generating systems, giving rise to various kinds of cellular, physiological, 
and biological responses. In contrast to the large number of GPCRs, the number of identified effectors 
is considerably smaller. 
 Because many cells express multiple types of GPCRs that signal through limited types of effectors, 
it is not surprising that cross-regulation occurs in the signaling pathways of GPCRs, thereby leading to 
diverse physiological responses. Moreover, there is growing evidence that GPCR stimulation 
modulates upstream and downstream events of other receptor-mediated signaling pathways, which 
results in complicated and sometimes unpredictable outcomes [37].  
 
1.4.1 GPCR Constitutive Activity  
Evidences have demonstrated that GPCRs may exhibit constitutive activity in the absence of 
their agonists. A two-state, active and inactive receptor state model has been proposed to account for 
constitutive activity in which GPCRs exist in equilibrium between inactive and active states [49]. An 
agonist increases the activity of its GPCR above the basal level, presumably through shifting GPCRs 
into an active state capable of interacting with downstream-signaling G proteins. Thus, agonists 
stabilize the active state and display positive intrinsic activity by increasing the activity of a receptor 
above its basal level, resulting in an increase in receptor activity. In contrast, inverse agonists stabilize 
the inactive state and exhibit negative intrinsic activity by decreasing the receptor activity below the 
basal level. That is to say an inverse agonist decreases the GPCR activity below its basal level, by 
stabilizing GPCRs in an inactive state uncoupled from G proteins. Therefore, constitutive activity of 
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GPCRs can be selectively blocked by ligands that are inverse agonists [47].  
A variety of human diseases are attributed to a constitutive activity of GPCRs that is caused 
by naturally occurring mutations [50]. Consequently, selective inverse agonists open up new 
therapeutic strategies for these types of human disorders. Since the level of constitutive activity is 
typically proportional to the number of active receptors, inverse agonism is usually most noticeable 
under conditions of high receptor expression, such as occurs in over expressed systems [47, 51].  
 
1.4.2 GPCR Oligomerization 
For long it was accepted that the mechanism of ligand binding and signal transduction by 
GPCRs were mediated by monomeric receptors. However, recent evidence reveal that GPCRs may 
exist as homodimers, or may associate with other GPCRs to form heterodimers [52-53]. This 
association may alter the function of both receptors, yielding in a distinct functional unit with novel 
properties [54-56]. Since tissue-selective expression of GPCR heterodimers and their differential 
activation offer exciting perspectives for the development of tissue- and receptor-subtype-selective 
drugs, these phenomena have promising potential in both basic and clinical research fields [48, 53]. 
Currently it is widely accepted that dimerization is fairly common in the GPCR superfamily 
members and that protein-protein interactions are essential to the organizational structure and 
function of cell signaling networks. Dimerization is thought to be important for various aspects of GPCR 
function such as formation of ligand-binding sites, signal transduction, receptor biogenesis, and down-
regulation etc. An increasing number of experimental studies have been published showing that 
various classes of GPCRs form dimers and, or even higher order homo-oligomers [58-63]. 
The number of experimental reports showing that GPCR oligomerization has pharmacological 
and functional implications is also growing [56, 64-68].   For example, It was recently reported that 
inhibition of dimerization in β2-adrenergic receptor by addition of a synthetic peptide corresponding 
to TM6 of the receptor limit agonist activation of adenylyl cyclase [69]. Studies on the δ-opioid receptor 
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dimerization provided evidence that the addition of certain agonists would inhibit or reverse receptor 
dimerization, meaning the δ-opioid receptor was likely internalized from the cell surface as a monomer 
in response to agonist challenge [59]. Thus, the study of dimerization has significance since 
abnormalities of dimer formation may alter the function of the receptors which results in serious 
disease although specifically for G protein activation and signaling, it is not resolved whether a single 
GPCR molecule is sufficient or a dimer is necessary [70-71].  
Structure wise, various TM domains have been implicated to participate in receptor 
oligomerization in different receptor systems, suggesting that the structure of oligomers formed in 
different GPCRs may not be the same. In fact two modes of association of the TM helices of GPCR 
monomers into dimers have been proposed. Contact dimerization (figure 1.4a.) which shows the 
packing of two different TM bundles with separate binding sites through interactions at interfaces that 
otherwise would face the lipid environment [62], and domain-swapped dimerization (figure 1.4 
b.),which involves interpenetration of transmembrane bundles whereby the interacting TMs from two 
different polypeptides appear as interlaced units [72-74].  
 
 
Figure 1.4: The proposed types of GPCR oligomerization, contact dimers (a) and domain-swapped dimers (b). 
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The studies on class C receptors provide valuable information that the N-terminal region may also 
participate into oligomerization as well as transmembrane domains. The N-terminal Venus flytrap (VFT) 
module is one of main characteristic for class C receptors, which is structurally and functionally 
homologous to bacterial periplasmic proteins that bind amino acids, sugars and ions [75]. It was 
reported that VFTs are important for dimerization of this receptor class. Additionally, it is known that 
cysteine-rich domains (CRDs), localized between VFT and transmembrane domains potentially has a 
role in dimerization [76-78]. 
 
 
 
1.5 GPCRs as drug targets  
 
As stated above GPCR represent a significant number of the human genome proteins. Due to 
their extensive involvement in human pathophysiological processes, development of therapeutically 
viable agents that counteract the effects these receptors is, therefore, potentially very attractive [79]. 
Much of the conceptual framework regarding how to study receptor function evolved from 
pharmacological investigation of drug action. The equations and models that describe the interaction 
of chemicals with receptors comprise what is generally known as pharmacodynamics. Although 
largely adapted from enzyme kinetics, the principles necessarily differ from those of enzyme-
substrate interactions in that they deal with chemicals that are not changed by the receptor, but 
rather interact in a reversible manner to produce a change in the state of the receptor that is then 
transmitted to the cellular host [79-80]. 
The identification of constitutive, or intrinsic, activity of GPCRs has had major impact on 
receptor theory. Constitutive activity may be considered to be an equilibrium state of a GPCR between 
its ground state of no activity and its fully activated state. The identification of agents that inhibit this 
ligand-independent receptor activity has led, in turn, to the concept of inverse agonism and neutral 
antagonism. Inverse agonists are able to bind to constitutively active receptor and produce opposite 
response to that of agonist.  A neutral antagonist itself has no effect on the activity of the receptor, 
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but it can prevent the interaction of agonists or inverse agonists with the receptor, although it does 
not affect the equilibria of different receptor conformations. Traditionally, antagonists are defined as 
agents that block receptor-mediated effects elicited by agonists by competing for receptor occupancy. 
Other antagonists of function mediate their effects by interacting with another allosteric site rather 
than in the binding pocket of the native agonist, the orthosteric site [80]. Figure 1.5 shows the position 
of orthosteric and allosteric site in a prototypical rhodopsin-like GPCR. 
 
 
Figure 1.5: The position of orthosteric (in orange) and allosteric (in green) binding site in typical rhodopsin-like GPCR. 
 
In many cases, inverse agonists were originally characterized as antagonists on non-
constitutively active GPCRs and their inverse agonism is primarily seen when they interact with 
constitutively active GPCRs.  Thusly, approximately around 85%, of all known GCPR antagonists are in 
fact inverse agonists [81]. The existence of constitutive activity has required a reconsideration of how 
we think about GPCR antagonists.  Recently, antagonist agents have been observed to have negative 
intrinsic activity, or behave as inverse agonists, and decrease the basal agonist-independent or 
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constitutive activity of the receptor. As a result a clear distinction on the concept is employed and 
neutral antagonists are defined as agents that block both agonist and inverse agonist binding but 
produce no response on the receptor. Neutral antagonists considered to be relatively rare in 
pharmacology [80, 82-84]. 
In the drug discovery research, more success have been found in the identification of non-
peptide antagonists for peptide-activated GPCRs [85]. Peptide-based ligand design encounters several 
major considerations that limit clinical applications such as rapid degradation by many specific or non-
specific peptidases under physiological conditions poor absorption and transportation because of 
their high molecular mass or the lack of specific delivery systems, especially for some peptides which 
require the passage through the blood-brain-barrier to act in the central nervous system  and 
conformational flexibility which allows a peptide to bind to more than one receptor or receptor 
subtype leading to undesirable side effects. Thus, to counteract these problems, non-peptide and 
peptide-mimetic ligands have emerged as an important option and strategy in drug design [85-87].  
 
 
1.6 Crystallographic structures of the GPCRs 
  Structures of GPCRs at high resolution are essential for a better understanding of the structure 
and function of these receptors: from receptor conformational changes upon receptor activation to 
computational structure-activity studies leading to drug discovery. Indeed, the availability of a high-
resolution crystal structure of the drug target receptor is of critical importance in the drug discovery 
process. Crystallographic structures of GPCRs at high resolution were not available until 2000, when a 
breakthrough in determining the crystal structure of bovine rhodopsin, a prototype class A GPCR was 
achieved at the resolution of 2.8 Å [88]. However, due to the difficulties associated in crystallizing the 
GPCRs such as the intrinsically unstable properties of the GPCRS, the technique used to crystallize 
rhodopsin was not successful in crystallizing the other GPCRs [89-90]. 
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To improve the stability of membrane proteins, several innovative techniques have been 
developed and applied to the crystallization of GPCRs. One of the most important innovations is to 
substitute the flexible region of the protein that hampers the crystallization with a structurally rigid 
domain to increase the stability of the GPCR [91]. Other innovations include increasing the 
thermodynamic stability of a GPCR by selected mutations and the use of the lipid cubic phase and 
new detergents to facilitate GPCR crystallization [92-93].  
Through application of the innovative techniques, the structure of the β2 adrenergic receptor  
was crystallized [94], and similar technique used to crystallize the β2 adrenergic receptor have also 
been successfully applied to the other GPCRs and have led to a flurry of GPCR structures. To date 
more than 100 structures of about 25 different GPCRs belonging to four classes have been 
determined (none of the adhesion class GPCR has yet been crystallized) [95].  
All these structures have greatly advanced our knowledge of GPCRs structure and provided 
insightful information about their function. However, there are still many structures to be solved. In 
fact, there are more than 1000 GPCR encoding genes and about equally number of GPCRs. Moreover, 
most of these have been identified as drug targets. To cope with this shortage of structures 
computational methodologies, such homology modeling can help to provide structures at the atomic 
resolution at various levels of accuracy after a refinement process. In fact the available 
crystallographic GPCRs structures have increased the repertoire of templates used for modeling 
purposes. Moreover, molecular modeling can also help to understand the dynamical behavior of 
these receptors. Indeed, a crystal structure is a static picture corresponding to the conformation in 
an energetically favorable state, whereas a GPCR is a dynamic entity that can exist in various states. 
As a result, little is known about how the conformations changes of GPCRs can be associated with the 
signaling of the GPCRs or as it is critical in drug design process, how the conformation change is 
regulated by different ligands.  Thus, and molecular dynamics simulation have been employed to 
understand the dynamical behavior of GPCRs [96-98]. These methodologies and theories governing 
them are discussed in chapter 2. 
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The goal of this thesis is to construct accurate models for GPCRs. This has been applied specifically 
to the structures of the B1 and B2 bradykinin receptors and to understand the heterodimerization of 
the serotonin-galanin heterodimer. Models of the receptors were constructed by homology 
modeling. For this purpose we developed and analyzed a refinement technique of the initial models 
constructed by homology modeling based on molecular dynamics. 
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2.0 Chapter summary 
Molecular target (receptor) characterization through computer modeling techniques and 
application of their results in the drug discovery process is an important aspect of development of 
new pharmacotherapies.  Novel modeling techniques, in particular the way to use theoretical models 
as a basis for rapidly searching large three dimensional structure activity relationship databases for 
the discovery of molecules with therapeutic values among previously available compounds, is an area 
of technological advancement that has rapidly grown in the recent years. 
The research studies carried out in this thesis will be done using computational chemistry 
methods. Computational chemistry is the development and application of data-analytical and 
theoretical methods, mathematical modeling and computational simulation techniques to the 
study of biological, chemical and behavior of systems. Traditionally, forming large models of 
systems has been via a mathematical model, which attempts to find analytical solutions to 
problems and thereby enable the prediction of the behavior of the system from a set of parameters 
and initial conditions.   
This chapter aims to explain the theoretical aspects of the methodologies used to model 
intermolecular interactions of molecular targets with ligands of interest.  There are two levels of 
modeling molecular interactions. One is based on quantum mechanics, which was not used in this 
thesis study and thus will not be described in this chapter. The other, molecular mechanics uses 
empirical forms which was the method of choice for the present study. The specific methods used in 
each of the particular topics develop in this work are described in each of the corresponding thesis 
chapters. Henceforth, merely the theoretical and methodological aspects will be discussed here and 
are valid for chapter 3-6 when nothing else is stated.   
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2.1 Introduction  
As a distinct scientific discipline, drug discovery is a 20th century endeavor that has undergone 
continuous evolution as the scientific skill bases that support the process have increased in 
sophistication. From the historical perspective, much of the process of drug discovery through the 
early 1940s was serendipitous and dependent on plant sources. The technology base was synthetic 
chemistry, often based on dyes, with qualitative testing of compounds as anti-infective agents, in 
whole animals, with microbiology and limited biochemistry to support compound evaluation. Among 
the drugs from this era were the fungal antibiotics [1-4].  
Advancements in enzymology and protein biochemistry led to the emergency of a second phase 
of drug discovery. Many of the biological pathways and processes were identified as enzymologists 
and pharmacologists discovered new enzymes, receptor ligands, and their functions. Thus, though 
serendipity was still a major factor, drugs were now directed toward distinct molecular targets.  The 
evolution of this phase was rapid, with increased institutional and commercial support of the 
biomedical sciences, growing sophistication in computational processing and the availability of the 
personal computer [3, 5]. 
 The third phase of drug discovery is represented by the popular vision of computer aided 
discovery and development of molecules that not only treat the symptoms of the disease , such as in 
the case of asthma, but also lead to finding the cure for the disease. The potential for rigorous 
targeting of therapeutic agents to molecular targets whose genetics, structure, function, and 
pathophysiology are well understood is a noble goal [3]. 
 But such a noble goal is hampered by uncertainty. For example, when a molecular target is 
selected there is still uncertainty as to whether stimulation or inhibition of that target will be effective 
in a given disease state. This makes the whole process to be hypothesis driven. Thus, to a major extent, 
the design, synthesis, and testing of new molecules selective for a given target frequently provide the 
tools by which a hypothesis can be evaluated. If the hypothesis proves to be wrong, information is 
added to the scientific literature but no drug is developed [6-7].  
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This is the working approach to drug discovery that is frequently unappreciated and unreported. 
If drug targets and the design of their ligands were as simple as the application of new technologies, 
more than a higher percentage of the effort in drug discovery would reach fruition in the identification 
of clinical candidates. As it stands, 80 percent of the effort is valuable, if ultimately nonproductive, 
hypothesis testing [7-8]. 
However there are high hopes in drug discovery research afforded by the development of a high 
degree of “rationality” (rational drug design).  Rationality in drug discovery process represents an 
intellectually rigorous approach incorporating computer-aided molecular design, limited but 
sophisticated chemical synthetic effort and highly focused biological assays [9-10]. More often, 
rational drug design suggests with the knowledge of the three-dimensional (3D) structure and 
sequence of various drug targets, to design new compounds by iteration, on a computer. Thus, the 
drug design process may become significantly less of a risk and more quantitavely resource efficient 
[8, 10]. 
 
 
2.2 Computer-Aided drug discovery  
Computer-aided or in silico drug discovery consists of the use of computational methodologies 
based on established chemical and biophysical knowledge and their application in the drug discovery 
process. The process can be carried out by comparison of the structural features of a set of diverse 
ligands or by studying the structure of the ligand (drug) - receptor (target) complex with the aim to 
postulate ligand refinements. Thus, in silico methods can be classified as ligand based or structural 
based methodologies [11-13]. 
In silico methods primarily aim to rationalize, increase the efficiency, speed and cost-effectiveness 
of the drug discovery process. Some successful applications of in silico methods in drug discovery 
include identification of hits against variety of target families (including GPCRs, protein kinases, 
proteases and nuclear hormone receptors. In silico methods also boast success in elucidation of 
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structure-activity relationships of compounds and lead optimization [14-19].  
Rapid advancement in cheaper, faster computational power and accessibility coupled with a 
continuous improvement in biophysical modeling algorithms are the primary reasons that in silico 
methods are now firmly established as complementary methods to experimental drug discovery [20]. 
In silico methods are routinely applied in the development of high-quality 3D protein models (e.g. 
homology modeling) [21-23], identify hits using molecular docking or virtual screening methods, 
optimize lead compounds, predict biological activities using compound-based modeling methods such 
as quantitative structure activity relationship, QSAR [24], predict the absorption, distribution, 
metabolism, excretion and toxicity profiles of compounds [25], and design focused chemical libraries 
for experimental screening design [26]. 
 
2.2.1 Ligand-based in silico methods 
 
The underlying principle for ligand-based in silico methods is that, molecules with similar 
chemical structure will have similar biological profiles [27-28]. These methods are chemistry aware, 
relatively easier to develop and aim to identify compounds based on a small set or even one single 
active compound. They are further classified into 2D or 3D methods. In 2D methods, molecules are 
represented as graphs where nodes correspond to atoms and edges to bonds or in a linear notation 
such as SMILES. To identify similar compounds in a 2D space graph theory methods or fingerprint 
methods are used to represent a fixed length vector of chemical substructure characteristics [29]. 3D 
methods such as pharmacophore based approaches use a 3D representation of a molecule and its 
relevant stereochemical features. This requires steric or electronic features for optimal protein-ligand 
interaction and subsequent biological activity, to develop a computational model that specifies spatial 
relationships between the pharmacophoric features. A pharmacophore can be defined as the abstract 
description of the molecular features which are necessary for molecular recognition of a ligand by a 
biological macromolecule. Complementary features from the protein may also be incorporated in the 
model building process. However in case of pharmacophore models the conformational space of 
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compounds must be determined and a biologically relevant conformation must be selected.   
Figure 2.1 illustrates how ligand-based methods are implemented. Ligand based methods are 
easier to develop and implement, but fall short in the identification of novel compounds for drug 
discovery or rationalizing bimolecular interactions. The second type of computer-aided drug design 
i.e. structure-based drug design offers several methods to complement ligand-based computational 
methods [30-32]. 
 
 
Figure 2.1: The ligand based method scheme, whereby the molecules are either are represented as graphs where nodes 
correspond to atoms and edges to bonds (3D pharmacophores) or as a fixed-length vector of chemical substructure attributes 
(2D fingerprint). The QSAR ligand based design correlates compound structural features to its biological activity by a 
mathematical model [22].  
 
 
2.2.2 Structure-based in silico methods 
 
 
In drug discovery process structure-based drug design is a computational process that relies 
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on the availability of 3D protein structures or models. Molecular docking or high throughput docking 
(the computational equivalent of high throughput screening) are some of the most important aspects 
of structure-based drug design methods. Structure based design process consists of identifying 
potential binding sites where the small molecules (ligand) may interact with the target, a virtual 
screening of chemical library, the docking process where compounds are positioned in the binding site 
and scoring compounds that estimates the likelihood of binding to the target (scoring and ranking [22, 
33-34].  
 
 
 Figure 2.2: The structure based drug discovery scheme as applied in this thesis study. 
 
 
Molecular docking aims to prioritize a reduced set of compounds that have a higher 
probability of being active in subsequent experimental analysis. This methodology has been 
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successfully applied in several drug discovery stages e.g.: development of target-specific compound 
libraries, hit identification, and lead optimization. Docking applications have been benefited by the 
continual development of docking algorithms, cheaper and faster computational resources and an 
increasing availability of high quality protein structures [35-37]. However, molecular docking and in 
turn structure-based drug design has two major problems such as 3D crystallographic structures of 
many therapeutic proteins are currently unavailable [23] and poor handling of receptor or ligand 
flexibility in docking algorithms [38]. 
A rational computational drug discovery study requires a high-quality 3D structure of the target 
receptor. So that, the availability of a high-resolution crystal structure of the target receptor is of 
critical importance. Crystallographic structures are considered as close as you can get to "reality" 
of a biochemical event. Where GPCRs are concerned the number of available crystallographic 
structures is dismal in comparison to the number of GPCR in the human to study (there are more 
than 30 GPCRs crystallized, while there are approximately 800 GPCRs). As mentioned in previous 
chapter this is mainly due to the difficulties associated with crystallizing the GPCRs [39-40].  
In the absence of crystallographic structures of GPCRs and other therapeutic proteins, 
computational methods are used to develop 3D protein models at atomic resolution. 
Computationally modeled proteins may be considered reasonable substitutes until a corresponding 
crystallographic structure is available. Protein models may provide structural and biochemical 
functional insights to researchers for various biomedical research needs. However models 
developed by automated methods have limited accuracy and applicability for drug discovery 
projects. Henceforth the development of novel and more accurate protein modeling methods is an 
important problem and an area of active research in the drug discovery domain [20, 23, and 39]. 
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2.3 Homology modeling  
The fundamental principle of homology modeling is that proteins with similar sequence will share 
similar 3D structures. Homology modeling consists of four main steps. The first two steps are the 
identification of a homologous protein preferably with a high-resolution crystallographic protein 
structure which will serve as the template and sequence alignment stage. Sequence alignment is 
primarily a bioinformatics based method in which two or more protein sequences are rearranged such 
that similar protein residues and regions (motifs) are aligned in a columnar representation. Sequence 
alignment is particularly important as it serves as the input and basis of homology model building 
process. The third stage is model construction and the final stage is model assessment. 
 While the first two steps are often essentially performed together, as the most common methods 
of identifying templates rely on the production of sequence alignments, the final process can be 
performed iteratively to improve the quality of the final model [41-44]. The degree of homology and 
quality of alignment often plays an important role in the quality of the model structure. Generally, if 
the sequence identity between template-target exceeds 50% highest quality models are generated 
and if it is less than 25% such models are speculative at best [21]. Figure 2.3 shows the 4 stages of 
homology modeling and what steps are taken in each stage. 
The model construction stage involves transferring of the 3D Cartesian coordinates of the 
template to the corresponding residues of the target sequence obtained from the sequence alignment 
stage. Then subject to restraints satisfaction a rough or crude model is constructed. Spatial restraints 
expressed as probability density functions such as used in the software MODELLER and MOE (used 
extensively to develop preliminary homology models in this thesis) were developed from extensive 
statistical analysis of protein families that quantify relationships between alpha carbons (Cα) distances 
between backbone residues and corresponding main chain dihedral angles. The probabilities are 
calculated from the range of distances and angles of a particular residue type, conformation and 
sequence similarities between proteins present in the set [45].  
 
 42 
Methodology 
 
 
Figure 2.3: A simplified illustration of the homology modeling process, adopted from [46]. 
 
Regarding the loops, Modeller builds loops by optimizing a series of probability density functions 
describing backbone geometry based on amino-acid type, and then refined with an energetic 
minimization procedure [45]. While for MOE, Loops are modeled first, in random order. For each loop, 
a contact energy function analyzes the list of candidates collected in the segment searching stage, 
taking into account all atoms already modeled and any atoms specified by the user as belonging to 
the model environment (e.g. a ligand bound to the template or structural waters). These energies are 
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then used to make a Boltzmann-weighted choice from the candidates, the coordinates of which are 
then copied to the model [47]. Generally, rough models are built to maximize the molecular 
probability density functions given the sequence alignment between the target and template proteins. 
The crude model is then iteratively optimized to a low energy state to refine the positions of all heavy 
(non-hydrogen) atoms. Energy minimization using conjugate gradient method is used to refine the 
crude models (45).  
In the final stage, models are assessed using the discrete optimized protein energy method [48]. 
They assign a probability or energy score to each possible pairwise interaction between protein amino 
acids and combine them into a single score for a given model. Typically, several models are built and 
ranked before selection for advanced refinement procedures or direct applications. The protein 
geometry of the final model should be inspected with quality evaluation tools such as the 
Ramachandran plot of the backbone dihedral angles in order to confirm that the model is sterically 
sound and consistent with typical values found in crystal structures [45, 47-48]. 
Overall each step of the modeling process can contribute to the errors in the final model. 
Depending on the degree of sequence identity and the quality of alignment their accuracy as 
compared to the crystal structure can be up to less than 2Å Cα atom root-mean-square deviation 
(rmsd). Errors of this magnitude, particularly in the binding site, can result in wrong side chain 
orientations thus misrepresenting receptor-ligand complementarity. This can potentially negate the 
applicability of the model in a drug discovery project. Thus it is important to develop and apply 
methods that incorporate receptor flexibility in the modeling process to generate accurate side-chain 
orientations to improve quality of protein models [49-50]. 
In the drug discovery process, the use homology modeling has been successfully applied in various 
stages of the process. For example, homology models have been applied among others to discover 
novel leads for MCHR-1 receptors for anti-obesity [51, in building cdc25 phosphatase for structural 
based virtual screening of leads for anti-cancer therapeutics [52], alpha-glucosidase for diabetes [53] 
and CK1-delta for Alzheimer therapeutics [54]. In 14 some other examples, homology models have 
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been developed to investigate the role of certain residues in the biological function of the protein via 
mutagenesis experiments [55-56].  
Class A-GPCRs are a special case for homology modeling as they exhibit low sequence identity 
among members of the family (~20%). However this drawback is compensated by the conserved 7 TM 
structural characteristic shared by all Class A GPCRs and the conserved motifs found along the TMs 
[57]. The current consensus of opinion in GPCR homology modeling is that the template selection 
should be data driven and knowledge-based, incorporating information such as high sequence 
similarity and a priori assessment of the expected structural features of the receptor to model such as 
loop morphology, similarity in binding-pocket regions etc. [57-58]. Chapter 3 of this thesis is dedicated 
solely to investigation of the effects template selection has on the homology modeling.  
The modeled receptor is a limited approximation for use in drug discovery since its construction 
does not consider the rearrangement due to the bound ligand (a molecular docking effect) and the 
effect that the lipid bilayer may cause to the protein structure. These two effects can be captured in 
the model thorough molecular dynamics simulations [59]. 
 
 
2.4 Molecular docking  
In recent years molecular docking has become an important tool for drug discovery. The focus of 
molecular docking is to computationally simulate the target-ligand recognition process. The 
associations between biologically relevant molecules such as proteins, nucleic acids, carbohydrates, 
and lipids play a central role in signal transduction. Furthermore, the relative orientation of the two 
interacting partners may affect the type of signal produced (agonism vs. antagonism). Therefore 
docking is useful for predicting both the strength and type of signal produced [60-61].  
The goal of molecular docking is to achieve an optimized conformation for both the protein and 
ligand and relative orientation between protein and ligand such that the free energy of the overall 
system is minimized. To understand the ruling principles whereby protein receptors recognize, 
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interact, and associate with molecular substrates and inhibitors is of paramount importance in drug 
discovery efforts [60]. Protein-ligand docking aims to predict and rank the structures arising from the 
association between a given ligand and a target protein of known 3D structure. The fact that proteins 
are in constant motion between different conformational states with similar energies is still often 
disregarded in docking studies, even though protein flexibility is known to allow increased affinity to 
be achieved between a given drug and its target [60, 62 ]. 
  Furthermore, binding-site location and binding orientation can be greatly influenced by 
protein flexibility. Combining all these aspects, it is very important to have a good docking program. 
There have been a number of attempts to compare the strength of different docking programs, where 
the comparison is often divided into assessment of the search algorithm and the scoring function. 
Scoring functions are fast approximate mathematical methods used to predict the strength of the non-
covalent interaction (also referred to as binding affinity) between two molecules after they have been 
docked. Each attempt at an unbiased comparison clearly stated that it is very difficult to rank and 
assess different optimization strategies, particularly with increased algorithms complexity [60, 62-64].  
 
2.4.1 Protein-ligand docking 
Predicting the binding modes and affinities of compounds when they interact with a protein-
binding site lies at the heart of structure-based drug design. The protein-ligand docking in this thesis 
study have been done using Genetic Optimization for ligand docking (GOLD) software for rough 
models [65], and Glide software from Schrodinger suite of programs for refined models [66-67]. 
Generally speaking, once you have decided, your ligands (drugs) and target protein, the docking 
program, will "dock" your ligands to the target protein by exploring many biophysically possible ways 
that the given compound(s) can bind to the target. The combination of position and orientation of 
a ligand relative to the receptor along with its conformation in docking, is known as a ligand pose, 
and is assigned a score based on the pre-determined scoring functions. Upon completion of docking 
all compounds to the target protein, they are ranked and selected for subsequent validations based 
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on their corresponding scores and binding poses [60]. 
GOLD uses a genetic search algorithm and allows for full ligand flexibility, as well as rotational 
flexibility for the protein-receptor polar hydrogens [60, 62, 68-70]. GOLD has one of the most 
comprehensive test sets from the entire surfeit of docking programs, comprising 100 different 
protein complexes and has achieved a 71% success rate in identifying the experimental binding 
models. However, systematic problems in ranking very polar ligands and in ranking general ligands 
in large cavities have been reported [60, 65, 70]. Like all docking programs, GOLD has three main 
parts, first, a scoring function to rank different binding modes; the Goldscore function is a molecular 
mechanics–like function with four terms: 
 
 
 
 
Where by : 
 Shb_ext   is the protein–ligand hydrogen-bond score  
 Svdw_ext   is the protein-ligand van der Waals score. 
 Shb_int      is the contribution to the Fitness due to intramolecular hydrogen bonds in the ligand.  
 Svdw_int   is the contribution due to intramolecular strain in the ligand. 
Second part of GOLD is the mechanism for placing the ligand in the binding site; GOLD uses a 
unique method to do this, which is based on fitting points; it adds fitting points to hydrogen bonding 
groups on protein and ligand, and maps acceptor points on the ligand on donor points in the protein 
and vice versa. Additionally, GOLD generates hydrophobic fitting points in the protein cavity onto 
which ligand CH groups are mapped. The last part of GOLD software is the search algorithm to explore 
possible binding modes; GOLD uses a genetic algorithm (GA) in which the parameters such as dihedrals 
  𝑮𝑶𝑳𝑫 𝑭𝒊𝒕𝒏𝒆𝒔𝒔  =  𝑠ℎ𝑏_𝑒𝑥𝑡  +  𝑠𝑣𝑑𝑤_𝑒𝑥𝑡 + 𝑠ℎ𝑏_𝑖𝑛𝑡 + 𝑠𝑣𝑑𝑤_𝑖𝑛𝑡  
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angles of ligand rotatable bonds, ligand ring geometries (by flipping ring corners), dihedrals angles of 
protein -OH groups and NH3 groups and the mappings of the fitting points (the position of the ligand 
in the binding site) are modified and optimized [65, 70]. At the start of a docking run, all these variables 
are randomized. Whenever GOLD software was used in this thesis chapter, the default GOLD 
parameters and Goldscore scoring default parameters were used which includes flipping ring corners, 
planar and pyramidal nitrogen, allowing rotatable H2O molecules, diverse poses during placing and 
rotating interacting hydrogen bonds [70].  
Glide software on the other end, can run in rigid or flexible docking modes treating the ligand as 
a rigid body or generating conformations for the input ligand respectively. The ligand poses that Glide 
generates pass through a series of hierarchical filters that evaluate the ligand’s interaction with the 
receptor. The initial filters test the spatial fit of the ligand to the defined active site, and examine the 
complementarity of ligand-receptor interactions using a grid-based method patterned after the 
empirical scoring function. Poses that pass these initial screens enter the final stage of the algorithm, 
which involves evaluation and minimization of a grid approximation to the all atoms optimized 
potentials for liquid simulation (OPLS-AA) non-bonded interaction energy (ligand receptor). Finally, 
the minimized poses are re-scored using Glidescore scoring function [66-67, 71].  
Glidescore is based on initial empirical scoring function, but includes a steric-clash term, adds 
other rewards and penalties such as buried polar terms (devised by Schrödinger to penalize 
electrostatic mismatches), amide twist penalties, hydrophobic enclosure terms, excluded volume 
penalties and is calculated by;  
 
 
The van der Waals term (vdW) calculates repulsion and attraction parameters between the atoms 
of the receptor and the ligand. The force is very significant if the contact surface is large and when the 
𝑮𝒍𝒊𝒅𝒆𝒔𝒄𝒐𝒓𝒆 =  (0.05 ∗  𝑣𝑑𝑊) + (0.15 ∗  𝐶𝑜𝑢𝑙)  +  𝐿𝑖𝑝𝑜 +  𝐻𝑏𝑜𝑛𝑑 +  𝑀𝑒𝑡𝑎𝑙 +  𝑅𝑒𝑤𝑎𝑟𝑑𝑠  
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molecules are close. The Coulomb energy term (Coul) calculates electrostatic interactions between 
the atoms of the receptor and the ligand. This force draws molecules closer together or further apart 
according to their electrical charge. The two terms are calculated with reduced net ionic charges on 
groups with formal charges (e.g. carboxylates and metals). The lipophilic term (Lipo) is calculated for 
lipophilic receptor- and ligand atoms, rewarding favorable hydrophobic interactions. The Hydrogen 
bond term (Hbond) is calculated for all complementary possibilities of hydrogen bonds between the 
atoms of the receptor and the atoms of the ligand. Hydrogen bonds give a favorable contribution to 
affinity. If the ligand is a strong hydrogen bonder the solvent will attract it and make the receptor less 
favorable. If the receptor has hydrogen bonding qualities this can attract the ligand into binding. The 
term is separated into three different components depending on the donor and acceptor. Either both 
are neutral, one is charged and one is neutral or both are charged. The first of these contributions 
(both neutral) is found to be the most stabilizing and the last (both charged) is the least important. 
The metal-ligand interaction term (Metal) is calculated for metal atoms in the receptor and all 
acceptor and acceptor/donor atoms in the ligand. Only the interactions with highly polar acceptor 
atoms or anionic atoms are included. Only if the net metal charge in the apoprotein (enzyme without 
its prosthetic group) is positive, the preferences for polar or anionic ligands are included. The Site term 
(Site) calculates polar interactions in the active site. Non-hydrogen-bonding polar atoms in a 
hydrophobic region are rewarded.  
The term called Rewards provides rewards and penalties for different features, such as a 
hydrophobic enclosure, buried polar groups and other terms that are not explicitly mentioned. In 
addition penalties for frozen rotatable bonds (RotB) are given. If the ligand is very flexible the 
equilibrium will be shifted against the solvent because the degree of disorder (ΔS) is greater here, thus 
causing a lower free energy. The free energy of the system should be as small as possible. A low 
(negative) energy indicates a stable system, and thus a likely binding interaction [66-67]. 
In this study, when Glide software was used for molecular docking it was used in flexible mode 
and scoring done using “extra precision” Glidescore (XP score) scoring method . Flexible mode 
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automatically generates conformations for each input ligand and the XP scoring method aims to weed 
out false positives and to provide a better correlation between good poses and good scores. The XP 
scoring function includes additional terms over the normal Glidescore scoring function. Specifically, 
XP score rewards occupancy of well-defined hydrophobic pockets by hydrophobic ligand groups. 
Hydrophobic reward terms are employed in Glidescore in the form of lipophilic-lipophilic pair terms, 
while other empirical scoring functions use lipophilic surface-area contact terms for this purpose. 
Research have shown that simple pair terms underestimate hydrophobic effects in certain well-
defined cases. The hydrophobic term in XP score was developed to offset this underestimation. The 
term confers up to several kcal/mol of additional binding energy in favorable cases, and substantially 
improves enrichment factors. XP score also includes improvements to the scoring of hydrogen bonds 
as well as detection of buried polar groups, and detection of π-cation and π-π stacking interactions 
[72]. 
 In a comparison study of protein-ligand docking programs, it was noted that Glide software 
exhibits excellent docking accuracy, high enrichment across a diverse range of receptor types and 
reliably finds the correct binding modes for a large set of test cases .i.e. virtual screening.  It 
outperformed other docking programs in achieving lower rmsd from native co-crystallized structures 
especially is [60]. Thusly, for the final, refined model all the molecular docking calculations, either 
virtual screenings or pharmacophore based was done using Glide software, while GOLD was used for 
initial molecular docking in the rough models due to the high flexibility exploration the software offers. 
 
2.4.2 Protein –protein docking 
 
Proteins often carry out their functions through the association with other proteins forming multi-
protein complexes. Several theoretical algorithms have been designed to predict the 3D structure of 
protein-protein complexes using docking algorithms for this purpose. These programs as well as Web 
servers such as PIPER, GRAMM-X, HEX, 3D Garden, SmoothDock, Rosetta and PatchDock aim to 
assemble two separate protein components into a biologically relevant complex structure, ideally 
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close to the native structure [73]. 
The ability to accurately predict protein complexes also opens the potential for rational drug 
design and protein engineering [74-75]. A comparison study on the diverse protein-protein docking 
programs concluded that due to its features,  Global RAnge Molecular Matching (GRAMM) software 
is one of the best [76], henceforth the protein-protein docking calculation performed in this study was 
done using GRAMM (GRAMM docking).  
GRAMM docking uses an empirical approach to smoothing the intermolecular energy function by 
changing the range of the atom-atom potentials. The technique locates the area of the global 
minimum of intermolecular energy for structures of different accuracy. The quality of the prediction 
depends on the accuracy of the structures. Thus, the docking of high-resolution structures with small 
conformational changes yields an accurate prediction, while the docking of ultra-low-resolution 
structures will give only the gross features of the complex. [73, 77]. 
Protein docking is based on complementarity between interacting proteins which could be 
geometric, electrostatic, hydrophobic, or all three. To create different docking models, one protein is 
fixed in space while the second protein is rotated and translated around the stationary protein. 
Performing a truly comprehensive global search with the receptor and ligand would require a large 
investment of computational power which is not practical with current resources. As a result most 
protein docking prediction programs start with rigid body searches or by geometric matching. In this 
initial stage GRAMM simplify the protein structure as a rigid body representation on a 3D Cartesian 
grid then a docks by searching, using Fast Fourier Transform (FFT) based method, for degrees of 
overlap between the pairs of grids. FFT-based method of searching allows the evaluation of many 
docked conformations on a grid using a correlation-type scoring function [78-79].  For example for 
two protein (a and b), projected in 3D grid (N x N x N) points, their discrete functions are presented 
by; 
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And 
 
 
Whereby l, m, and n are the indices of the 3D grid (l, m, n = {1…N}). Any grid point is considered 
inside the molecule if there is at least one atom nucleus within a distance r from it, where r is of the 
order of van der Waals atomic radii. To distinguish between the surface and the interior of each 
molecule, a value of 1 is retained for the grid points along a thin surface layer only and other values 
are assigned to the internal grid points. Therefore: 
 
 
 
And  
 
 
 
 
Whereby the surface is defined as a boundary layer of finite width between the inside and the 
outside of the molecule. The parameters p and 8 describe the value of the points inside the molecules, 
and all points outside are set to zero. GRAMM docking accomplished stage one by matching surface 
through calculating correlation functions. The correlation between the discrete functions ?̅? and ?̅? is 
defined as: 
 
 
𝑎𝑙,𝑚,𝑛 = {
1   𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
 
  0   𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
      
                                                                               [1a] 
𝑏𝑙,𝑚,𝑛 = {
1   𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
 
  0   𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
  
                                                                                [1b] 
?̅?𝑙,𝑚,𝑛 = 
{
 
 
 
1   𝑜𝑛 𝑡ℎ𝑒 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
𝜌   𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒                      
0  𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒                     
 
           [2a] 
?̅?𝑙,𝑚,𝑛 = 
{
 
 
 
1   𝑜𝑛 𝑡ℎ𝑒 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
𝜌   𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒                      
0  𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒                     
 
           [2b] 
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Where by α, β and γ are number of grid steps by which molecules b is shifted in respect to 
molecule a in every dimension.  Figure 2.4 shows the outcome of equation [3]. If there is no contact 
between the two molecules [3] = zero, If there is a contact between the surfaces the contribution to 
the correlation value [3] is positive. If one molecule penetrates into the other [3] (figure 2.4 c). Such 
penetration is physically forbidden, thus a distinction between surface contact and penetration must 
be clearly formulated by assigning large negative values to ρ in ?̅? and small non-negative values to δ 
in ?̅?. Hence, if the shift vector { α, β, γ} is such that molecule b penetrates molecule a, the multiplication 
of the negative numbers (ρ) in ?̅? by the positive numbers (1 or δ) in 𝑏 ̅results in a negative contribution 
to the overall correlation value [80].  
Positive correlation values are obtained when the contribution from surface contact 
outweighs that from penetration. Thus, a good geometric match (as in figure 2.4 d) is represented by 
a high positive peak, and low values reflect a poor match between the molecules. Simply put, 
correlation value for each displacement is simply the score for overlapping surfaces corrected by the 
penalty for penetration [80]. 
 
 
𝑐?̅?,𝛽,𝛾 =∑∑ ∑?̅?𝑙,𝑚,𝑛 ∙ ?̅?𝑙+𝛼,𝑚+𝛽,𝑛+𝛾,
𝑁
𝑛=1
𝑁
𝑚=1
𝑁
𝑙=1
 
                                                                                                             [3] 
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Figure 2.4: Different relative positions of 2 molecules. a) No contact, b) limited contact, c) penetration (in black), and d) good 
geometric match [80]. 
 
 
Since the initial docking stage will generate multiple docked model complexes, they will need to 
be filtered to select the best conformations based on their scores [78]. GRAMM re-ranks the models 
resulting from initial stage by running a local minimization with soft van der Waals interaction, 
clustering of predictions within the same local minima, and rescoring with the target function 
combining Lennard-Jones [79]. Finally, the models can be refined by incorporating flexibility into the 
protein sidechains as well as the backbone [80]. GRAMM-X displays their top scoring models based on 
soft Lennard-Jones potential, evolutionary conservation of predicted interface, statistical residue-
residue preference, empirical binding free energy and atomic contact [79, 81]. At this moment, the 
models are ready for the utilization. 
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2.5 Molecular Dynamics Simulations 
Despite the fact that they are normally represented as static structures, molecules such as protein 
are in fact dynamic. In this thesis, study chapters 3-6 uses techniques of classical molecular dynamics 
simulation (MD simulation) to refine the structures resulted from homology modeling. This point aims 
to give a basic introduction to the equations that the method of MD relies on. 
All the atoms of a molecule are subject to a harmonic movement because of forces, which result 
from the interactions between atoms. And although the main purpose of molecular dynamics 
simulations is modeling of molecular motions, molecular dynamics simulations are also applied for 
structural optimization. MD simulation calculates the time dependent behavior of a molecular 
system and provides detailed information on the fluctuations and conformational changes of 
proteins [82-83]. Thus one can study both the thermodynamic properties and/or time dependent 
(kinetic) phenomena.  
One way to investigate the range of accessible configurations is to simulate the motions or 
dynamics of a molecule numerically. This can be done by computing a trajectory, a series of molecular 
configurations as a function of time, by the simultaneous integration of Newton's equations of motion. 
If the force on each atom is known, it is possible to determine the acceleration of each atom in the 
system. Integration of the equations of motion then yields a trajectory that describes the positions, 
velocities and accelerations of the particles as they vary with time. From this trajectory, the average 
values of properties can be determined. The method is deterministic; once the positions and velocities 
of each atom are known, the state of the system can be predicted at any time in the future or the past.  
[82-85].  
Starting from a coordinate set taken from a starting structure, the interactions among atoms and  
the position  are defined and velocities calculated and assigned to each atom (typically from a 
Boltzmann distribution at a given temperature) using a numerical method such as the Verlet method 
[86]. The successive coordinates and velocities are obtained by integrating the Newton’s equation for 
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the motion in each coordinate direction according to the forces derived from the gradients of the 
interaction potentials involving the atom. The equations of motion; 
 
 
 
and  
 
    
for all atoms (i = 1, 2 ,...,N) of the molecular system. The atomic coordinates, r, and the velocity V, of 
atom, i, with mass, mi, thus become functions of time. The force Fi exerted on atom i by the other 
atoms in the system is given by the negative gradient of the potential energy function V which in turn 
depends on the coordinates of all N atoms in the system: 
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[7] and [8] form the so-called leap-frog scheme for integrating Newton's equations of motion. The 
leap-frog algorithm is used due to the fact that a large number of particles are interacting with each 
other [85].  
The numeric integration is carried out step-wisely and is limited to the fastest motion in the 
system. Typically a time step of 1 to 10 fs is used for molecular systems. Thus a 100ps (10-10 seconds) 
molecular dynamics simulation involves 105 to 104 integration steps. The process is repeated at each 
discrete time step. The trajectory of each individual object can be tracked by connecting its states to 
form a time series. The time evolution of the entire system can be viewed as a fiber bundle of time 
series in the phase space. Even using the fastest computers only very rapid molecular processes can 
be simulated at an atomic level [83, 85]. Therefore, for atomistic simulations the step size is usually 1 
fs, or 2 fs if restraining bond lengths, generally done using SHAKE [87] and LINCS [88] algorithms. As 
with any aspect of modelling, the accuracy of the predicted dynamics will depend on the validity of 
the underlying assumptions of the model. In this case the model is essentially defined by the force 
field that is used [84]. 
Generally, factors that govern the outcome of MD simulations includes the starting configuration 
of the system, how you will treat temperature and pressure (statistical ensemble), boundary 
conditions, solvation effect, choice of the degrees of freedom, how you treat the non-bonded 
interactions, integration time step (the bigger the time step the higher the computing power/cost), 
and the force field parameters (how the atoms are described in your system) [83, 85]. 
As with any aspect of modeling, the accuracy of the predicted dynamics will depend on the validity 
of the underlying assumptions of the model. In this case this is essentially defined by the model for 
the intermolecular interactions (or potential energy) used. That model is a mathematical function 
(force field) that describes how the value for the potential energy depends on the spatial arrangement 
of all the atoms [85]. 
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2.6 Atomic Force fields 
The calculation of the interaction energy within a classical description of a molecular system 
requires a force field. A force field is built up from two distinct components, a set of equations used 
to generate the potential energies (and their derivatives, the forces) and the parameters used in 
these equations. There are four main force fields in common use for simulating biological 
macromolecules AMBER [89], CHARMM [90-92], GROMOS [87] and OPLS [93]. The force field used 
in describing all the components of the molecular system, such as the protein, water molecules, 
and ions is OPLS-AA.  
Atoms basically interact with each other through van der Waals forces and electrostatic forces. 
When they are covalently bonded to others, strong forces hold them together as stable chemical 
groups. The intramolecular potential energy [9] is typically represented by harmonic oscillators for 
bond stretching and angle bending, a Fourier series for each torsional angle, and Coulomb and 
Lennard–Jones (LJ) accounting for the interactions between atoms separated by three or more 
bonds. The latter two terms -referred together as non-bonded terms- are evaluated between all 
atom pairs in the system to yield the intermolecular energy. Such force fields compute the energy 
as a sum of terms representing bond elongation, angle and dihedral deformation, and non-bonded 
interactions with the following general form; 
 
Whereby the three first summations correspond the bonded terms (that include atoms 
connected up to three consecutive bonds) and the last two refer to the non-bonded ones. All 
summations can be easily calculated from the coordinates of the system at a given time. For each 
pair of bonded atoms (i and j), the stretching term is computed as; 
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Whereby  Krij is the stretching force constant and rij and r°ij are the distance between atoms and its 
equilibrium bond length, respectively. For every group of three bonded atoms (i, j and k), the angle 
term is described as; 
 
 
 
Whereby Kθijk is the bending force constant, θijk and θoijk are the angle between atoms and its 
equilibrium value, respectively. For every group of four bonded atoms (i, j, j, l), the dihedral term 
is often represented as a cosine expansion; 
 
 
 
Whereby  kφijkl is a dihedral constant affecting the barrier height, n is number of minima in a 360º 
rotation, and φijkl and φoijkl are the dihedral angle and the equilibrium value according the 
biochemical convention (trans φ=180º, cis φ=0º and gauche φ=60º/300º), respectively. The first 
non-bonded term is often represented by a 6-12 Lennard-Jones potential, a simple mathematical 
model [94], that accounts for two distinct forces (an attractive and a repulsive) that neutral atoms 
and molecules are subject to; 
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Whereby Aij and Bij are parameters that depend from on each pair of atoms. The first term 
accounts for the attractive forces at long range (van der Waals or dispersion) and the other for the 
repulsive forces at short range, resulting from the overlap between electronic orbitals. In MD 
simulations, it is the non-bonded interaction that are more important than the bonded interactions. 
It is the non-bonded interactions among the atoms of a macromolecule that affect its secondary 
structure. It is the non-bonded interactions among the atoms of different molecules that organize 
them into crystals, complexes and other assemblies. 
 Finally, the last term in the force field equation [9] is a Coulombic potential describing the 
electrostatic interactions; 
 
 
 
Where qi and qj are the charges of atoms i and j, rij the relative distance between them and ɛ｡the 
vacuum permittivity.  
 
 
2.7 Statistical ensemble 
In order to relate the microscopic features of individual atoms and molecules to the 
macroscopic or bulk thermodynamic properties of materials one needs to use statistical mechanics 
methods. In this context, an ensemble formalizes the notion that, repeating an experiment again 
and again, a physicist may expect to observe a range of different outcomes under the same 
macroscopic conditions, but unable to control microscopic details.  Different macroscopic 
environmental constraints lead to different types of ensembles, with particular statistical 
characteristics. The three most important ensembles used in MD simulations of biological systems 
includes Micro-canonical ensemble (NVE), Canonical ensemble (NVT) and the Isothermal–isobaric 
(NPT) ensemble. 
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The NVE requires keeping the total energy of the system constant (e.g. system thermally 
isolated). The system is assumed to be isolated in the sense that the system cannot exchange 
energy or particles with its environment, so that (by conservation of energy) the energy of the 
system remains exactly known as time goes on. The initial N and V account for a constant number 
of atoms and volume such as a fixed box shape. Although the NVE is confined to around a constant-
energy surface, it is not necessarily uniformly distributed over that surface: if the gradient of energy 
in phase space varies, then the NVE is more concentrated in some parts of the surface than others. 
NVT is the statistical ensemble that represents the possible states of a mechanical system 
in thermal equilibrium with a heat bath at a fixed temperature. It shares its energy with a large heat 
reservoir or heat bath allowing the system to exchange energy assuming that the heat capacity of 
the reservoir is so large as to maintain a fixed temperature for the coupled system [99]. Like in NVE, 
the initial N and V account for a constant number of atoms and volume (i.e. a fixed box shape).  
The NPT ensemble is analogous to the NVT one, but imposes a barostat in the same spirit as 
the temperature coupling that maintains a fixed pressure instead of considering a constant volume. 
It corresponds most closely to laboratory conditions with a flask open to ambient temperature and 
pressure [99]. 
For lipid bilayers, pressure control occurs under constant membrane area (NPAT) or constant 
surface tension "gamma" (NPγT). Thus, the NPT ensemble will be used in this study. As previous 
stated, all the molecular components of the MD systems in this thesis study will be described using 
the OPLS-all atom force field parameters. This includes for the water model TIP3P, TIP3P water 
model has been shown to provide a good compromise between quality and computational cost and 
thus will be used the water model for the simulations in this study [95]. Ions and lipids palmitoyl-
oleyl phosphatidylcholine (POPC) whose force field were taken from OPLS for its use in the 
GROMACS package 4.6 [96-98]. As an added advantage, OPLS all-atom force field includes explicit 
representation of all atoms, including non-polar hydrogens [93]. 
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2.8 Conclusions to chapter 2 
Once a decision has been made to target a particular therapeutic area (such as analgesic, 
antidepressants, anti-infective etc.), it is very clear the road to drug discovery will depend on a number 
of things such as the existence of potential molecular targets, existing technologies and scientific 
expertise among others. While others factors such as marketability of the drug play important role, it 
is the scientific side of the process that will determine the important aspects of the drug discovery 
process (e.g.  Duration, costs).  
If the molecular targets do exist in a researchable manner, for example crystallographic structures, 
the drug discovery process can proceed via ligand based or structure based method needing both in 
house and commercial application to be used in process such as molecular docking, high-throughput 
virtual screening, pharmacophore design etc. The drug discovery process will become more costly 
both in material/methodology and time consuming if there is no molecular targets available in 
researchable manner. At this stage atomistic homology models of the molecular targets will have to 
be constructed and refined or optimized. This will involves the time-consuming and often resource 
consuming (computing powers) methods such as MD simulation to prepare the molecular targets 
ready for the drug discovery process. 
This chapter dealt with the discussion of the theoretical and methodological aspects of the whole 
process of preparing the molecular targets ready for the drug discovery process albeit one should 
consider these preparatory process is also part of the drug discovery process as it set a tone and have 
a considerable impact on the outcomes of the drug discovery process. That is to say, good 
methodology makes better drug discovery tools and leads to good drug. 
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3.0 Chapter summary 
Analysis of the diverse available crystallographic structures of GPCRs suggests that although they 
share a common seven helix bundle, there are specific features that differentiate them that might be 
relevant for ligand design. This underlines the interest in solving novel GPCR crystallographic 
structures. However, despite the fact the number of crystallographic structures is steadily increasing, 
there are still challenges that hamper the availability of new ones. In the absence of a crystallographic 
structure for a specific receptor, homology modeling remains one of the most important techniques 
for constructing 3D models of proteins.  
In this chapter, the results of an investigation devoted to understand the use of molecular 
dynamics as refinement process for models of GPCRs produced by homology modeling are described. 
Specifically, several atomistic models of rat M3 muscarinic receptor were constructed using diverse 
templates, including the human M2 muscarinic receptor, the human histamine 1 receptor and the 
bovine rhodopsin receptor using the MOE software. These homology models were refined with 
tiotropium docked in the orthosteric site by means of the GLIDE software. Furthermore, in order to 
determine the effect of ligand in the refinement process, two additional models of the M3 receptor 
were constructed and refined. The first had N-methyl scopolamine bound inside and the second did 
not include any ligand. The five models were embedded in a lipid bilayer prior to refinement process 
and molecular dynamics simulations were carried out using GROMACS. Finally, the resulting models 
were compared with the crystallographic structure of rat M3 muscarinic receptor. 
The results show that molecular dynamics simulations of the protein embedded in a lipid bilayer 
improve the starting homology models and a sampling time of 500ns is adequate for the refinement 
process. Specifically, the refinement process can correct the length of the TM segment of the target 
receptor, the accuracy of the model greatly depends on the proximity of the template and the target 
in the phylogenetic tree and finally, although the presence of a ligand produces a faster equilibration 
of the system. 
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3.1 Introduction 
Prediction of 3D structures of GPCRs is motivated by their importance in biological systems and 
the difficulties associated with their structure determination by experimental procedures.  Knowledge 
of the 3D structure of GPCRs is important for understanding the molecular mechanisms underlying 
diseases and syndromes caused by mutations in these receptors, as well as for the structure-based 
design of small molecules acting as therapeutic treatments [1-3]. In fact, GPCRs account for the majority 
of best-selling drugs and about 40% of all prescription pharmaceuticals on the market [3-5].   
Despite the number of crystallographic structures of GPCRs available has increased steadily 
during the last few years, there are still challenges that hamper the availability of new ones, including 
their low-expression yields, low receptor stability after detergent extraction from native membranes, 
and high conformational heterogeneity. With so little structural information available, homology 
modeling has become a widespread technique to get insights into the structure-function relationships 
of the receptors and facilitate the discovery of chemicals capable of modulating their activity [6-13].  
Thus, homology modeling is used to construct atomic resolution models that could be used in virtual 
screening studies, to accurate predict ligand binding pocket, to study drug-receptor recognition as well 
as well as the clarification of experimental data [12-14]. However, reliable modeling of GPCR-ligand 
complexes for the vast majority of receptors with unknown structure remains to be one of the most 
challenging goals for the rational drug discovery process [15-16].  
The publication of the crystallographic structure of rhodopsin at atomic resolution provided for 
the first time a template to construct realistic models of GPCRs by homology modeling [11, 17]. This 
structure has been widely used as template to construct models of diverse members of the rhodopsin-
like family [11-12, 16, 18]. Although sequence identity with other GPCRs is small (about 20% on average) 
conservation of specific features among all the members of the rhodopsin-like family provides support 
for its use as template [11, 19]. In spite of the success, the suitability of the rhodopsin template to 
accurately predict the structure of other GPCRs was soon questioned [14, 20-21]. A critical point was 
made regards its low sequence identity with other GPCRs and also, the high diversity of ligand-binding 
 76 
Effect of template selection on the modeling of GPCR structures by homology modeling 
features observed among different GPCRs [20]. The publication of the crystallographic structures of 
diverse ligand-GPCR complexes a few years later, made these drawbacks more evident, as inferred from 
the results of the diverse community-wide GPCR-Dock assessment competitions. In these studies it was 
established a 35%–40% sequence identity between target and template as an empirical cutoff for 
reliable homology based prediction of ligand-receptor interactions [12 14].  
Presently, homology modeling approaches of GPCRs achieve close-to-experimental accuracy for 
small rigid orthosteric ligands when templates with high sequence identity are used [15]. However, 
there still many issues that need to be addressed to improve the quality of the models of GPCRs 
constructed by homology modeling. Diverse reports published recently address issues like template 
selection [22-24]; inclusion of knowledge-based constraints into the modeling process [24-25]; 
modeling of the extracellular loops [26-27] and on structure refinement [10, 28-30].  
In this chapter, both the effect of the template selection and the use of molecular dynamics 
simulations for the refinement of GPCRs models constructed by homology modeling were investigated. 
Specifically, the use of templates located at diverse distances from target receptor in the GPCR 
phylogenetic tree; the use of MD for the refinement process as well as the effect of including a ligand 
bound onto the orthosteric site. To reach the aforementioned objective, a “semi-blind” homology 
modeling study of the rat M3 muscarinic receptor whose crystallographic structure is available, was 
carried out using the human M2 muscarinic receptor with and without an antagonist bound to it, the 
human H1 histamine receptor and bovine rhodopsin as templates.  The study is semi-blind since the 
crystallographic structure of the target is available, hence provides an evaluation opportunity for both 
the final models and applied methods used in the construction of the models. 
 
 
 
 
3.2 Methodology 
Several computational chemistry methodologies are applied in the constructions of atomistic 
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3D models of GPCR. The notion that amongst homologues, protein structures are more conserved 
than protein sequences is the widely accepted underlying principle when constructing an unknown 
atomic-resolution model of the "target" protein from its amino acid sequence and a template an 
experimental 3D structure of a related homologous protein [6, 9-10, 14-16].  
While the overall architecture between the target and template GPCR are conserved, for 
example the 7TM motif, there are number of factors that need to addressed and corrected or refined 
in order to get a final model. The noted differences includes, the length and orientation of the TM 
helices, orientation of sidechains,  differences in the extracellular and intracellular loops ,  the 
presence and extent of helical distortions (kinks and bulges). Thus, a good refinement model is needed 
to correct the noted differences and help annotated the expected structure and features of the final 
model [14-16]. 
 
3.2.1 Constructing GPCR homology model by homology modeling  
 
Homology models of the rat muscarinic M3 receptor were constructed from diverse templates 
including the human muscarinic M2 receptor [31], the human H1 histamine receptor [32], and bovine 
rhodopsin [17] using comparative modeling by the Molecular operating Environment (MOE) software 
[33]. The sequence of the rat M3 muscarinic receptor was retrieved from the Uniprot database (ID: 
P08484), whereas those of the templates were retrieved from the corresponding crystallographic 
structures (PDB entry code: 3UON for the human muscarinic M2, 3RZE for the human histamine H1 
and 1GZM for bovine rhodopsin). Residues of the T4 Lysozyme were removed from the respective 
templates and sequence alignment was done between the target and the templates using MOE-Align 
tool. 
All muscarinic receptors subtypes contain a long ICL3, where by only the N and C terminal 
portion are essential and of needed coupling specificity of G-protein. A large portion of ICL3 can be 
deleted without interfering with the general functions of the receptor [34]. Thus, muscarinic receptors 
need just the N terminus and C-terminus residues of the ICL3 for general receptor functions.  
 78 
Effect of template selection on the modeling of GPCR structures by homology modeling 
Accordingly, in order to simplify the construction of the atomistic model of the rat M3 receptor 
without compromising its accuracy, a major part of the intracellular loop (ICL3) was not included in 
the modeling, using instead a stretch of three residues at each end of helices TM5 and TM6, 
respectively that were subsequently linked. Thus, the crystallographic structure of the M2 muscarinic 
receptor had over 90% of the ICL3 residues removed and accordingly, based on comparative sequence 
alignment these residues were removed from the target residues and realignment was commenced. 
For rhodopsin and histamine based models a single comparative alignment was performed with the 
target ICL3 residues exclusion done solely based on those not aligning with template N and C terminals 
of the ICL3. Once the realignment was completed and checked for inspection of unwanted gaps in the 
TM regions, homology models were constructed.  
Models generated were validated visualizing the bonds or clashes in between atoms in the 
models and by computing the values of the backbone torsional angles and plotting them in a 
Ramachandran map to show the distribution of angles observed in a single structure.  
 
3.2.2 Molecular docking 
 
Once the structure validation process was completed, the highest ranking starting models for 
each of the three templates was selected for refinement. In a step forward two ligands (Figure 3.1), the 
inverse agonist Tiotropium that was also co-crystalized with the published M3 structure [35], and the 
non-selective antagonist N-methyl scopolamine (NMS) were docked onto the orthosteric site of the 
starting models and guided by the structural information available on GPCRs. The docking process was 
carried out using the Glide software from the Schrodinger programs [36-37]. The resulted poses were 
rank ordered by binding and docking score, poses were rank ordered using the XP score function of 
GLIDE [38]. Final poses of each of the compounds was selected based on their ranking and similarity to 
the pose previously reported [18, 35]. This permitted continuation to the next step, molecular dynamics 
simulation to refine the “rough” homology models.  
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Figure 3.1:  The structures of the Tiotropium and N-methyl scopolamine (NMS), the ligands used in this study 
 
 
Henceforth, four protein-ligand complexes of M3 muscarinic receptor, the first based on M2 
muscarinic receptor and bound to Tiotropium, second also constructed using M2 receptor as a template 
with NMS bound to it, and the last two complexes based on the human histamine 1 receptor (bound 
with NMS) and bovine rhodopsin receptor (bound with NMS) as templates were refined using molecular 
dynamic simulations.   
 
3.2.3 Model refinement 
 
Models were refined using molecular dynamics (MD) simulations. For each of the models, the 
starting structure was embedded into a box consisting of equilibrated 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) lipids and water molecules and equilibrated according to the procedure 
described previously elsewhere [39-40]. The box had an initial size of 10.3 x 8.0 x 10.2 nm3 (XYZ), 
organized in such a way that the bilayer plane was oriented on the XY plane. Before protein insertion, 
the box contained 256 lipids (corresponding to an area per lipid of 0.64 nm2) and circa 17,000 water 
molecules. The protein was placed in the center of the box, and the overlapping molecules were 
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removed. Specifically, all water molecules with oxygen atoms closer than 0.40 nm to a non-hydrogen 
atom of the protein, as well as all lipid molecules with at least one atom closer than 0.25 nm to a non-
hydrogen atom of the protein were removed. This resulted in a final system containing 188 lipids and 
circa 14,655 water molecules. Removal of these atoms introduced small voids between the protein and 
water or lipid molecules that disappeared during the first part of the MD simulation, in which a 
progressive adjustment of the lipid bilayer and water molecules to the protein takes place.  
Next, 105 randomly selected water molecules were replaced by 45 sodium and 60 chloride ions, 
providing a neutral system with a concentration approximately 0.2 M on sodium chloride. This 
concentration is fairly similar to that found in biological organisms, although they exhibit different intra- 
and extra-cellular ion concentrations. Both the protein, ligand, ions and TIP3P water model parameters 
were describes using OPLSAA [41], while sampling was carried out for 500ns using GROMACS package 
4.6 [42-43]. It should be noted that the same box (size and features) were used for each of the five 
models refinement. While the number of the water and lipid molecules displaced by the addition of the 
protein in the box were slight different depending on the size of the protein, it bears no effect of the 
final concentration of ions. Hence the parameters and condition employed in the refinement process 
were similar to all models, barring their inherent differences i.e. protein size, type of ligand included 
etc. 
 
 
 
 
 
3.3 Results and discussion 
As detailed in the previous section, the procedure to construct atomistic models of GPCRs by 
homology modeling involves the selection of a template; sequence alignment between target and 
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template sequences; construction of a starting model and its verification; a refinement process. And 
as prior stated the goal of this thesis chapter study is to investigate the performance of molecular 
dynamics simulations when used in the refinement process. For this purpose, the relevance of 
template selection, ligand inclusion, as well as the length of the simulation on the quality of the models 
of GPCRs constructed were investigated.  
In the present study atomistic models of M3 receptor were constructed by homology modeling 
using diverse templates and compared with the crystallographic structure of the rat muscarinic M3 
receptor. Templates selected for the present study include the human muscarinic M2, the human 
histamine H1 more distant and bovine rhodopsin as a very distant template. The selection of a 
template in this study was based on their proximity to the target M3 receptor in the GPCRs 
phylogenetic tree. The effect of the ligand in the refinement process was also investigated. Therefore 
molecular dynamic simulations were conducted using the M2 muscarinic as template with Tiotropium 
or NMS docked in the orthosteric site and the results obtained were compared with the simulation of 
M2 muscarinic template based modeled without ligand inclusion.  
In order to understand the performance of molecular dynamics in the refinement process the 
starting structure of each model must be considered. Starting models were constructed by using the 
sequence of the target receptor, arranging them on the corresponding positions to the sequence of 
crystallographic structure of the template as determined by the prior sequence alignment. In fact, 
starting models present different distances to the target M3 crystallographic structure that parallel to 
those of the corresponding starting crystallographic structures. Thus, the muscarinic M2 receptor 
exhibits a root-mean-square deviation (rmsd) of all the alpha carbons of 1.6 Å, whereas this value rises 
to 1.9 Å for the histamine H1 receptor and to 2.3 Å for rhodopsin and are in accordance to their 
distances in the phylogenetic tree. These differences will be also shown in the respective starting 
models and consequently the models constructed will have to undertake changes of the same order 
to provide an accurate model of the target receptor.  
Pairwise sequence alignments were carried out as described in the methods section. Sequence 
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alignment of the rat muscarinic M3 receptor with the human muscarinic M2, the human histamine 
H1, and bovine rhodopsin show sequence identities between of 60%, 34% and 17%, respectively. 
These values increase to 79%, 41% and 23% when only the transmembrane (TM) regions are 
considered. Interestingly, the best score of sequence identity is found between TM3 and the lowest 
between TM1 in all the cases (Figure 3.2). 
 As mentioned above the intracellular loop ICL3 is very long and had to be removed for modeling 
purposes. This deletion bears no consequences to the overall structure of the GPCR or the orthosteric 
binding pocket. In the case of the M2 muscarinic receptor based models this was easily facilitated by 
using the alignment of the sequence of target and template and removal of the aligned residues 
missing in the sequence of the human M2 crystallographic structure. Since both the human histamine 
H1 and rhodopsin receptors have relatively short ICL3, the removal was simply done on the unaligned 
sequences between sequences of templates TM5 and TM6. This had a major effect on the length and 
in some extent the conformation of both TM4 and TM5 of histamine H1 and rhodopsin based models. 
 Sequence alignments were used to construct the models of the rat M3 muscarinic receptor 
using the diverse templates selected for the present study. For each of the templates alternative 
models were generated using template backbone coordinates with alternative side chain 
conformations using an extended rotamer library implemented in MOE. Following this process a 
number of independent models based on loop and side chain placements scored by a contact energy 
function can be generated. From these a model is selected for refinement based on the score and the 
least number of steric violations. 
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Figure 3.2:  Sequence alignment of target and the templates used annotating TM3 (in orange) and TM1 (in green) as area with 
highest and lowest similarity, respectively. 
 
3.3.1 The length of the refinement process 
 
The refinement process aims to relax the structure of the target protein in an environment close 
to the native one. This was carried out in the present work through the use of MD simulations of the 
protein embedded in a lipid environment. The final model of the target protein is produced as the 
energy minimized structure obtained from the average of a set of configurations sampled during the 
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production run. Accordingly, in order for the procedure to provide reliable results simulation times 
need to be long enough to have a reasonable sampling after equilibration [39].  
Monitoring of the refinement process can be carried out by inspection of the time evolution of 
the rmsd in regard to the starting structure. As can be seen in Figure 3.3 for both the whole protein 
(a) as well as the transmembrane regions (b), the equilibration process takes around 250-300 ns, 
except for the model constructed from the bovine rhodopsin that equilibration is achieved short after 
200ns. More specifically, rmsd time evolution of the whole protein (a) or the transmembrane region 
(b) follow the same trends although values of the latter are smaller, suggesting that the loops provide 
an important contribution to the rmsd. Furthermore, as can be seen the models of M3 constructed 
using the M2 muscarinic receptor exhibit a rmsd of around 2.3 Å in regard to the starting structure, 
smaller than the model constructed from the histamine H1 receptor of around 2.7 Å and lower than 
the rmsd observed with the model constructed from rhodopsin that reaches around 3.0 Å. These 
results correlate well to the rmsd of the templates suggesting that rhodopsin and histamine suffer 
larger structural changes than the M2 muscarinic to get transformed into the M3 muscarinic receptor 
as can be expected from the distance of the different templates to the modelled receptor in the 
phylogenetic tree.  
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(a) 
 
(b) 
 
Figures 3.3: The time evolution of the rmsd considering the alpha carbons of the whole protein (a) and when considering only 
the alpha carbons of the TM bundle residues (b), for each of the model simulations. 
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3.3.2 The average structures 
 
Analysis of the trajectories permitted the best conditions to construct a working model of the 
target receptor. From Figure 3.3 the time evolution of the rmsd for each of the models constructed, 
exhibits fluctuations up to approximately halfway of the trajectory and then begin to be stable. 
Therefore, for each trajectory of the model refinement process at least 200ns after stabilization of the 
simulation can be considered for analysis. Accordingly, working models for further analysis were 
selected using the average structure of the last 50 ns of the trajectory.  
The working models or refined model structures presented here are simply minimized average 
structure of the simulated “rough” homology model. That is to say, after running molecular simulation 
of a system containing the rough receptor /receptor complex, an average structure of a chosen receptor 
trajectory is calculated and then minimized in vacuo. An average structure is obtained after the root 
mean square fluctuations (rmsf) of atomic positions in the trajectory are calculated then-after fit to a 
reference initial frame (in this case the beginning of a chosen stable trajectory timeframe).  The rmsf 
values of the average structures are then converted and saved as average coordinate B-factor values. 
Analysis of the (rmsf) of each of the residues along the refinement process is shown in Figures 
3.4. The Figure shows the fluctuations of the models along the last 50 ns. Inspection of Figure shows 
that the highest fluctuation are in the loops region both intracellular and extracellular, as expected. 
Specifically, ECL1 and ICL3 loops in rhodopsin based model, ICL2 in the M2 based model that was 
refined with NMS, ECL2 of the human histamine base model as well as ICL3 of all the models shows 
the largest fluctuations. 
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Figures 3.4: The rmsf of the refined models during the last 50ns of the molecular simulations. 
 
 
3.4 Effect of template selection 
 
The selection of a suitable template is of paramount importance in homology modeling. While 
a correct sequence alignment is key and a good refinement process can help to correct mistakes of 
the modeling process, our results show that the choice of the template is important for model 
accuracy.  
First, lets analyze the differences in the length of the loops and TM region between the 
constructed rough models, refined models (average structure) and the crystallographic structure. 
Table 3.1 lists the residues involved in each of the TM regions for the homology models, refined 
models (in green) and the crystallographic structure of M3 muscarinic receptor. 
 
Table 3.1: Comparison of residues in TMs for the homology models, refined models (in green) and the crystallographic 
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structure of M3 muscarinic receptor. 
 
 
Regarding the differences in the TM length between the rough and refined models, it is very 
encouraging that the refinement process is capable to correct the length of the TM segments.  For 
example in the starting model TM3 is five residues longer in  the rough models based M2 muscarinic 
receptor than in crystallographic  structure of M3 receptor. However, during the refinement process 
the length of the helices from the M2 based model is shortened, ending only one residue shorter than 
the crystallographic structure. In histamine receptor based model, the same TM3 ending is also five 
residue longer and completely corrected to be equal with M3 crystallographic structure after 
refinement process. The correction is afforded albeit not completely but the effort presented is 
significant enough to recommend the methodology for other GPCR homology modeling.  
TM 
region 
M3 
Crystallographic  
structure   
M3
M2
 M3
M2
 
NMS 
M3
M2 
with 
Tiotropium 
M3
HRH1 
with 
Tiotropium 
M3
RHO
 with 
Tiotropium 
TM1 W66 - V95  W66-V95 W66-V95 W66-V95 F70-K92 I64-F93 
W66-V95 W66-V95 W66-V95 F70-F93 V65-F93 
TM2  V102 - M131  V102-M131 V102-M131 V102-M131 V102-I130 I103-I130 
V102-M131 V102-M131 V102-M131 V102-I130 T101-Y128 
TM3  L139 – T171  G137-Y176 G137-Y176 G137-Y176 G137-Y176 N138-I170 
N138-I170 N138-T171 N138-T171 A140-T171 L139-Y167 
TM4  T182 - V211  T182-V211 T182-V211 T182 - V211 T182-A203 T182-L205 
T182-V211 T182-V211 T182 - V211 K183-Q208 R180-W200 
TM5  P229 – K256  P229-K256 P229-K256 P229-K256 P229-E257 E228-K260 
P229-K256 P229-K256 P229-K256 P229-E257 P229-E259 
TM6  L492 – T514  K488-T515 K488-T515 K488-T515 I484-C517 A489-T514 
A490-T515 Q491-T515 Q491-T515 K488-C517 I484-T514 
TM7  K522 – C546  K522-C546 K522-C546 K522-C546 K522-L546 K522-C546 
K522-C546 K522-C546 K522-C546 K522-L546 K522-C546 
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While the length of the intracellular and extracellular loops can be gauged from the above table 
3.1, the shape and orientation adopted by those loops, especially the extracellular loops (Figure 3.5) 
is of significant importance in homology modeling especially when the constructed models is to be 
used in the study ligand allosterism  or in designing ligand of interest. 
 
 
Figure 3.5:  Comparison between the loops M3 crystallographic structure (green) and the refined M3 models made from M2 
refined without ligand (blue), M2 refined with ligand NMS (magenta), M2 refined with ligand Tiotropium (cyan), histamine 
receptor H1 (brown) and Rhodopsin receptor (Red). 
 
 
 
As shown is Figure 3.5, the extracellular loop regions in the constructed models are very 
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different from those of the M3 crystallographic structure. For example in rhodopsin based model ECL2 
is so different in shape and morphology, length and the occupying space. While the same ECL2 in those 
modeled from M2 muscarinic as template occupies the same space, adopt a somewhat similar shape 
and structural features, with the highest similarity observed in the model refined with ligand 
Tiotropium bound while that without ligand showing the higher deviation from the ECL2 of the 
crystallographic structure.  Table 3.2 shows the dihedral angles for residues in the ECL region of both 
the crystallographic structure in comparison to those of the refined average structures. 
 
Table 3.2: Dihedral angle (in degrees) for the ECL regions of M3 crystallographic structure Vs refined average structures 
(ECL1 residue # 131-136, ECL2 residue # 214-222 and ECL3 residue # 515-520) 
 
Clearly, the resulting ECL are also impacted by the choice of the template used, and how the 
model was refined. However, the rmsd of the between the alpha carbons of the constructed models 
and the crystallographic structure in general is tied to this. In particular explaining the loops that seem 
to occupy different space as such in the case of ECL2 of rhodopsin based and ECL3 of the histamine 
based constructed model.  
Second, comparison of the distance between the rough model, the refined model and the target 
Dihedral Dihedral 
residues 
Crystallogr
aphic 
structure 
 
M2->M3  
 
M2->M3 
+ NMS 
M2->M3 
+ 
Tiotropium 
Histamine-> 
M3 +  
Tiotropium 
Rhodopsin-> 
M3 + 
Tiotropium 
ECL1-1 N-R-W-A -107.1 -89.137 -100.208 -113.438 -57.709 97.597 
ECL1-2 R-W-A-L 174.5 136.118 138.438 104.12 -14.663 2.466 
ECL1-3 W-A-L-G 76.0 77.527 27.671 78.351 -122.438 4.853 
        
ECL2-1 T-V- P-P -155.3 -112.204 -107.778 -120.051 -109.049            -
121.127 
ECL2-2 V- P-P-G -86.3 -107.187 -101.638 -105.511 -79.735 -152.381 
ECL2-3 P-P-G-E 55.0 148.892 7.041 43.588 31.452 -77.230 
ECL2-4 P-G-E-C 47.3 34.782 83.542 64.672 95.754 -86.521 
ECL2-5       G-E-C-F -149.3 -139.267 -34.945 -153.601 -94.472 107.164 
ECL2-6 E-C-F-I 123.6 138.713 -156.9 131.849 -66.969 60.848 
        
ECL3-1 F-C-D-S -140.7 -1.271 -139.917 -142.147 47.916 15.743 
ECL3-2 C-D-S-C 33.9 46.808 3.294 0.656 48.326 4.000 
ECL3-3 D-S-C-I 105.3 77.83 97.969 114.569 50.473 -115.992 
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crystallographic M3 structure shows interesting results. Tables 3.3-3.7 shows the rmsd of the whole 
structures (a) and the TM region (b) for all the models constructed, comparing the template selected, 
the constructed rough model, 3 different types of refined model and the crystallographic structure of 
M3 Muscarinic receptor (the target).  The 3 different types of refined average structure depicted here 
are calculated from using different dielectric constant (ratio of the permittivity of a substance to the 
permittivity of free space) during the process of in vacuo minimization for the average structure. 
 
Table 3.3: The comparative rmsd between the whole structures (a) and only TM bundle when M2 muscarinic receptor was 
used as template and refined without ligand. D= Dielectric constant during in vacuo minimization. 
 
(a)       
 All residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00 1.559     0.531 2.047 1.905 1.885 
2. M3 
crystallographic  1.559 0.00 1.590 1.906 1.900 1.947 
3. Rough M3 
model                         0.531 1.590 0.00 2.068 1.988 1.985 
4. Average D=1 2.047 1.906 2,068 0.00     0.797 1.008 
5. Average D=2 1.905 1.900 1.988    0.797 0.00 0.621 
6. Average D=4 1.885 1.947 1.985 1.008     0.621 0.00 
       
(b)  
      
 
      
 TM residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00 0.946     0.473 1.801 1.728 1.762 
2. M3 
crystallographic                          0.946 0.00 1.164 1.904 1.819 1.861 
3. Rough M3 
model                         0.473 1.164 0.00 2.050 1.978 1.980 
4. Average D=1 1.801 1.904 2.068 0.00     0.795 1.004 
5. Average D=2 1.728 1.819 1.978     0.795 0.00     0.620 
6. Average D=4 1.762 1.861 1.980 1.004     0.620 0.00 
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Table 3.4: The comparative rmsd between the whole structures (a) and only TM bundle when M2 muscarinic receptor was 
used as template and refined with ligand NMS. D= Dielectric constant during in vacuo minimization. 
 
(a)       
 All residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00 1.559     0.531 1.911 2.072 2.075 
2. M3 
crystallographic  1.559 0.00 1.590 1.997 1.798 2.113 
3. Rough M3 
model        0.531 1.590 0.00 1.840 2.074 2.157 
4. Average D=1 1.911 1.997 1.840 0.00 1.165 1.201 
5. Average D=2 2.068 1.798 2.074 1.165 0.00     0.951 
6. Average D=4 2.075 2.113 2.157 1.201      0.951 0.00 
       
       
(b)       
 TM residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00     0.946     0.471 1.701 1.756 1.834 
2. M3 
crystallographic         0.946 0.00 1.158 1.765 1.696 1.902 
3. Rough M3 
model         0.471 1.158 0.00 1.836 2.070 2.152 
4. Average D=1 1.701 1.765 1.836 0.00 1.160 1.200 
5. Average D=2 1.756 1.696 2.070 1.160 0.00     0.950 
6. Average D=4 1.834 1.902 2.152 1.200 0.950 0.00 
 
 
 
Table 3.5: The comparative rmsd between the whole structures (a) and only TM bundle when M2 muscarinic receptor was 
used as template and refined with ligand Tiotropium. D= Dielectric constant during in vacuo minimization. 
 
(a) 
       
 All residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00 1.559     0.531 2.198 2.171 2.228 
2. M3 
crystallographic  1.559 0.00 1.590 2.001 1.742 1.944 
3. Rough M3 
model     0.531 1.590 0.00 2.174 2.061 2.122 
4. Average D=1 2.198 2.001 2.174 0.00 0.882 1.230 
5. Average D=2 2.171 1.742 2.061     0.882 0.00     0.861 
6. Average D=4 2.228 1.944 2.122 1.230      0.861 0.00 
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(b) 
       
 TM  residues 1 2 3 4 5 6 
1. M2 
crystallographic  0.00     0.946     0.531 2.057 1.986 2.054 
2. M3 
crystallographic      0.946 0.00 1.157 1.940 1.641 1.853 
3. Rough M3 
model     0.531 1.157 0.00 2.170 2.055 2.118 
4. Average D=1 2.057 1.940 2.170 0.00 0.876 1.224 
5. Average D=2 1.986 1.641 2.055    0.876 0.00     0.859 
6. Average D=4 2.054 1.853 2.118 1.224 0.859 0.00 
 
 
Table 3.6: The comparative rmsd between the whole structures (a) and only TM bundle when human histamine receptor was 
used as template and refined with ligand Tiotropium. D= Dielectric constant during in vacuo minimization. 
 
(a)       
 All residues 1 2 3 4 5 6 
1. HIS 
crystallographic  0.00 1.885     0.344 2.622 2.046 2.132 
2. M3 
crystallographic  1.885 0.00 2.121 2.556 2.369 2.453 
3. Rough M3his 
model                         0.344 2.121 0.00 2.654 2.045 2.179 
4. Average D=1 2.622 2.556 2.654 0.00 1.113 1.281 
5. Average D=2 2.046 2.369 2.045 1.113 0.00     0.845 
6. Average D=4 2.132 2.453 2.179 1.281     0.845 0.00 
       
 
       
(b)       
 TM residues 1 2 3 4 5 6 
1. HIS 
crystallographic  0.00 1.527     0.331 2.375 1.996 2.086 
2. M3 
crystallographic  1.527 0.00 1.801 2.552 2.368 2.439 
3. Rough M3 
model                         0.331 1.801 0.00 2.650 2.041 2.173 
4. Average D=1 2.375 2.552 2.650 0.00 1.108 1.275 
5. Average D=2 1.996 2.368 2.041 1.108 0.00     0.835 
6. Average D=4 2.086 2.439 2.173 1.275     0.835 0.00 
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Table 3.7: The comparative rmsd between the whole structures (a) and only TM bundle when bovine rhodopsin receptor was 
used as template and refined with ligand Tiotropium. D= Dielectric constant during in vacuo minimization. 
 
(a) 
 All residues 1 2 3 4 5 6 
1. RHO 
crystallographic        0.00 2.318     0.744 3.173 3.371 3.277 
2. M3 
crystallographic  2.318 0.00 2.308 3.707 3.183 3.002 
3. Rough M3 
model                         0.744 2.308 0.00 2.906 2.927 2.982 
4. Average D=1 3.173 3.707 2.906  0.00 0.986 1.257 
5. Average D=2 3.371 3.183 2.927     0.986 0.00 1.007 
6. Average D=4 3.277 3.002 2.982 1.257 1.007 0.00 
       
       
(b)       
 TM residues 1 2 3 4 5 6 
1. RHO 
crystallographic  0.00 2.297     0.734 2.701 3.063 2.927 
2. M3 
crystallographic  2.297 0.00 2.239 3.666 3.090 2.912 
3. Rough M3 
model                        0.734 2.239 0.00 2.890 2.910 2.970 
4. Average D=1 2.701 3.666 2.890 0.00     0.980 1.249 
5. Average D=2 3.063 3.090 2.910    0.980 0.00 1.000 
6. Average D=4 2.927 2.912 2.970 1.249 1.000 0.00 
 
 
While in some cases the rough model seemed to have much better rmsd when compared with 
the crystal structure, it should be noted that the rough model are not refined (may contain structural 
kinks) and there are trade off afforded by the refinement process such as correction of the length of 
TM segments of the constructed models and relaxing the structure kinks, and refining the binding 
pocket.  Clearly, the dielectric constant used in the minimization of the receptors plays a significant 
role. Implicit methods for modeling protein electrostatics require dielectric properties of the system 
to be known, in particular, the value of the dielectric constant of protein. However, the protein 
dielectric constant is not a constant but is a complex function reflecting the properties of the protein 
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structure and sequence [44]. By comparing the rmsd value obtained when dielectric of 1, 2 or 4 was 
used, the rmsd values obtained when dielectric constant of 2 was used are much closer to the rmsd 
M3 crystallographic structure than 1 or 4. Hence all average structures (the refined models) presented 
here were obtained after in vacuo minimization at a dielectric constant of 2. 
 
 
3.5 Analysis of the refinement process 
In order to understand the role played by molecular dynamics as refinement method of the 
initial models generated by homology modeling, the evolution of the distance (rmsd of the C) 
between the different models and the crystallographic structure of the target along the refinement 
process was analyzed. Figure 3.6 (a) shows the evolution during the refinement process of the residues 
of the TM region for the different M3 models generated in the present work and the M3 
crystallographic structure and similarly, Figure 3.6 (b) shows the rmsd evolution considering the whole 
protein. As can be seen the Figures clear stress the marked differences of the starting points that 
correlates well with the distance of the difference templates in the phylogenetic tree. The most 
interesting result is the negative slope exhibited by the rmsd vs time, suggesting that the refinement 
process improves moderately the quality of the models. Improvements measured on the a rmsd are 
between 0.5-0.8 Å. In contrast, no improvement is observed when all the atoms of the protein are 
considered, probably due to the fluctuations of the loops along the trajectory.  
Interestingly, the differences observed in these Figures differ slightly from those of Table 3.7 
because there comparison is made with the average structure and because of the TM regions used 
here for comparison are those as defined in the rough model at the beginning, while in Table 3.7 was 
calculated using TM as defined in refined model. 
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(a)  
(b) 
 
Figure 3.6. (a) rmsd evolution along the trajectory of the distance between the TM regions of the different M3 models computed 
in this work and the M3 crystallographic structure computed using the alpha carbons. (b) same as (a) considering the whole 
protein. 
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3.6 The effect of ligand addition in simulation process 
The addition of a ligand in the refinement process provides significant advantages to the 
constructed atomistic models during the refinement process. For example, as shown in Figure 3.4 (a), 
the convergence of models with a ligand bound is achieved relatively faster when ligand is included in 
the refinement process. Notably, it took 25 ns for M2 based model receptor refined with Tiotropium 
bound system and 50ns for that containing NMS to equilibrate, while about 300ns were required for 
the M2 based receptor model that was refined without any ligand to equilibrate. Interestingly, shorter 
equilibration times were observed for Histamine H1 and Rhodopsin based models since they were 
refined with a ligand inside. Which further prove the addition of a ligand in the refinement process 
makes the process more robust since convergence is observed at earlier times in models refined with 
ligand bound in the system rather than those without ligand.  It should also be taken into account that 
much shorter times can be observed if only the helical section of the receptors is considered Figure 
3.3 (a).  
These results show a comparative and that has also experimental credence to the stability that 
addition of a ligand offers to the protein system. For example, several studies including the T4L fusion 
protein crystallography strategy, and other experimental studies have provided with evidence that 
supports the idea that ligand (both agonist and antagonists) binding stabilize a receptor. Also an 
increasing number of ligand bound crystallographic structure of GPCR give credence to stabilization 
properties of ligands [45-49]. 
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3.7 Comparison between the constructed models and the M3 muscarinic crystallographic 
structure 
3.7.1 Crystallographic structure Vs Modeled structure (M2 muscarinic receptor template)  
As explained above, three different models that use the M2 muscarinic receptor as template 
were constructed and refined. The addition of the ligand in the refinement process does not only have 
effect on the time it takes the receptor to equilibrate, it also affects the structure features of the final 
refined model.  Looking from the extracellular side the orthosteric binding site appears more compact 
(Figure 3.7: a-c) as in the crystallographic structure while in rough models it is more significant vacuous 
(data not shown but can be gauged from the difference in the rmsd between rough and refined models 
(table 3.3-3.5).Furthermore, the outward bend seen at the extracellular end of TM4 is present in both 
the refined models and the crystallographic structure of the M3 receptor. 
 
1.90 Å 
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Figure 3.7: Comparison between the crystallographic structure of M3 muscarinic receptor and refined models constructed 
using M2 receptor refined without ligand (a), with ligand NMS (b) and with ligand Tiotropium (c). Their comparative rmsd is 
also noted. 
 
1.79 Å 
1.74 Å 
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Another difference between the crystallographic structure and the models constructed from 
the M2 muscarinic receptor as a template is observed in the length of the TM regions, specifically in 
the TM3 and TM6.  The refinement process attempted to correct the length and was successful in TM3 
for the models refined ligand and for that refined without a ligand the differences was residues to one 
residues (Table 3.1). For TM6, the refinement process was able to reduce the difference in length from 
four to two residues in the structure refined without ligand and four to one residue in both of the 
structure refined with a ligand.   
 
3.7.2 Crystallographic structure Vs Modeled structure (human histamine 1 and bovine rhodopsin 
receptor as template)  
 
Comparison of the models generated form human H1 and bovine rhodopsin point to the 
absence of the pronounced outward bend at the extracellular end of TM4 found in the crystallographic 
structures of the M2 and M3 muscarinic receptors (Figure 3.8 (a )and (b)). In the model of M3 
constructed using the histamine H1 receptor with bound Tiotropium yields a ECL3 extracellular loop 
that does not fit well with the structure of the target (Figure 3.5). 
In regard to the length of the TM segments the refinement process reduces slightly the 
differences found in the starting structure (Table 3.1), but differences are still remarkable. For example 
for the model constructed using as template the human histamine 1 receptor, TM1 is seven residues 
shorter; TM2 and TM3 are one residue shorter; TM4 four residues shorter catching up part the eight 
residues shorter of the starting model; TM5 is remains one residue longer; TM6 is seven residues 
longer correcting in part the eleven residues of the starting structure and TM7 is corrected to the 
correct TM length. 
 The differences in the intracellular end of TM5 and thusly the ICL3 where lysozyme is attached 
in the crystallographic structure of histamine 1 receptor can be attributed to the resulting differences 
in length for TM3. This also affects or is affected by the residues in the target ICL3 that had to be 
significantly reduced. As previously mentioned ICL3s of muscarinic receptor subtypes are long and can 
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be reduced without affecting the overall function of the receptor. 
In the model of M3 muscarinic receptor constructed using the crystallographic structure of 
bovine rhodopsin receptor and refined with Tiotropium bound, the extracellular loop ECL2 does not 
fit well with the structure of the target ECL2 it appears to occupy a slight different space. In regard to 
the length of the TM segments the refinement process reduces slightly the differences found in the 
starting structure (table 3.1), but differences are here are the most highest recorded. With the 
template being also the furthest from the target in the phylogenetic tree, and having the lowest 
sequence similarity between template and target, all the noted can be thusly attributed.  To annotate, 
TM1 is one residue shorter; TM2 is two residues; TM3 is four residues shorter; TM4 is reduced to eight 
residues shorter by the refinement process; TM5 is three residues longer and TM6 is seven residues 
shorter while TM7 is perfectly corrected by the refinement process. 
(a) 
 
 
 
 
 
2.36 Å 
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(b) 
 
Figure 3.8: Comparison between the crystallographic structure of M3 muscarinic receptor and refined models constructed 
using human histamine 1 receptor and refined with Tiotropium (a), and that constructed using bovine rhodopsin receptor and 
refined with Tiotropium (b). Their comparative rmsd is also noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.66 Å 
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3.8 Conclusions to chapter 3 
In validating both the constructed models and the methodology used to construct them, both 
the choice of the template as well as the length and manner (with ligand Vs without ligand) were 
observed. Clearly, the simulation time of 500 ns is an adequate simulation time to evaluate and make 
conclusion on the objectives. The refinement process is also able to correct the length of the TM 
helices from the starting rough models. 
 While the constructed atomistic models capture most of the features of the M3 receptor, the 
rmsd and general structure conformation observes here shows that the higher the sequence 
homology between the target and the template the better the results. By comparing phylogenetically 
distant (bovine rhodopsin receptor), to the closest evolutionary templates (M2 muscarinic receptor), 
a clear effect of evolutionary distance between the templates and our target receptor was observed. 
Hence, the higher the sequence homology between the target and the template, the more accurate 
the models constructed and the accuracy correlates with the distance between the template and the 
target receptors in the phylogenetic tree. 
Moreover, inclusion of a ligand on the modeling makes the refinement process more robust since 
the convergence is observed at earlier times in model refined with ligand bound rather than in those 
refined without ligand. This approach is more suitable in such occasions where time and resources are 
limited in modeling target receptors. Unfortunately this cannot overcome much the hurdle of choosing 
unsuitable receptor template. Analysis of both the rmsd, the rmsf and the equilibration times during 
the trajectory in the model refinement process support this conclusion. At 17% and 34 % sequence 
homology with our target refinement with ligand did not improve the quality of the resulting model, it 
did however have effect on equilibration time. While this in itself is not a deterrent for general virtual 
screening purpose, for those receptor-ligand whose some of the interaction are mediated by residues 
in the loops, more attention must be paid in designing loops separately  for example chimeric,  in order 
to elevate the quality of the results.  
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However, since the addition of a ligand affect the length of the sampling time and the template 
selection the structural quality of the resulting models, all these factors needs to be preferably applied 
upon when constructing homology models. 
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4.0 Chapter summary 
Bradykinin (BK) is a nonapeptide involved in several physiological and pathophysiological 
conditions including among others, septic and hemorrhagic shock, anaphylaxis, arthritis, rhinitis, 
asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for 
therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors 
known as B1R and B2R. Although there are several B1 antagonists reported in literature, their 
pharmacological profile is not yet optimal, thus new molecules need to be described.   
Knowledge of the stereochemical requirements of the ligand-receptor at this receptor could help 
in this direction. The absence of a crystallographic structure of B1R prompted a construction of an 
atomistic model of the B1R. The model was constructed by homology modelling using the chemokine 
CXC4 and bovine rhodopsin receptors as template. The model was further refined using molecular 
dynamics with the protein embedded in a POPC bilayer. Simulations were run for 600 ns.  
From the simulations, an average structure was obtained that later used for docking studies using 
Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, 
Chroman-28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study show the role 
of specific receptor residues in ligand binding. These results permitted the definition of a 
pharmacophore that describes the stereochemical requirements of antagonist binding, and were used 
in the development of new compounds with varied activity B1R inhibition profile depending on the 
number of pharmacophoric points fulfilled by the designed antagonistic molecules. 
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4.1 Introduction 
Bradykinin (BK) is a member of the kinin family, a group of structurally related polypeptides that 
act locally to induce vasodilation and smooth muscle contraction. Kinins are liberated from the 
kininogens through the action of a set of serine proteases called Kallikreins.   There are two types of 
kininogens, high-molecular weight kininogen and low molecular weight kininogen; cleavage of high-
molecular weight kininogen by kallikreins produces BK (Figure 4.1) and cleavage of low-molecular 
weight kininogen produce Kallidin (a decapeptide that has the same amino acid sequence as BK with 
the addition of a Lysine at the N-terminus) [1-2].  Kallidin is sometimes referred to as Lys-BK, and will 
thusly so be referred as from this point onwards where appropriate. 
The kinins are converted into vasoactive peptides and the major physiological role appears to be 
the local response to tissue injury and as an agent to aid in tissue repair. Therefore, both tissue and 
plasma Kallikreins found are activated to produce the kinins by a number of physiological traumas. 
Once produced, BK and Lys-BK have a number of pharmacological effects which are virtually identical 
for the two peptides. Despite their similar pharmacological profiles, BK has by far been the most 
extensively studied of the two peptides [1, 3-4]. 
 It should be noted that BK is also a very powerful vasodilator that increases capillary permeability 
and in addition constricts smooth muscle and stimulate pain receptors. Thus, BK is involved in several 
pathophysiological conditions including among others septic and haemorrhagic shock, anaphylaxis, 
arthritis rheumatoid, rhinitis, asthma, inflammatory bowel disease etc. [1-4].  
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       Figure 4.1: Chemical structure of the peptide bradykinin (BK) 
Most physiological and pathophysiological effects of the kinins are believed to be mediated by 
the activation of two GPCRs: BK receptor 1 (B1R) and BK receptor 2 (B2R). The physiological ligands 
acting on B2R in humans are BK and Lys-BK. In contrast, BK is believed to be the only kinin acting on 
the B2R in rat and mouse. However, a decade ago a Kallidin-like peptide (KLP=Arg-BK) was isolated 
from plasma and urine of rats. The naturally occurring metabolites of Kallidin and BK, des-Arg10-
Kallidin (desArg10-Kallidin) and des-Arg9-BK) are binding with high affinity to the B1R [5]. 
The pharmacological properties of the B1R in binding the endogenous kinin peptides are known 
to differ across species. Molecular cloning has revealed that these pharmacological differences arise 
from the diversity within the BDKRB gene [6]. The amino acid sequences of both receptors show an 
overall homology of only 36%, however, with higher areas of homology in the transmembrane regions. 
Despite their relative low homology, the receptors appear to share similar signal transduction 
pathways, such as activation of phospholipase C that leads to the release of inositol phosphates and 
increase in intracellular [Ca2+] levels, in response to binding of agonists [7]. 
In separate binding assays, the potency order of agonists were established (Table 1) and 
demonstrated that the removal of the C-terminal arginine is essential for high affinity on the B1R and 
detrimental for affinity toward the B2R. This holds true for Kallidin and des-Arg10-Kallidin, which have 
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higher affinities for the human and rabbit B1Rs compared with BK and des-Arg9-BK, respectively. 
However, the pharmacology of the mouse receptor is unique in that it possesses a 2-3-fold selectivity 
for des-Arg9 -BK over the agonist des-Arg10-Kallidin [8]. 
While B2R are constitutively expressed in tissues, B1R molecules are not normally expressed in 
tissues but behave as key inducible molecules. In fact B1Rs are normally absent and may be highly 
upregulated following inflammatory stimuli (bacterial endotoxin, LPS-12h, ischemia, IL1, TNFαβ). This 
is an unusual characteristic of G-protein-coupled receptors. In fact, the pattern of induction of B1R 
resembles more closely to tyrosine-kinase-linked receptors. Kinin B1R seem to be upregulated under 
the same conditions described for the inducible pro-inflammatory enzymes (COX-2, iNOS). More 
recent reports indicate the existence of a crosstalk between B1R and B2R.  
 
Table 4.1: Affinity Estimation (Ki) of kinins obtained using radio-ligand binding assay for recombinant kinin receptors, adopted 
from [3]. 
                   Humans             Mice              Rabbits 
Peptide  B1R B2R B1R B2R B1R B2R 
Bradykinin > 10,000 0,54 200 0,48 >5000 4.5  
Kallidin (Lys-BK) 2.54 0.63 510 0.52 19 2  
des-Arg9 -Bradykinin 1930 8100 0.7  6400 32 >1000 
Des-Arg10-Kallidin 0.12 >30,000 1.7 25,000 0.23 >1000 
 
 
Evidence also shows that persistent stimulation of B2R may result in B1R receptor 
upregulation. It is worth noting that stimulation of B2R receptors leads to transient increases in Ca2+ 
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concentration and to the fast desensitisation of these receptors.  For the B1Rs, they do not seem to 
be susceptible to desensitisation mechanisms and their stimulation results in sustained elevations of 
Ca2+ concentration [9]. Both receptor subtypes for kinins can be expressed by the same cell types: 
vascular cells (endothelial, smooth muscle), fibroblasts, epithelial cells, nervous cells, and various 
tumor cells [3].Accordingly, BK antagonists have long been sought after for therapeutic intervention. 
However since the B2R is constitutively expressed on the membranes of most cells and most of the 
physiological and pathological processes of BK are mediated through this receptor, most attempts to 
develop antagonists of BK have been directed at the B2R. As it can be deduced, the fundamental 
distinction for ligand binding between the two receptors is that the B2R requires the whole 
nonapeptide for effective binding and activation, while the B1R selectively binds to the desArg9 
metabolites of BK and Lys-BK [1-4].  
While stride has been made in the antagonism of B2R with the market release of Icatibant a 
peptidic antagonist of the receptor, there is no drug currently in the market designed to antagonize 
the B1 bradykinin receptor [10-11]. The B1R is not normally expressed in tissues, but has recently 
received a greater amount of attention as pre-clinical studies has implicated the expression of B1R in 
establishing and maintaining the signaling of chronic and inflammatory pain [3,12-13]. Furthermore, 
studies have also indicated B1R to be involved in hyperalgesia and leucocyte infiltration through the 
activation of a cytokine network. Thusly effective and selective and B1R antagonist are desirable as 
therapeutic agents for the treatment of both pain and inflammation [14-18]. 
The goal of the present work is to carry out a structure-activity study of B1R antagonism, taking 
into account the stereochemical features of diverse non-peptide antagonists and the way these 
features translate into ligand anchoring points of complementary regions in the receptor, through 
the analysis of the respective ligand-receptor complexes.  
The compounds selected for the present study include: Compound 11 (1) [19-21], Compound 12 
(2) [22-23], NPV-SAA164 (3) [24-25], Chroman-28 (4) [26-27], SSR240612 (5) [28] and PS020990 (6) [29] 
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shown in Figure 4.2. Compounds were docked into a refined model of the B1R constructed by homology 
modeling following the procedure explained in the methods section and the complexes were 
subsequently analyzed for their ligand-receptor interactions. The outcome of this study is summarized 
on a 3D pharmacophore that explains the observed structure-activity results and provides insight into the 
design of novel molecules with antagonistic profile.  
           
Figure 4.2: Chemical structures of the B1R antagonists studied in the present work. Compound 11 (1), Compound 12 (2), 
NPV-SAA164 (3), Chroman-28 (4), SSR240612 (5) and PS020990 (6). 
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4.2 Homology modeling of the B1R 
 
A starting model of the human B1R was constructed by homology modeling using the chemokine 
CXCR4 [30] as template that shares about 25% overall sequence similarity with the B1R. The template 
was selected due to its proximity to B1R in the GPCRs phylogenetic tree among those GPCRs whose 
crystallographic structure is known. The sequences of the two receptors were aligned, taking into 
account the conserved motifs found in all GPCRs, as well as the location of the six disulfide bridges. 
Since the chemokine CXCR4 lacks the helical TM8, residues of B1R known to be in the TM7 of all class 
GPCR starting from  the highly  conserved NPXXY motif [31] were modeled from the crystal structure 
of the bovine rhodopsin pdb entry code: 1GZM [32]. These motifs, together with salt bridges are 
important factors in constraining the conformation of the extracellular and transmembrane domains 
of the B1R. From the aligned sequences a starting model of the receptor was constructed using the 
Modeller 9 version 8 (9v8) software [33].   
Model validation was carried out using the Molecular operating Environment (MOE) program 
[34]. In a subsequent step the B1 antagonist Compound 11 (1 in Figure 4.2) was docked into the 
starting model using the GLIDE software [35]. The choice of this ligand was due to the abundant 
information available from the effect of mutations on its binding affinity [19-20]. Finally, the ligand-
receptor complex was refined using molecular dynamics of the system embedded in a lipid bilayer.  
Specifically, the protein was embedded in a box consisting in a 1-palmitoyl-2- oleoyl-sn-glycero-
3-phosphocholine (POPC) lipids and water molecules generated and equilibrated according to the 
procedure described previously. The box had an initial size of 9.5 x 9.7 x 15.6 nm3 (XYZ), organized in 
such a way that the bilayer plane was oriented on the XY plane. Before protein insertion, the box 
contained 256 lipids (corresponding to an area per lipid of 0.64 nm2) and about 15,000 water 
molecules. The protein was placed in the center of the box, and the overlapping molecules were 
removed. Specifically, all water molecules with oxygen atoms closer than 0.40 nm to a non-hydrogen 
atom of the protein, as well as all lipid molecules with at least one atom closer than 0.25 nm to a non-
hydrogen atom of the protein were removed. This resulted in a final system containing 242 lipids and 
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approximately 11,000 water molecules. Removal of these atoms produced small voids between the 
protein and water or lipid molecules that disappeared during the first part of the MD simulation, in 
which a progressive adjustment of the lipid bilayer and water molecules to the protein takes place. 
Next, 172 water molecules were randomly selected and replaced by 79 sodium and 93 chloride ions, 
providing a neutral system with a concentration approximately 0.2 M on sodium chloride. This 
concentration is fairly similar to that found in biological organisms, although they exhibit different 
intra- and extra-cellular ion concentrations. Sampling was carried out for 600ns using GROMACS 
package 4.6 [31].  
The final model of the B1R was generated from the average structure of the molecular dynamics 
trajectory using the last 100 ns. The average structure of the receptor was subsequently minimized in 
a two-step process using the steepest descent method with a distance dependent dielectric constant 
of 2. First, side chains are optimized with the backbone atoms constrained to be subsequently released 
in a second minimization. This structure was used for further docking studies using the GLIDE [35] 
software. Due to the flexibility of the ligands, the docking process was carried out using a set of unique 
conformations resulted from thorough conformational searches. Poses were rank ordered using the 
XP score function of GLIDE [37]. Final poses of the compounds were decided based on their ranking 
and fulfillment of site directed mutagenesis information available. 
 
 
4.3 Results and discussion 
 
As mentioned above, in the absence of a crystallographic structure, an atomistic model of B1R 
was constructed by means of homology modelling.  As explained in chapter 3, several experimental 
challenges hampers the availability of crystallographic structures of GPCRs, including their low-
expression yields, low receptor stability after detergent extraction from native membranes, and high 
conformational heterogeneity. Although the number of the crystallographic structures available has 
steadily increased during the last few years, homology modelling remains to be one of the important 
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techniques to construct 3D models of proteins. However, in order for the models constructed to be as 
accurate as possible, the procedure requires a careful choice of the template and a robust refinement 
procedure [39-41]. This is important because from the analysis of the diverse known structures, 
although they share a common seven helix bundle, each structure exhibits specific features that might 
be relevant for ligand design [42].  
The N terminal of the B1R as well as TM1-TM6 and part of TM7 was constructed using CXCR4 
chemokine receptor (PDB entry code 3ODU) [30] as a template, while the part of TM7 starting from 
the conserved motif NPXXY was constructed using bovine rhodopsin as a template (pdb entry code 
1GZM) [32]. Figure 4.3 shows the alignment of the sequences of the CXCR4 and B1Rs carried out taking 
into account the conserved motifs found among GPCRs, as explained in the methods section. This 
procedure is crucial for the assignment of the transmembrane regions. This information is then given 
as input to the Modeller software that produces a rank order set of models based on a scoring 
function. The final model selected for refinement was the one with the least steric conflicts from those 
that incorporated all the specified constraints considered to be conserved among GPCRs. 
Previous experience in GPCR homology modeling [39] suggests that the presence of the ligand 
permits a faster equilibration of the system.  Accordingly, Compound 11 was docked into the initial 
model. Several docking attempts were carried out using diverse conformations that were generated 
automatically as explained in the methods section. The final complex considered for refinement was 
selected based on the degree of fulfilment of diverse site directed mutagenesis studies. The B1R –
Compound 11 complex was embedded into a pre-equilibrated bilayer of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and water and subjected to a molecular dynamics simulation. Time 
evolution of the root mean square deviation (rmsd) of the alpha carbons of the protein as well as 
those of its helical bundle subset is shown in Figure 4.4. Inspection of the Figure indicates that when 
all the alpha carbons of the protein are considered equilibration is reached after 350 ns, whereas when 
the helical bundle subset is used equilibration is reached about 100 ns earlier.  
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Figure 4.3: Sequence alignment of human B1R, human CXC4 chemokine receptor and bovine rhodopsin receptor (TM8 only). 
 
These results support the choice made in the present work of using the last 100 ns of the 
refinement process for the generation of an atomistic model of the B1R. As explained in the chapter 
3, the last 100 ns segment of the molecular dynamics trajectory was used to generate an average 
structure that was subsequently minimized in a two-step process using the steepest descent method 
with a distance dependent dielectric constant of 2.  
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Figure 4.4: Time evolution of the rmsd of the B1R during the refinement process. In black is the rmsd of the alpha carbons of 
the protein and in red the rmsd of the alpha carbons of the helix bundle subset. 
 
The orthosteric site of the B1R can be described as a large highly hydrophobic pocket formed 
by TM2, ECL1 and TM7 including residues like Trp93, Ile97, Phe101, Phe299, Phe302 and a on the bottom 
left of the binding pocket. Interestingly most interactions at this side of the pocket involving Trp93, 
Phe101 and Phe299 are coupled through quadrupole-quadrupole interactions. On the bottom right of 
the binding both polar and hydrophobic residues makes the binding site. Residues such as Asn114 in 
TM3, Arg202 of TM5 and Tyr266 of TM6 are found on this binding pocket side. On the other hand, at the 
top and mouth of the binding site there are several polar residues including, Glu196 and His199   of TM5, 
Glu273 and Gln277 of TM6 and Glu287, Asp288, Asp291 of TM7.  Figure 4.5 shows the orthosteric pocket of 
the receptor. Described below are the bound conformation of each of the diverse antagonists used in 
this study, obtained from docking studies on the refined model. 
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(a)                                                                             (b) 
Figure 4.5: (a) Lateral view of the orthosteric binding pocket of the human B1R modeled in complex with compound 11, ( b) 
same as (a) viewed from the extracellular side (aerial). 
 
 
 
 
4.4 Antagonist of B1Rs  
 
Compound 11 
 
Developed by Merck research laboratories, compound 11 exhibits notable binding affinity for 
B1Rs in various animal species. In humans the Ki value of the compound is 0.034nM and decreases to 
0.05nM in rabbit, 1.28nM in dogs and 62nM in rats [21]. The compound was discovered through an 
initial high-throughput screening, which led to the development of dihydroquinoxalinone as lead 
compound. Through homology modeling studies and structure-activity relationship studies (SAR), the 
affinity and potency of the lead molecules was optimized and leading to compound 11 [19]. Compound 
11 has shown to antagonize both des-Arg9-BK and Lys-des-Arg9-BK induced contraction of the rabbit 
isolated aorta [18]. 
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As can be seen in Figure 4.6, our B1R-compound 11 complex shows both the 
dihydroquinoxalinone moiety and the aromatic ring on the substituted sulfonamide (phenyl 
sulfonamide) added at the second nitrogen of the lead molecule occupying the hydrophobic pocket 
formed Try103, Ile97 among other at the bottom of the binding pocket. A poor interaction can be noted 
between the Asn114 and the dihydroquinoxalinone moiety N1, but substitution of N1 with methyl 
group diminished the potency thus it was deduced sulfonamide was the key to further modification.  
Similar results were obtained by Merck researchers from a homology modeling study using 
the bovine rhodopsin crystal structure as template in the process of lead optimization of compound 
11.  Mutagenesis studies shows that mutations at residues Ile97, Trp98, Asn114, Gln295, Asp291 and Glu273 
affect the binding affinity at various degrees while mutation in Asn298 has little impact on the binding 
affinity [20], implying that the residues Ile97, Trp98, Asn114, Gln295, Asp291 and Glu273 are among those to 
interact directly with the Compound 11. 
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Figure 4.6: Pictorial view of B1R antagonist Compound 11 bound to the B1R. 
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Via the imidazole ring which has been noted to boost affinity to subnanomolar affinity, both 
TM6 residue Glu273 and TM7 Asp291 sidechains interacts with Compound 11 by forming hydrogen 
bonds. Hydrogen bonds are also observed between sulfonyl oxygen of the sulfonamide, Nitrogen and 
carboxyl group of the dihydroquinoxalinone and sidechains of Gln295 in TM7, Asn114 in TM3 and Arg176 
at the N terminus of ECL2 respectively. Comparatively in our model, Trp98 is seen at the end of TM2 
(N terminus of ECL1) also the mouth of the hydrophobic pocket of the binding site and its aromatic 
sidechain is positioned away from the binding pocket. 
 It can be speculated that Trp98 contributes to facilitate the passing of the ligand to the pocket 
rather than on binding itself.  Instead the dichlorophenyl moiety is situated at a suitable distance for 
hydrophobic interactions with Ile97 and π-π interactions with Trp93 of TM2. In TM6, hydrophobic 
interaction between Tyr266 and the benzyl side of the dihydroquinoxalinone group is observed. 
Another hydrophobic interaction between the sidechain of His199 in TM5 and the phenyl group 
attached to the imidazole is observed. Asn298 in TM7 is observed to be close enough to interact with 
the sulfonyl oxygen but the conformation is unsuitable for hydrogen bond formation. Mutagenesis 
data indicate that Asn298 has little effect in the binding of the antagonists. Indeed, mutagenesis studies 
suggest that any hydrophobic residue at this position is suitable for binding. These findings are in 
agreement with aforementioned SAR and mutagenesis studies results. 
 
Compound 12 
Like Compound 11, compound 12 was also developed by Merck research laboratories through 
optimization of novel benzodiazepines found to be B1R antagonists through in-house screening [22]. 
Replacement of dimethylamine group at the terminus end of the lead compound with hydrogen 
rendered the resulting compound unable to bind to B1R, but modification of the chemical group to 
piperidine led to an increase in activity and doubled the affinity. Further modification at piperidinyl 
with an addition on nitrogen, making a pyridine-piperazine group had a desirable effect on the affinity 
of the compound albeit with dependence to the position of the added nitrogen. At position 2 or 3 
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marked a notable decrease in affinity, so was the deletion of the pyridine nitrogen. Thusly a 4-
pyridinylpiperazinyl group was deemed important and reduced basicity at this position was attributed 
to a decrease in the binding affinity. On the other end ,at the core benzodiazepine C-5 position  an 
addition of phenethyl group rather than shorter alkyl group c-hexyl enhanced affinity by 4-fold  at 
human and 9-fold at rat B1R [22]. 
This SAR information agrees with the bound conformation obtained when Compound 12 was 
docked to the refined human B1R model. Present results (Figure 4.7) show that the 4-
pyridinylpiperazinyl interacts with several residues at the hydrophilic mouth of the binding pocket. 
Specifically, the 4-pyridnyl- end forms a  hydrogen bond with the side chain of Asp291 in TM7 while the 
piperazine group interacts with His199 in TM5. An interaction with Gln295 in TM7 is mediated through 
the carbonyl group found in the middle of the molecule. In addition, the ligand forms a hydrogen bond 
between the carbonyl of the diazepine ring and Asn114. Aromatic residues at the bottom left of the 
binding pocket (Trp93 in TM2, and Phe299 in TM7) are shown to be π-π stacked by the benzyl group 
while phenethyl moiety is seen to interact with both the Trp93 in TM2 and the Phe101 of the ECL1. In 
the absence of mutagenesis studies information, our results are in accord with the SAR studies 
information. 
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Figure 4.7: Pictorial view of B1R antagonist Compound 12 bound to the B1R. 
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NPV-SAA164 
Developed by Novartis, NPV-SAA164 is an orally bioavailable antihyperalgesic that acts as a 
B1 antagonist with Ki of 8nM in HEK293 cells expressing human B1R and no activity in rat B1R [24-25]. 
Through in-house successful screening of non-peptidic B2 antagonists [38], binding affinity to B1 was 
assayed and led to the development of lead molecule 2-alkylamino-5-sulfomoybenzamide. Further 
investigation of the moieties in the lead molecules and their SAR optimization yielded NPV-SAA164. 
Although there are no mutagenesis studies available that can help to understand the effect of diverse 
mutations on the binding of NPV-SAA164 to B1R, but there is information about the effect of diverse 
chemical substitutions on the lead molecule [23] that can be analyzed through view of the complex 
model (Figure 4.8). For example, chemical replacement of the morpholine group to primary or 
secondary amide rendered the molecule inactive and to chlorine resulted to in lower affinity while 
those to tertiary amide improved the activity suggesting that at this position an ability to form both a 
hydrogen bond (both accepting and donating) is favored. In our B1R - NPV-SAA164 complex model, 
the morpholine group can be seen interacting with Arg202 in TM5 as well as Tyr266 in TM6. Asn114 can 
also be seen exposed to the moiety.  
The two phenyl groups in the lead compound are observed to bind in the aromatic pocket of 
our B1R model, the groups adopt a branched out conformation that allows NPV-SAA164 to interact 
with both the Trp93 at the bottom of the aromatic pocket in TM2 and both Phe101 in ECL1 and Leu292 in 
TM7, at the top of the aromatic pocket. At the mouth of the binding pocket, the methyl-piperazine 
group form hydrogen bonds with the side chain of Asp291 in TM7. Furthermore the piperidine moiety 
is positioned to interacts with the aromatic imidazole ring of His199 in TM5 and the carbonyl group 
linking morpholine and phenyl-sulfonamide can be seen directly interacts with Gln295 via a hydrogen 
bond. 
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Figure 4.8: Pictorial view of B1R antagonist NPV-SAA164 bound to the B1R. 
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Chroman-28 
Chroman-28 developed by Amgen Inc., is a potent and selective antagonist of human, primate, 
rat, and rabbit B1Rs with anti-inflammatory activity and Ki between 0.7 nM at human B1Rs [26].  
Chroman-28 was developed through efforts to optimize spatial placement of lipophilic sulfonamide 
and basic amine moieties previous noted to be important for binding affinity and activity as B1R 
antagonist [39]. The earlier resulting compound had moderate activity against B1R and selectivity over 
B2. Addition of one methylene group in order to extend the distance between the two groups yielded 
another lead but did not improve the activity. Further modification on the second lead aimed at 
decreasing the flexibility of the compound so as to minimize the entropic penalty associated with 
adopting the preferential binding conformation led Chroman-28 and its analogues with improved 
potency [26, 45].  
The SAR results for Chroman-28 and analogues at the piperidine group position showed that 
a hydroxyl group or a small amine NH2 decreases the pharmacokinetic properties of the lead 
compound, a pyrrolidine group or butyl amine improves the activity while a methylated piperidine 
decreases the activity. Furthermore changing the Chroman group to tetrahydro-naphthalene also had 
negative impact of the activity while modification at the sulfonamide to a bulkier aryl sulfonamide 
(naphthysulfonamide) led to an improvement in both activity and cellular potency [41] 
Figure 4.9 shows the adopted conformation of Chroman-28 in our refined human B1R model. 
Hydrogen bonds are also observed between sulfonyl oxygen of the sulfonamide and residue Gln295 in 
TM7, oxygen of the Chroman group and His199 (including a hydrogen – aromatic ring interaction), 
Asp291 in TM7 and the piperidine nitrogen, and carbonyl group of the amide group and Arg202 both of 
TM5. Furthermore the sulfonyl oxygen also interacts with Arg176 at the N terminus of ECL2 via a 
hydrogen bond. The naphthalene group in aromatic pocket can be seen quadruple- quadruple interact 
with Trp93 in TM2, as well as Phe101. Phe299 in TM7 and Ile97 in TM2, a notable important residue in B1 
antagonism, are in the vicinity to interact with the naphthalene group. Tyr266 residue at TM6 can be 
seen to interact with the phenyl group, albeit at a bit longer distance. 
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Figure 4.9: Pictorial view of B1R antagonist Chroman-28 bound to the B1R. 
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SSR240612 
SSR240612, exhibits an inhibitory profile of Lys-des-Arg9 binding in HEK cells expressing human 
B1R and MRC5 human lung fibroblast B1 expressing cells. Developed in 1997 by Sanofi research 
laboratories in France, SSR240612 was the first B1R antagonist with proven efficacy and oral 
bioavailability in models of pain and inflammation [28, 47]. In published literature, there are no reports 
on SAR nor site directed mutagenesis studies conducted on the compound. Taking in account the XP 
glide scores for the docking calculation performed with this molecule as well as bound conformation 
of other non-peptide B1R antagonists, Figure 4.10 shows a putative bound conformation of 
SSR240612. 
An amide carbonyl at the middle of the molecule is observed to interact with Gln295 at TM7 
via hydrogen bond. On the other hand, a hydrogen bond is observed between the sulfonyl oxygen of 
sulfonamide and the side chains of residues Arg174 at TM4 and Asn114 in TM3. Apparently, the 
sulfonamide behaves as a linker of two binding pockets. Specifically, the methoxy-naphthalene group 
on the right side interacting with residue Tyr266 in TM6 and Asn298 in TM7 and on the left side, the 
benzyl group in benzodioxole moiety interacting with aromatic ring of Trp93 sidechain while the oxygen 
in diaxole interacts with Asn96 via hydrogen bond. Like in Chroman-28, the piperidine nitrogen 
(dimethyl-piperidine in SSR240612) also forms a hydrogen bond with Asp291 in TM7. 
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Figure 4.10: Pictorial view of B1R antagonist SSR240612 bound to the B1R. 
PS020990 
Discovered by Pharmacopeia (Princeton, NJ) from a throughput screening program using 
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encoded combinatorial libraries, PS020990 exhibits a potent antagonist profile on human B1R, 
inhibiting 3H-Des-Arg10-Kalidin at IMR-90 cells with a K1 of 1nM. A set of active compounds permitted 
to generate an initial structure activity relationship which was later used to develop additional 
compounds with improved potency. When PS020990 and several  compounds in the same lead series 
was assessed for inhibition at B2R, PS020990 and the related compounds  were found to be inactive 
or with little activity , hence  suggesting PS020990 to be a high selective B1R antagonists at reported 
a >1000-fold over B2R [29].  
Present docking studies reveal (Figure 4.11) that the imidazole ring of PS020990 sits at the 
polar top end of the binding pocket interacting with the His199 in TM5 with its charged nitrogen also 
at a suitable distance to bond with Asp291 in TM7 via hydrogen bond. The oxygen atom of the 
cyclohexyl-propanamide moiety also forms a hydrogen bond with Gln295 in TM7, while one of the 
pyrimidine nitrogens interact with Arg202 and hydroxyl group of the Tyr266. In the bottom of the binding 
site, one of the chlorophenyl group adjacent to the cyclohexyl-propanamide rests at the center of the 
aromatic site, coordinating the π-π interactions with Trp93 of TM2 that also involves Phe299 of TM7. 
Finally, the remaining chlorophenyl sits close to the backbone of Asn114. 
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Figure 4.11: Pictorial view of B1R antagonist PS020990 bound to the B1R. 
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4.5 Designing pharmacophore of BKRB1 antagonists  
Comparison of the ligand-receptor complexes of the diverse antagonists used for the present 
study allows the definition of a pharmacophore that explains the observed structure-activity 
relationship observed. The proposed pharmacophore is shown in Figure 4.12 and it is defined 
considering geometrical constraints on ligand moieties. It consists of five pharmacophoric points that 
all the ligands studied in the present study fulfill.  
 
Figure 4.12: Proposed pharmacophore for the B1R antagonism. Distance between pharmacophoric points are: 
d(1,2)= 9.2 A; d(1,3)=13.1; d(1,4)= 1.5; d(1,5)=9.5; d(2,3)=5.1; d(2,4)=7.6.; d(2,5)=9.3; d(3,4)=7.8; d(3,5)=9.5; 
d(4,5)=5.7. 
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The first point, at the polar mouth of the binding pocket, is represented by a proton donor 
center that complements an interaction with Asp291 and/or Glu273 and /His199; point 2 is either a proton 
donor/proton acceptor center that will interact with either Gln295; point 3 is a hydrophobic ring that 
will interact with Trp93 and/or Phe299; point 4 is a proton accepting center that will interact with Asn114 
and/or Arg176; point 5 is a proton donor and /or proton acceptor site that will interact with Arg202, 
Asn298 and the side chain of Tyr266. 
 Thus, Compound 11 fulfils point 1 by means of the 2-phenyldihydroimidazole; point 2 by the 
sulfonamide oxygen; point 3 by means of the chlorophenyl moiety; point 4 by the oxygen of the 
dihydroquinoxalinone group and point 5 by means of by the oxygen of the amide linker group. For 
Compound 12, point 1 is fulfilled by the 4-pyridinepiperazine moiety; point 2 is fulfilled by means of 
the amide linker moiety; point 4 by both the cyclohexyl group and the benzyl moiety of the 
benzodiazepine and point 4 and 5 are fulfilled by the carbonyl group of the diazepine moiety. In the 
case of the NPV-SAA164 point 1 is fulfilled by the methyl-piperazine group nitrogen; point 2 by means 
of the carbonyl group linking to the morpholine group that fulfills point 4; point 3 by both the phenyl 
group providing maximum coverage of the pocket side, point 5 by means of the sulfonyl oxygens of 
the sulfonamide. Chroman-28 covers the pharmacophore point 1 by using the chroman-7-
methylpiperidine, point 2 and point 4 by means of the oxygens of the sulfonamide group; point 3 is 
fulfilled by the naphthalene rings and point 5 by the linker amide carbonyl group. In SSR240612 point 
1 is fulfilled by the dimethyl-piperidine group; point 2 is fulfilled by the carbonyl group of the amide 
linker; point 3 is fulfilled by the benzodioxole moiety; while the sulphonyl oxygen fulfils point 4 and 
point 5 is fulfilled by the methyl-propanamide group. Finally, in the case of compound PS020990 point 
1 is fulfilled by the imidazole group; point 2 by the carbonyl group of the cyclohexyl propanamide 
moiety; point 3 by means of the chlorophenyl group adjacent to the cyclohexyl propanamide moiety 
and point 5 by means of the nitrogen of the pyrimidine ring. 
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4.6 Designing novel B1R antagonists: Proof of concept 
The pharmacophore described above was later used in the discovery of novel structures with 
antagonistic activity for B1R by virtual screening. For this purpose a search was made in few databases 
of 3D structures of compounds including the Available Chemical Directory (ACD), the Derwent World 
Drug Index, the National Cancer Institute (NCI) and Maybridge for approximately 500,000 compounds. 
A separated searches for compounds fulfilling five, four and three pharmacophoric points yielding a 
large set of compounds was carried out. A selected group of them were purchased and tested for their 
B1 antagonistic activity.  
Biological assays permitted to identify new highly diverse hits with structures that do not 
resemble those used for pharmacophore development. The success rate achieved to identify new hits 
with an antagonistic activity by virtual screening was approximately one third of the selected 
molecules, as previously found by other authors [48]. Table 4.2 shows the structures as well as the 
antagonistic activity to the human bradykinin B1R of a selected group of hits that are disclosed to give 
support to the pharmacophoric hypothesis developed in this work.  
These molecules were docked onto the receptor model and inspected for fulfillment of the 
pharmacophore. Information regarding the number of pharmacophoric points fulfilled by each of the 
hits is also included in Table 4.2. Interestingly, the antagonistic activity observed experimentally 
correlates well with the number of pharmacophoric points fulfilled by these molecules. 
As an example, Figure 4.13 shows compound #3 bound to the B1R showing the fulfillment of 
the pharmacophoric points. The ligand is shown to fulfill 3 pharmacophoric points 3, 4 and 5.  While 
it does have a charged amine moiety that can interacts with the Asp291, and thus fulfil point 1, the 
amine is positioned at a long distance unsuitable for a proper interaction. This emphasize on the 
reason why most of the B1R antagonist  published are big as they need to span out to all 
pharmacophoric points for suitable activity. 
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Table 4.2. Structures of the new hits discovered together with their antagonistic effect towards the human B1R and the number 
of pharmacophore points fulfilled. 
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Figure 4.13: Pictorial view of compound #3 of Table 4.2 bound to the B1R with the pharmacophore points represented as 
spheres of different colors 
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4.7 Conclusions to chapter 4  
 
Models of the bound conformation of diverse non-peptide human B1R antagonists were 
constructed and the stereochemical features of the complexes were analyzed with the aim to find 
common trends. To accomplish this, an atomistic model of the receptor was constructed by homology 
modeling, using the human CXC4 chemokine and bovine rhodopsin receptor as template (chimeric 
template). Antagonists selected for the present study included Compound 11, Compound 12, NPV-
SAA164, Chroman-28, SSR240612 and PS020990, covering the maximum possible diversity. 
Complexes with the bound conformation of each of the antagonists were constructed by docking the 
molecules into the receptor. Due to the flexibility of the ligands and the size of the orthosteric site of 
the receptor, several docking attempts were carried out for each of the molecules. The final 
conformation was selected by the scoring function and the results of both SAR and site directed 
mutagenesis studies available in the published literature. 
Our results suggest that there are certain anchoring points that are found in more than one 
compound permitting the definition of a common pharmacophore. This consist of five points that 
defined on the features of the ligand include proton donor (point 1); a proton acceptor/proton donor 
center (point 2); a hydrophobic ring (point 3); proton acceptor/proton donor center (point 4 ) and 
proton donor/proton acceptor. 
The pharmacophore was used in a subsequent study to guide a virtual screening process. The 
results permitted to identify a set of compounds some of which were purchased and in vitro tested for 
their capability to antagonize the B1R. Consequently, a subset of compounds with highly diverse 
structures that give support to the validity of the pharmacophoric hypothesis described in this work, was 
also disclosed. 
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5.0 Chapter summary 
 
Bradykinin (BK) is a member of the kinin family, released in response to inflammation, trauma, 
burns, shock, allergy and some cardiovascular diseases, provoking vasodilatation and increased 
vascular permeability among other effects. Their actions are mediated through at least two G-protein 
coupled receptors B1R, a receptor up-regulated during inflammation episodes or tissue trauma and 
B2R that is constitutively expressed in a variety of cell types.  
The goal of the thesis chapter was to carry out a structure-activity study of B2R antagonism, 
taking into account the stereochemical features of diverse non-peptide antagonists and the way these 
features translate into ligand anchoring points to complementary regions of the receptor, through the 
analysis of the respective ligand-receptor complex. Hence, an atomistic model of the B2R was built by 
homology modeling and subsequently refined embedded in a lipid bilayer by means of a 600ns 
molecular dynamics trajectory. The average structure from the last hundred nanoseconds of the 
molecular dynamics trajectory was energy minimized and used as model of the receptor for docking 
studies. For this purpose, a set of compounds with antagonistic profile, covering maximal diversity 
were selected from the literature. Specifically, the set of compounds include Fasitibant, FR173657, 
Anatibant, WIN64338, Bradyzide, CHEMBL442294, and JSM10292. Molecules were docked into the 
B2R model and the corresponding complexes analyzed to understand ligand-receptor interactions. 
The outcome of this study is summarized in a 3D pharmacophore that explains the observed structure-
activity results and provides insight into the design of novel molecules with antagonistic profile. 
 To prove the validity of the pharmacophore hypothesized, a virtual screening process was also 
carried out. The pharmacophore was used as query to identify new hits using diverse data bases of 
molecules. The results of this study revealed a set of new hits with structures not connected to the 
molecules used for pharmacophore development. A few of these structures were purchased and 
tested. The results of the binding studies show about a 33% success rate with a correlation between 
the number of pharmacophore points fulfilled and their antagonistic potency.  
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5.1 Introduction 
 
As explained in the previous chapter, the pharmacological actions of kinins are mediated by at least 
two GPCRs: B1R and B2R. While the former is up-regulated during inflammation episodes or tissue 
trauma, the latter is constitutively expressed in a variety of cell types. Thus, the majority of kinins effects 
in vivo have been attributed to the B2R. For the B2R, agonists bradykinin (BK) and Lys-BK exhibit much 
higher affinity than the des-Arg9-BK metabolites which bind only to the B1R, being Lys-desArg9-BK a 
potent B1R agonist. Due to their diverse roles, such as in mediating pain and inflammation there has been 
a remarkable interest for identifying potent B2R antagonists for therapeutically intervention. 
Coincidentally, among the two kinins receptors, B2R is the most studied [1- 4].   
Since the chemical synthesis of BK for the first time in the early 60s [5] diverse analogs with agonistic 
activity have been reported, providing key information about the relevance of every residue for ligand 
activity. Analogs with antagonistic activity were not available until 1985, when Pro7 in BK was replaced 
by an aromatic D-amino acid [6]. This led to the first generation of antagonists with the synthesis of potent 
analogs, including D-Arg-[Hyp3, D-Phe7]-BK (NPC-567) (Hyp = hydroxyproline); D-Arg-[Hyp3,Thi5,8,D-Phe7]-
BK (NPC-349) (Thi = thienylalanine); or D-Arg-[Hyp3,D-Phe7,Leu8]-BK, among the most active compounds 
reported [7,8]. Although this first generation of antagonists was useful to understand the involvement of 
BK in many pathophysiological processes, these compounds exhibit drawbacks that prevent them to be 
used for therapeutical intervention. Specifically, they exhibit low affinity for the B2R compared to BK itself 
and are not selective, showing higher affinity for B2R. Interestingly, removal of their C-terminal arginine 
by carboxypeptidases results in a decrease of affinity for the B2R, turning them selective B1R antagonists. 
A second generation of antagonists with improved pharmacological profile was designed on the basis 
that the C-terminus of BK adopts a β-turn when bound to the receptor, as had been suggested from 
spectroscopic and molecular modeling studies [9] and confirmed more recently, from solid state NMR 
experiments [10]. Thus, with the help of conformationally constrained unnatural amino acids, diverse 
analogs designed to mimic the secondary structural motif of BK at the C-terminus were synthesized. 
These studies resulted in the discovery of several potent antagonists, including icatibant (formerly known 
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as HOE-140) with sequence D-Arg0-[Hyp3-Thi5-D-Tic7-Oic8]-BK (Tic = tetrahydroisoquinoline; Oic = 
octahydroindole carboxylic acid) [11] or NPC17731 (D-Arg-[Hyp3, D-HypE(trans-proyl)7, Oic8]-BK) [12]. In 
a parallel effort, the search for the shortest peptide sequence retaining antagonistic activity lead to 
conclude that adoption of a β-turn conformation at the C-terminus is a necessary condition for high 
affinity to the B2R, but not sufficient. This conclusion came from the analysis of the binding affinity of 
diverse cyclic peptides inspired on the C-terminus of icatibant. Thus for example compounds like the 
cyclo-(Gly-Thi-D-Tic-Oic-Arg) [13] or cyclo-(Pro-Orn-D-Tic-Oic-Arg) [14] show poor antagonistic affinity for 
the B2R.  
Accordingly, the affinity of icatibant and analogs was rationalized in terms of the interactions of the 
compound with the receptor, such that the β-turn at the C-terminus was thought to occupy a hydrophobic 
region on the orthosteric pocket, whereas the N-terminal arginine were thought to interact with the 
negatively charged residues Asp266 and Asp284 putatively located at the mouth of the receptor [15]. As an 
indirect proof of concept, the high affinity peptide D-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-cyclo[Dab6-D-Tic7-
Oic8-Arg9] (Dab = diaminobutyric acid) (MEN11270) exhibits a cyclic structure at the C-terminus mimicking 
the β-turn secondary structure and preserves the N-terminal segment of icatibant [16]. 
The second generation of B2 antagonists represented an improvement in regard to the first one. Thus, 
in addition to have designed antagonist with high affinity for the B2R, these compounds are highly 
selective and exhibit an improved pharmacokinetic profile due to their higher resistance to enzymatic 
degradation. However, they exhibit a limited oral bioavailability. Thus Icatibant, the first B2R antagonist 
to reach the market and currently used for the symptomatic treatment of acute attacks of hereditary 
angioedema in adults with C1-esterase-inhibitor deficiency, needs to be administered via subcutaneous 
injection [17]. In order to improve the oral bioavailability, research efforts were put forward to design 
non-peptide B2 selective antagonists.  
This third generation of B2R antagonists includes diverse molecules disclosed during the 90s and the 
beginning of the XXI century [18, 19]. Specifically, WIN64338 developed at Sterling Winthrop was the first 
B2R non-peptide antagonist disclosed (4 in Figure 5.1) [20]. Other compounds were disclosed in the 
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following years, including a series of compounds developed at Fujisawa, like FR173657 (2 in Figure 5.1) 
[21]; bradyzide developed at Novartis (5 in Figure 5.1) [22]; anatibant developed at Fournier (3 in Figure 
5.1) [23] or fasitibant developed at Menarini (1 in Figure 5.1) [24]. These compounds are high affinity B2R 
selective antagonists with limited oral bioavailability. The major drawback of these compounds is their 
high molecular mass, which ranges between 500 and 600. Aimed at finding compounds with lower 
molecular mass, scientists at Jerini carried out a medicinal chemistry optimization process, using the 8-
benzyloxy-2-methyl-quinoline moiety that is the common scaffold of several of the non-peptide 
antagonists listed above, as starting structure. Their study led to the design and synthesis of JSM10292 a 
potent B2R antagonist with similar affinity and selectivity to the previous compounds, but with lower 
molecular mass [25].  
The objective of this chapter is to carry out a structure-activity study of B2R antagonism, taking into 
account the stereochemical features of diverse non-peptide antagonists and the way these features 
translate into ligand anchoring points to complementary regions of the receptor, through the analysis of 
the respective ligand-receptor complex. For this purpose, a set of compounds from the literature covering 
maximal diversity were selected. The compounds selected for the present study include Fasitibant (1) 
[24], FR173657 (2) [21], Anatibant (4) [23], WIN64338 (5) [20], Bradyzide (6) [22], CHEMBL442294 (7) 
[25], and JSM10292 (8) [26], shown in Figure 5.1. Compounds were docked into a refined model of the 
B2R constructed by homology modeling, following the procedure explained in the methods section and 
the complexes were further analyzed for their ligand-receptor interactions. The outcome of this study is 
summarized on a 3D pharmacophore that explains the observed structure-activity results and provides 
insight into the design of novel molecules with antagonistic profile.  
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Figure 5.1. Chemical structures of the B2R antagonists studied in the present work. Fasitibant (1), FR173657 (2), Anatibant 
(3); WIN64338 (4); Bradyzide (5); CHEMBL442294 (6); JSM10292 (7) 
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5.2 Modeling of Bradykinin B2R 
A starting model of the human B2R was constructed by homology modeling using the chemokine 
CXCR4 receptor as template. The template was selected due to its proximity to B2R in the GPCRs 
phylogenetic tree among those GPCRs whose crystallographic structure is known. The sequences of the 
two receptors were aligned, taking into account the conserved motifs found in all GPCRs, as well as the 
location of the disulfide bridges. These motifs, together with salt bridges are important factors in 
constraining the conformation of the extracellular and transmembrane domains of the B2R. From the 
aligned sequences a starting model of the receptor was constructed using the Modeller 9 version 8 (9v8) 
software [27]. Model validation was carried out using the Molecular operating Environment (MOE) 
program [28]. In a subsequent step the B2R antagonist Fasitibant (compound 7 in Figure 5.1) was docked 
into the starting model using the GLIDE software [29]. The choice of this ligand was due to the abundant 
information available from site directed mutagenesis experiments [30].  
Finally, the ligand-receptor complex was embedded in a lipid bilayer and refined using molecular 
dynamics. Specifically, the protein was embedded in a box consisting in a 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) lipids and water molecules previously equilibrated according to the procedure 
described elsewhere [31]. The box had an initial size of 9.5 x 9.7 x 15.6 nm3 (XYZ), organized in such a 
way that the bilayer plane was oriented on the XY plane. Before protein insertion, the box contained 256 
lipids (corresponding to an area per lipid of 0.64 nm2) and about 15,000 water molecules. The protein 
was placed in the center of the box, and the overlapping molecules were removed. More specifically, all 
water molecules with oxygen atoms closer than 0.40 nm to a non-hydrogen atom of the protein, as well 
as all lipid molecules with at least one atom closer than 0.25 nm to a non-hydrogen atom of the protein 
were removed. This resulted in a final box containing 228 lipids and circa 11,000 water molecules. 
Removal of these atoms introduced small voids between the protein and water or lipid molecules that 
disappeared during the first part of the MD simulation, in which a progressive adjustment of the lipid 
bilayer and water molecules to the protein takes place. Next, 171 randomly selected water molecules 
were replaced by 81 sodium and 90 chloride ions, providing a neutral system with a concentration 
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approximately 0.2 M on sodium chloride. This concentration is fairly similar to that found in biological 
organisms, although they exhibit different intra- and extra-cellular ion concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Sequence alignment of human B2R (bottom) and CXC4 receptor. Transmembrane segments are 
inserted in boxes and sequence Identities are colored in blue. 
 
Sampling was carried out for 600ns using the GROMACS package 4.6 [32]. The refined model of the 
B2R was generated from the average structure of the last 100 ns of the molecular dynamics trajectory. 
The structure was subsequently minimized in a two-step process using the steepest descent method with 
a distance dependent dielectric constant of 2. First, side chains are optimized with the backbone atoms 
constrained to be subsequently released in a second minimization. This structure was used for further 
docking studies using the GLIDE [29] software. Due to the flexibility of the ligands, the docking process 
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was carried out using a set of unique conformations resulted from thorough conformational analysis. 
Poses were rank ordered using the XP score function of GLIDE. Final poses of the compounds were 
decided based on their ranking and fulfillment of site directed mutagenesis information available. 
 
 
5.3 Results and discussion 
 
Challenges such as low-expression yields, low receptor stability after detergent extraction from 
native membranes, and high conformational heterogeneity hampers the availability of new 
crystallographic structures of GPCR. In the absence of a crystallographic structure of the B2R, an atomistic 
model of B2R was constructed by homology modelling for the present study. Under these circumstances 
homology modelling remains one of the important techniques aimed at constructing 3D models of 
proteins, however in order for the models constructed to be as accurate as possible the procedure 
requires a careful choice of the template and a robust refinement procedure. This is important because 
from the analysis of the diverse known structures, although they share a common seven helix bundle, 
each structure exhibits specific features that might be relevant for ligand design [34]. The CXCR4 
chemokine receptor (pdb entry code 3ODU) [35] was selected as template for the present study due to 
its proximity with BK B2 in the phylogenetic tree of the class A family of GPCRs.  
Figure 5.2 shows the alignment of the sequences of the CXCR4 and B2Rs carried out taking into 
account the conserved motifs found among GPCRs, as explained in the methods section. This procedure 
is crucial for the assignment of the transmembrane regions. This information is then given as input to the 
Modeller software that produces a rank order set of models based on a scoring function. The final model 
selected for the refinement process was the one with the least steric conflicts from those that 
incorporated all the specified constraints considered to be conserved among GPCRs. 
Before proceeding to the refinement process, Fasitibant was docked into the initial model. Due to 
its flexible structure several docking attempts were carried out using diverse conformations that were 
generated automatically as explained in the methods section. The final complex considered for 
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refinement was selected based on the degree of fulfilment of diverse site directed mutagenesis studies. 
Special attention was given to residues Trp86, Ile110, Trp256, Asp266 and Tyr295 [30].  
The complex Fasitibant bound-receptor was embedded into a pre-equilibrated bilayer of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and water and subjected to a molecular 
dynamics simulation. Previous experience in GPCR homology modeling (data not shown), suggest that 
the presence of the ligand permits a faster equilibration of the system.  
Time evolution of the root mean square deviation (rmsd) of the alpha carbons of the protein as 
well as those of its helical bundle subset is show in Figure 5.3. Inspection of the Figure indicates that when 
all the alpha carbons of the protein are considered equilibration is reached after 300ns, whereas when 
the helical bundle subset is used equilibration is reached about 50ns earlier. These results support the 
choice made in the present work of using the last 100 ns of the refinement process for the generation of 
an atomistic model of the B2R. As mentioned in the methods section the last 100 ns segment of the 
molecular dynamics trajectory was used to generate an average structure that was subsequently 
minimized in a two-step process using the steepest descent method with a distance dependent dielectric 
constant of 2. Figure 5.4 shows the root mean square fluctuations (rmsf) of the average structure 
extracted. 
The orthosteric site of the B2R can be described as two hydrophobic pockets, a lager one formed 
between TM3, TM4, TM5 and TM6 including residues like Ile110, Met165, Leu201, Trp256, Phe259 and a smaller 
one formed between TM2, TM3 and TM7 including residues like Trp86 and Tyr295. Interestingly, the 
aromatic side chains Trp86, Trp256 and Tyr295 are coupled through quadrupole-quadrupole interactions. On 
the other hand, at the mouth of the site there are several polar residues including, Glu24, Gln33, Asp266, 
Asp284 and Gln288. Figure 5.5 shows the orthosteric pocket of the receptor. Below, the bound 
conformation of the diverse antagonists selected for the present study obtained from docking studies on 
the refined model are described. 
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Figure 5.3. Time evolution of the root mean square deviation (rmsd) of the bradykinin B2R during the refinement process. In black 
is the rmsd of the alpha carbons of the protein and in red the rmsd of the alpha carbons of the helix bundle subset. 
 
Figure 5.4. The rmsf of the average structure of B2R 
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(a)                                                             (b) 
 
Figure 5.5. a) Lateral view of the orthosteric binding pocket of the human B2R with antagonist Bradyzide bound. b) Same 
as a) viewed from the extracellular side (top). 
 
 
 
 
 
5.4 Antagonist of Bradykinin B2Rs  
 
5.4.1 Fasitibant 
Fasitibant (MEN16132) (1, in Figure 5.1) is a potent antagonist of the B2R with a Ki of 0.09 nM [30]. 
The structure of Fasitibant bound to the model receptor from the present docking study is shown in Figure 
5.5. In accordance with previous docking studies [30], the quaternary terminal amine interacts with Asp266 
and Asp284 at the mouth of the receptor, whereas the hydrophobic 8-benzyloxy-2-methyl-quinoline 
moiety gets deep into the orthosteric pocket. The involvement of the two aspartates in ligand binding is 
supported by site directed mutagenesis analysis [36]. Inspection of Figure 5.6 shows the 
tetrahydropyranyl moiety sitting in a hydrophobic region on top of Trp86, with a hydrogen bond 
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interaction between the heterocycle oxygen and the indole nitrogen of the triptophan side chain. This 
result is consistent with the fact that binding of Fasitibant to the Trp86Ala mutant is about 1200 times 
lower [30] and can be explained on the basis that the quadrupole-quadrupole interaction between the 
two rings and a hydrogen bond are lost in the mutant. Analyzing other functional groups of the ligand, 
one of the oxygens of the sulfonamide appears forming a hydrogen bond with Arg169; one of the chlorines 
of the dichlorobenzyloxy moiety forms a polar interaction with Arg169 and Asn107, whereas the other sits 
in a hydrophobic environment flanked by Phe259, Phe292 and possibly with Tyr295.  
Unfortunately, there is no mutagenesis data available about the involvement of Arg169 or Phe259 in 
the affinity of the ligand to give support to these interactions. At the molecule ending, the quinoline 
moiety sits in the vicinity of Ile110, Trp256 and Tyr295 interacting with the latter two through quadrupole-
quadrupole interactions.  Moreover, the interaction with Tyr295 is enhanced by the presence of a 
hydrogen bond between the quinoline amine group of the forms and the hydroxyl group of Tyr295. These 
results are consistent with diverse site directed mutagenesis data available. Thus, the mutant Ile100Ala 
reduces 300 times the affinity of Fasitibant and furthermore, the mutation Tyr295Phe reduces the affinity 
100 times, whereas the mutation Tyr295Ala 755 times, suggesting a dual role as aromatic/hydrophobic 
residue and as hydrogen bond donor/acceptor for Tyr295 [30].  
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Figure 5.6. Pictorial view of B2R antagonist Fasitibant bound to the B2R. 
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5.4.2 FR173657 
This Fujisawa compound (2 in Figure 5.1) is a potent B2R antagonist with an IC50 of 1.4 nM at the 
human receptor [21]. This compound is the result of an extensive medicinal chemistry program aimed at 
designing B2R selective antagonists from a hit found in a screening program for angiotensin II AT1 
antagonists. As can be seen the compound shares with Fasitibant the 8-benzyloxy-2-methyl-quinoline 
moiety and consequently, it could be thought that the compound binds in a similar manner, however site 
directed mutagenesis studies suggest that the bound conformation is different. Thus, for example the 
affinity of FR173657 is not affected by the mutation of Asp266 and Asp284 [36] or Ser111 and Trp256 [37], 
suggesting that these residues do not act as anchoring points in the bound conformation of the 
compound. In contrast, Trp86 and Tyr295 must be actively involved since their mutation to alanine 
decreases the affinity of the compound about 500 times [30]. 
 Bearing these results in mind, several docking attempts were carried out, obtaining diverse 
alternative poses. Analysis of the results in view of the site directed mutagenesis results available 
suggests that the ligand binds according to the ligand-receptor complex shown in Figure 5.7. Specifically, 
the molecule adopts a L-shape with the dichlorobenzyloxyl moiety found on top of Trp86, nicely 
interacting through a parallel π-π stacking in such a way that both chlorines in addition to sit in a 
hydrophobic environment, interact through a hydrogen bond with Asn107 and Gln288 respectively. 
 Unfortunately, there are not mutagenesis results of the role of these two residues, but structure 
activity studies of different analogs of FR173657 suggest that replacing the chlorines for methyl groups 
decreases the affinity about five times, supporting the existence of the hydrogen bond interaction [38]. 
The position of the dichlorobenzyloxyl permits to direct the quinoline moiety -similar as it is found in 
fasitibant- in the vicinity of residues Ile110 and Phe256 whose mutation is known to affect significantly 
ligand binding. An additional piece of information to support the position of the quinoline moiety comes 
from a CoMFA analysis described in reference 36. 
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 Figure 5.7: Pictorial view of B2R antagonist FR173657 bound to the B2R. 
 
 
 
Specifically, the authors proposed constraints for favorable groups to improve the affinity of the 
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ligand by extension of the molecule and these fit well with the positions of residues Trp256, Phe259 and 
Asn198 in the present ligand-receptor complex. On the other side of the molecule, structure activity studies 
of diverse analogs suggest the importance of this part of the molecule for obtaining good antagonists at 
the human B2R. Analysis of ligand-receptor complex shown in Figure 5.7 suggests that the amide groups 
interact with polar residues like Glu24 or Thr89 whereas the pyridine ring interacts with Phe94 and Tyr174 
through quadrupole-quadrupole interactions. These results agree well with the structure-activity studies 
carried out on these compound series. Specifically, the introduction of a phenylurea moiety induces an 
increase in the affinity one order of magnitude in guinea pig ileum membrane preparations and nearly 
two orders in A-431 cells that express the human receptor due to the favorable interaction with the side 
chains of Phe94 and Tyr174.  
 
5.4.3 Anatibant 
Previously known as LF 16-0687 (3 in Figure 5.1), Anatibant is a potent B2R antagonist of Fournier 
with an IC50 of 0.67 nM at the human receptor [23]. The compound shares the 8-benzyloxy-2-methyl-
quinoline moiety with the two antagonists described above, and in this case linked to a pyrrolidine 
sulfonamide with a 4-amidinofenil moiety as charged terminal group. Analysis of the different poses 
found in our docking studies in view of the site directed mutagenesis results available suggest the 
molecule sits inside the orthosteric site as shown in Figure 5.8. As can be seen the bound conformation 
of Anatibant shows similarities with that of Fasitibant. Indeed, the common 8-dichlorobenzyloxy-2-
methyl-quinoline substructure sits in a similar manner inside the receptor. However the stereochemical 
differences on the other side of the molecules force them to exhibit differential poses as discussed below.  
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Figure 5.8: Pictorial view of B2R antagonist Anatibant bound to the B2R. 
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The dichlorobenzyloxyl moiety of Anatibant binds in the same region of the receptor as Fasitibant, 
consequently the other moieties attached to it and shared between the two molecules, including the 
quinoline and the sulfonamide access similar regions of the receptor. Specifically, the sulfonyl groups 
exhibit hydrogen bonds with Asn107 and Arg169, respectively. Moreover, the side chain of the latter shows 
an additional hydrogen bond with one of the chlorides of the dichlorophenoxyl moiety. On the other 
hand, the quinoline moiety like in Fasitibant sits close to Tyr295 and interacts through a hydrogen bond 
and the quadrupole-quadrupole interaction between the two aromatic rings. Moreover, our docking 
studies also show the quinolone moiety interacting with Ile110, Trp256 and Phe259. These results are 
supported by mutagenesis studies, since the mutation of Tyr295 to Phe295 reduces the affinity one order 
of magnitude and to two orders of magnitude when mutated to Ala295 [39]. Similarly, the mutation of 
Trp256 to Ala256 decreases the affinity one order of magnitude. Moreover, this idea also explains the 
observed effect of the mutation Asn297Ala in close contact with Trp256 [39].  
There are no results available on the mutation of Ile110 or Phe259 on the affinity of the ligand, but 
according to the present modeling study it is expected one order of magnitude decrease as shown in 
Fasitibant [30]. On the other side of the molecule Anatibant and Fasitibant exhibit differential 
stereochemical features that force them to bind in a differential way. This idea is supported by 
mutagenesis studies, since the mutation of Asp266 or Asp284 to alanine decreases dramatically the binding 
affinity of Fasitibant but does not alter that of Anatibant [36]. As can be seen in Figure 5.8 the pyrrolidine 
ring sits perpendicular to Trp86 interacting through a quadrupole-quadrupole interaction, being its 
position reinforced by a hydrogen bond with the side chain of Arg169. The ring plays a fundamental role 
in distributing the rest of the molecule and this justifies the dramatic effect observed in the affinity of the 
compound when the residue is mutated to alanine [40].  From the pyrrolidine, the molecule extends 
towards the mouth of the receptor with the aminoiminophenyl moiety surrounded by polar residues 
including, Tyr174 of the second extracellular loop or Gln22 located at the N-terminus. Moreover, there are 
diverse polar residues that interact with the amide groups of the molecule, including Glu24, Gln33 and 
Gln288. The importance of the latter has been shown by mutagenesis studies [39]. 
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5.4.4 WIN64338  
This was the first non-peptide antagonist disclosed in the literature with a Ki of 64 nM in human 
IMR90 fibroblasts [20]. The antagonist was designed using a simple pharmacophore defined by two 
charged groups separated by a distance of about 10 Å – mimicking the distance between the two terminal 
arginines of BK in its bioactive conformation- linked by lipophilic groups [20]. From a hit obtained, 
subsequent medicinal chemistry efforts yielded the compound WIN64338 (4 in Figure 5.1). As can be seen 
the compound exhibits two charged groups at both ends surrounded by bulky hydrophobic groups, 
together with a naphtyl moiety. The results of our docking study of the compound onto the B2R model is 
shown in Figure 5.9. WIN64338 is much shorter than the rest of the compounds described so far and is 
consequently, expected to cover a smaller region of the binding pocket. Although there are no reports 
on directed mutagenesis studies conducted with the compound, structure activity studies underline the 
importance of the two charges for high affinity. 
As can be seen, the positively charged phosphine group nicely sits surrounded by two negatively 
charged residues Asp266 and Asp284, although the model suggest that is the latter that is involved in a 
charge-charge interaction. The other charge in the model interacts with the backbone of Cys184. In regard 
to the bulky cyclohexyl groups, one sits in the proximity of Trp86, whereas the other points toward the 
solvent in a region surrounded by Ala183 and Phe94 that provide a hydrophobic environment. Finally, the 
naphtyl group sits in the hydrophobic pocket in the proximity of Trp256, Phe259 and Ile110 similarly as does 
the quinoline moiety in the previous antagonists described. 
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   Figure 5.9: Pictorial view of B2R antagonist WIN64338 bound to the B2R. 
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5.4.5 Bradyzide  
Bradyzide (5, in Figure 5.1) is a potent, rat-selective B2 antagonist that causes a long lasting reversal 
of inflammatory hyperalgesia [22]. The compound is the result of a lead optimization from a hit 
discovered by random screening. Interestingly, the compound exhibits high affinity for the rat B2R (0.5 
nM) expressed in NG108-15 cell membranes, but much lower in human BK B2 expressed in Cos-7 cells 
(772 nM). The result of the docking study of this compound onto the B2R is shown in Figure 5.10. There 
are no mutagenesis studies available that can help to understand the effect of diverse mutations on the 
binding of Bradyzide to the B2R, but there is information about the effect of diverse chemical 
substitutions on the molecule [41] that can be analyzed through view of the complex model.  
Thus, the terminal charged amino nitrogen located at the end of the diaminoalkyl chain in 
Bradyzide sits at the mouth of the receptor, interacting with Asp266 in TM6 and Asp284 in TM7, although 
the model actually suggests that is the latter that is involved in a charge-charge interaction. Structure-
activity studies support this result by since elimination of this chain decreases the affinity about 100 times 
[41]. Furthermore, these studies also point to the basicity of the nitrogen as important feature to get 
better affinities, confirming the role of the terminal nitrogen in a charge-charge interaction. In the model 
the sulfone group provides an anchoring point to ligand through a hydrogen bond with Gln33 in TM1. 
Further down the ligand, the aromatic ring of the nitrobenzene moiety interacts with Trp86 in TM2 with 
the nitro group interacting with Asn107 via a hydrogen bond. The sulfur of the thiosemicarbazyl moiety 
establishes a hydrogen bond with Asn107 as has been previously suggested and though a hydrophobic 
interaction with Ile110; finally, the phenyl groups close to the thiosemicarbazyl moiety sit well in the 
aromatic region Thr256, Phe259, Tyr295. 
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Figure 5.10: Pictorial view of B2R antagonist Bradyzide bound to the B2R. 
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5.4.6 CHEMBL442294  
Designed by Novartis, ccompound (6, in Figure 5.1) was the most active compound of a series of 
benzodiazepines designed to mimic the β–turn adopted by BK in its bioactive form [25].  This 
peptidomimetic exhibits a binding affinity for the B2R in the micromolar range, result that is consistent 
with the low affinity exhibited by a series of cyclic peptides designed to mimic the C-terminus of BK [13, 
14]. These results indicate that mimicking the C-terminus of the peptide is necessary condition to get 
good binding affinity, but not sufficient. Docking of the molecule into the receptor generated diverse 
poses that were analyzed in order to understand the features of the ligand-receptor interaction Figure 
5.11 shows the ligand-receptor complex with the best docking score. 
 As can be seen the ligand adopts a pose covering a number of residues identified in the docking in 
previous ligands. In this case, the guanidinium moiety binds to Asp284 and Gln288 in such a way that allows 
the interaction of an aromatic ring with Trp86 and another with Trp256 and Phe259 in TM6. In addition, the 
ligand exhibits a hydrogen bond between the carbonyl of the diazepine ring and Arg169. 
 
5.4.7 JSM10292 
This compound (7, in Figure 5.1) is the result of an optimization process aimed to find low molecular 
mass non-peptide B2 antagonists based on the structures of previously disclosed compounds [26]. 
Specifically, inspection of the structure of diverse antagonist including FR173657 [21], compound 8d [38], 
Anatibant [23] and Fasitibant [30] shows that these molecules share a 8-benzyloxy-2-methyl-quinoline as 
common structural feature. Thus, the authors used this moiety as starting structure to follow a medicinal 
chemistry approach, leading to the compound JSM10292 that exhibits an IC50 of 8.7 nM in the human 
B2R, expressed in HEK293 cells [26]. Although the molecule shares a common substructure with those 
molecules used for its design, JSM10292 binds in different way. Analysis of different poses obtained 
during the docking process and analyzed according with the mutagenesis results available [42], it was 
selected as putative bound conformation the one shown in Figure 5.12. 
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Figure 5.11: Pictorial view of B2R antagonist CHEMBL442294 bound to the B2R. 
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Figure 5.12: Pictorial view of B2R antagonist JSM10292 bound to the B2R. 
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Indeed, the pyrazole substituent to the quinoline group sits close to Phe259 with one of the 
pyrazole nitrogens acting as proton acceptor in a hydrogen bond interaction with Thr263. Although there 
are not mutagenesis results on the role of the latter, the results underline the important role of Phe259 
acting as anchoring point of the bound conformation. The nitrogen of the quinolone ring and the oxygen 
atom of the benzyloxy moiety interact via a hydrogen bond with Tyr295; the nitrogen of the pyridine 
interacts with the side chain of Arg169, whereas the aromatic ring and its methyl group sit close to Ile110; 
the carbonyl oxygen of the trifluoropyridone moiety also interacts with Arg169 and the pyridone ring 
interacts with Trp86 whereas the trifluromethyl group interacts with Asn107. The bound conformation of 
JSM10292 found in the present study differs slightly of the one described in reference 40. The two models 
actually differ in the conformation of the ligands. In our model the ligand gets an extended conformation, 
whereas in their model the ligand adopts a conformation the trifluoropyridone ring folds back towards 
the pyridine ring. As result of the different conformation, the trifluromoiety interacts in the present 
model with Asn107 whereas in the other model gets close to Ser111. In fact, there are not mutagenesis 
results of the mutation of serine to alanine; however the replacement to lysine provokes a great loss of 
affinity [42]. However, due to the size of the lysine side chain in both models a steric hindrance is 
generated to perturb the binding of the ligand and consequently does not allow discriminating between 
the two models.  
 
 
5.5 Designing pharmacophore of BKRB2 antagonists  
Comparison of the complex ligand-receptor of the different antagonists used for the present study 
suggests the definition of a pharmacophore that explains the observed structure-activity. It consists of 
five pharmacophoric points that not all the ligands studied in the present study fulfill. The pharmacophore 
proposed is shown in Figure 5.12 and it is defined considering geometrical constraints on ligand moieties. 
Thus, point 1 is a proton donor center that will interact with Asp84 and/or Asp266; point 2 is either a proton 
accepting/proton donor center that will interact with either Gln32 or Gln288; point 3 is a hydrophobic ring 
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that will interact with Trp86; point 4 is a proton accepting center that will interact with Asn107 and/or 
Arg169; point 5 is an aromatic moiety that will interact with Trp256, Phe259 and Tyr295.  
Thus, Fasitibant fulfils point 1 by means of the terminal amine; point 3 by means of the 
dichlorophenoxyl moiety; point 4 by means of one of the sulfonyl oxygens as well as one of the chlorines 
and point 5 by means of the quinoline moiety. In the case of FR173657 point 2 is fulfilled by means of one 
of the amide groups; point 3 is fulfilled by means of the dichlorophenoxyl moiety that also fulfills point 4 
by means of one of the chlorine atoms; point 5 is fulfilled by means of the quinoline moiety. In the case 
of Anatibant point 2 is fulfilled by means of the pyrrodiline amide; point 3 by means of the pyrrolidine 
ring; point 4 by means of the sulfonyl groups and point 5 by means of the quinoline moiety. In the case 
of WIN64338 point 1 of the pharmacophore is fulfilled by the phosphine group; point 3 is fulfilled by one 
of the cyclohexanes; point 4 by the amide carbonyl and point 5 by means of the naphtyl moiety. In 
Bradyzide point 1 is fulfilled by the terminal amine; point 2 is fulfilled by one of the sulphonyl oxygens, 
although in this case the interaction is more likely with Gln33 in the vicinity of Gln288; point 3 is fulfilled by 
means of the nitrobenzene moiety and point 5 by means of the phenyl terminal groups. For 
CHEMBL442294 point 1 is fulfilled by the guanidinium moiety; point 3 by means of the phenyl substituent 
of the benzodiazepine scaffold and point 5 by means of the benzyl moiety. In the case of JSM10292 point 
1 is fulfilled by means of the pyrazole moiety; point 3 is fulfilled by means of the pyrazone moiety that 
also fulfils point 4 by means of the carbonyl group. Finally, point 5 is fulfilled by means of the quinoline 
moiety.  
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Figure 5.13: Proposed pharmacophore for the BK B2 antagonism. Distance between pharmacophoric points are: d(1,2)=8.8 
A; d(1,3)=17.4; d(1,4)=15.5; d(1,5)=12.2; d(2,3)=12.1; d(2,4)=12.2; d(2,5)=11.6; d(3,4)=7.2; d(3,5)=8.8; d(4,5)=10.3 
 
 
Present pharmacophore is in agreement for most part with previously B2R pharmacophore 
described in the literature. Specifically, the simple pharmacophore proposed by Salvino et al. [43] 
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consisting in two charges separated 10 Å that gave rise to the discovery of WIN64338, includes points 1 
and 4 of the present pharmacophore. On the other hand, in order to mimic the C-terminus of BK after a 
thorough exploration of the conformational space of the five bradykinin analogues, it was suggested a 
few years ago a partial pharmacophore for BK antagonism [44, 45]. This includes an ionizable positive 
charge, a hydrophobic group and an aromatic/hydrophobic group in a specific spatial arrangement of 4.5-
7.5 Å, 5.5-8-5 Å and 8.5Å. This pharmacophore is included in the more general pharmacophore described 
in the present work. Distances are not directly comparable since in the present pharmacophore distances 
are defined on the side chains of receptor residues and not on the chemical moieties. Thus, the ionizable 
positive charge is the moiety facing point 2 of the present pharmacophore; the hydrophobic group is the 
one facing point 5 of the present pharmacophore and the aromatic ring is the moiety interacting with 
point 3 in the present pharmacophore.  
 
Proof of concept 
The pharmacophore described above was later used in the discovery of new structures with 
antagonistic activity for the B2 bradykinin receptor by virtual screening. For this purpose a search was 
made in few databases of 3D structures of compounds including the Available Chemical Directory (ACD), 
the Derwent World Drug Index, the National Cancer Institute (NCI) and Maybridge for approximately 
500,000 compounds. We carried out separated searches for compounds fulfilling five, four and three 
pharmacophoric points yielding a large set of compounds. A selected group of them were purchased and 
tested for their B2 antagonistic activity.  
Biological assays permitted to identify new highly diverse hits with structures that do not resemble 
those used for pharmacophore development. The success rate achieved to identify new hits with an 
antagonistic activity by virtual screening was approximately one third of the selected molecules, as 
previously found by other authors [46]. Table 1 shows the structures as well as the antagonistic activity 
to the human bradykinin B2R of a selected group of hits that are disclosed to give support to the 
pharmacophoric hypothesis developed in this work.  
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These molecules were docked onto the receptor model and inspected for fulfillment of the 
pharmacophore. Information regarding the number of pharmacophoric points fulfilled by each of the hits 
is also included in Figure 5.11. As an example, Figure 5.13 shows compound #1 bound to the B2R showing 
the fulfillment of the pharmacophoric points. Interestingly, the antagonistic activity observed 
experimentally correlates well with the number of pharmacophoric points fulfilled by these molecules.  
 
Figure 5.14: Pictorial view of compound #1 of Table 1 bound to the B2R with the pharmacophore points represented as 
spheres of different colors. 
 
 
 
The chloromethybenzyl group interacts in the aromatic pocket Trp256, Phe259 and thus fulfilling 
pharmacophoric point 5, while the dioxopyrazollidine group fulfils point 2 via interactions with Gln288 
and the pyrrole group fulfills point 3 by interacting with Trp86. The hydrogens in benzylsulfonamide 
moiety do not position correctly for an interaction with point 1. 
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Table 5.1. Structures of the new hits discovered together with their antagonistic effect towards the human B2 bradykinin 
receptor and the number of pharmacophore points fulfilled. 
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5.6 Antagonistic selectivity of B2R over B1R 
 
Most of the antagonists studied in this chapter as well as those studied in chapter 4 are bulky 
compounds with high molecular weight covering a large volume of the binding site. These 
characteristics can be clearly seen and explained from the analysis of the receptor-ligand models 
developed in this work. These results permitted the development of the pharmacophoric hypothesis 
of B1R and B2R antagonism explained above. Comparison of these pharmacophores can be used in a 
step forward to understand ligand selectivity to the two bradykinin receptors.  
 
 
Figure 5.15: A superposition of the pharmacophores for B1R (in green) and B2R (in blue) showing similar pharmacophoric 
points 1-4. 
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Figure 5.16: A superposition of the pharmacophores for B1R (in green) and B2R (in blue) highlighting the pharmacophoric 
points 5 which differs in B1R and B2R. 
 
Certainly by looking at the proposed pharmacophores of the two receptors, it can be seen that 
the majority of the residues of the binding pocket involved and hence, the pharmacophores obtained 
are quite similar. In fact, pharmacophoric points 1-4 (an ionizable positive charge at point 1; a proton 
donor/ acceptor group at point 2; an aromatic/saturated ring at point 3 and another proton donor or 
acceptor group at point 4) are the same as shown in Figure 5.15. So, the main difference is found in 
pharmacophore point 5 (Figure 5.16) that involves a polar moiety in B1R and an aromatic ring in B2R. 
Moreover, point 5 in the B1 pharmacophore is located at a closer distance to point 1 than in the B2 
pharmacophore, where point 5 in the located deep in the binding pocket encompassing the large cleft 
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made by aromatic residues (Figure 5.17). More Specifically, in the B1R point 5 is defined as a proton 
donor or acceptor group that interacts with Arg202, Tyr266 and the side chain of Asn298 in TM5, TM6 and 
TM7 respectively, whereas in B2R this point is defined by an aromatic ring that interacts with residues 
of a hydrophobic cleft comprised by Trp256, Phe259 in TM6 and Tyr295   in TM7. 
 
 
Figure 5.17: A superposition of the pharmacophores for B1R (in green) and B2R (in blue) as they appear in receptor. 
 
The reason of the different location and nature of point 5 in the two pharmacophores can be 
attributed to a specific TM3 residue: Lys118 in B1R and the corresponding Ser111 in B2R. According to 
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the models described in this work the backbone of either of these residues is bonded to the backbone 
of a conserved Asn114/107 in TM3, a prominent residue making up the pharmacophore point 4, in such 
a way that the sidechain of residue Lys118 forms a hydrogen bond with the sidechain of residue Glu205 
in TM5, preventing the equivalent residues of point 5 of B2R in B1R from facing the binding pocket. In 
B2R the sidechain of Ser111 is short and does not interact with TM5, thus making the area vacuous and 
allows the orientation of the aromatic rings of Trp256, Phe259 in TM6 and Tyr295   in TM7 towards the 
binding pocket. This explains the results of a selectivity study of peptide agonist and antagonist 
towards B1R and B2R that found that the mutation of Lys118 for Serine B1R and vice versa in B2R, were 
responsible for discrimination of either receptor [47]. Specifically, mutating Ser111 to Lys111 in B2R led 
to the decrease of the affinity in BK and the peptide antagonist NPC17731, while increased the affinity 
of B1R selective antagonist, thus effectively turning the receptor, at least in terms of activity, from 
B2R to B1R. The change was attributed to the ability of the positive charge in the lysine to repel the C-
terminal arginine in B2R selective peptides such as BK and NPC17731 and to attract the negative 
charge of the C-terminal of B1R selective peptides which lacks the C-terminal arginine [47]. 
 
 This hypothesis can also explain the behavior of compound#3 in Table 1, found to be a specific 
binding inhibition (45%) in B2R but inactive in B1R. Figure 5.18 shows the bound conformation of 
compound#3 to the B2R. Considering the similarities in the binding pocket between B1R and B2R and 
consequently the pharmacophores, in B1R the fluorophenyl moiety would be oriented towards Lys118 
and could not properly fit because of steric hindrance. On the other hand, since the sidechain of Ser111 
in B2R orients away from the binding pocket, the fluorophenyl group comfortably rests on the 
hydrophobic cleft and make interactions with residues in the region such as Trp256.   
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Figure 5.18: Pictorial view of compound #3 of Table 1 bound to the B2R with the pharmacophore points represented as 
spheres of different colors. 
 
 To conclude, both receptors require large molecules to fulfill the five proposed 
pharmacophoric points. Moreover, in regard to receptor selective ligands, a particular attention must 
be paid to the moiety fulfilling pharmacophoric point 5. 
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5.7 Conclusions to chapter 5 
 
We have constructed models of the bound conformation(s) of diverse non-peptide B2 bradykinin 
antagonist and analyzed the stereochemical features of the complexes with the aim to find common 
trends. For this purpose an atomistic model of the B2R was constructed by homology modeling, using the 
CXC4 chemokine receptor as template. Antagonists selected for the present study include Fasitibant, 
FR173657, Anatibant, WIN64338, Bradyzide, CHEMBL442294 and JSM10292, encompassing the 
maximum possible diversity. Complexes with the bound conformation of each of the antagonists were 
constructed by docking the molecules into the receptor. Due to the flexibility of the ligands and the size 
of the orthosteric site of the receptor, several docking attempts were carried out for each of the 
molecules. The final conformation was selected by the scoring function and the results on site directed 
mutagenesis studies available.  
Our results suggest that there are certain anchoring points that are found in more than one 
compound permitting the definition of a common pharmacophore. This consist of five points that defined 
on the features of the ligand include a proton donor/positive charge (point 1), a proton acceptor/proton 
donor (point 2), an aromatic/cyclic moiety (point 3), a proton acceptor/proton donor (point 4) and a 
hydrophobic/aromatic moiety (point 5). 
The pharmacophore was used in a subsequent study to guide a virtual screening process. The 
results permitted to identify a set of compounds some of which were purchased and in vitro tested for 
their capability to antagonize the bradykinin B2R. In the present work a subset of the hits compounds are 
disclosed with highly diverse structures that give support to the validity of the pharmacophoric 
hypothesis described in this work. 
Finally, in order to design selective ligands, comparison of the pharmacophores of B1R and B2R 
suggest that specific attention must be paid to the moiety fulfilling pharmacophoric point 5. 
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6.0 Chapter Summary 
Currently, the number of reports in the literature citing specific examples of GPCR 
homodimers, heterodimers and oligomers are increasing. GPCR dimer formation has been 
reported to be responsible of aspects of GPCR regulation. However, the functional relevance and 
the presence of GPCR dimers in vivo is still a subject of great debate. The 5-Hydroxytryptamine 1A 
receptor and the galanin receptor 1, both belong to the rhodopsin-like family, both are known to 
interact with the same G protein subtype: Gi/G0 albeit in different manner and, have been 
described to heterodimerize, triggering an anomalous physiological state that eventually cause 
depression. On the other hand, zinc supplementation has been widely reported to improve 
treatment against major depressive disorders. In this chapter protein-protein interactions 
between the two receptors have been studied to establish a rational explanation for the role of 
zinc in the molecular processes associated with protein-protein interactions and the relationship 
with depression. Using homology modelling, atomic models of the receptors were constructed and 
refined using molecular dynamics simulations. Moreover, using MOE GRID program the 5-
Hydroxytryptamine 1A receptor was explored with a Zinc probe to identify prospective binding 
sites. Finally a heterodimer of the two receptors was constructed using GRAMM software and 
concluded that some of the Zn binding sites rest on the dimer interface preventing its formation.  
The results show three possible dimer interfaces: the first at TM4 and TM5, the second at TM6 
and TM7, and the last at TM1 and TM2. Analysis of the zinc sites and the heterodimer interfaces 
suggests that there is a coincidence between zinc binding sites and heterodimerization interfaces. 
The results also establish a rational explanation for the role of zinc in the molecular processes 
associated with heterodimer interactions and its relationship with depression, in agreement with 
previously reported evidence for the positive effects of zinc in depression treatment, and the 
involvement of dimer formation in the same disease. 
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6.1 Introduction 
 
Protein-protein interactions are key to carry out many of the functions of proteins including 
signal transduction, transport across membranes, cell metabolism or muscle contraction. Moreover 
diverse essential molecular processes within a cell are carried out by molecular machines that are 
built from a large number of protein components, organized by their protein-protein interactions. 
Thus, many proteins do not act in isolation and often, examination of the interaction between 
proteins provides plenty of information on their biological function together [1].  
In recent years a vast number of studies have demonstrated the capacity of many GPCRs to 
dimerize into homodimers or heterodimers [2-11]. Evidence for this ability has unambiguous been 
demonstrated for the glutamate class, including the calcium-sensing receptors, metabotropic 
glutamate receptors and taste-1 receptors that are stabilized by disulfide bonds between their extra-
cellular Venus flytrap motifs [12-14], and moreover the mutations that prevent the formation of 
these disulfide bonds also disrupt receptor dimerization [15]. In fact, for some of these receptors, 
dimerization has been shown to increase the affinity to their agonist and hence, dimerization can be 
regarded as the important aspect of optimal receptor function [16-17]. Moreover, the potential for 
dimeric interactions between rhodopsin-like GPCRs have been investigated extensively [18-25].  
Such interactions can result in alterations in ligand pharmacology, the nature of the signals 
generated (Figure 1), and cellular trafficking of the complexes [9-11].  
The 5-Hydroxytryptamine 1A receptor (5-HT1A), one of the receptor subtypes for the 
neurotransmitter serotonin (5HT) and the galanin receptor 1 (GALR1), a receptor subtype for the 
neuropeptide galanin, both belonging to the rhodopsin-like family, have been described to 
heterodimerize, triggering an anomalous physiological state that essentially would cause depression 
[26-27]. The two receptors also are known to interact with the same G protein subtype, the 
heterotrimeric Gi/0. The Gi/0 inhibits the production of cAMP from ATP [28].  
The 5-HT1A receptor is the most widespread among all the serotonin receptors. In the central 
nervous system, 5-HT1A is expressed presynaptically in the brain on the soma and dendrites of 5-HT 
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neurons located in the dorsal and medial raphe nuclei. Furthermore 5-HT1A is also expressed 
postsynaptically, particularly in the hippocampus, lateral septum, cortex, and amygdala area of the 
brain [29-30].  On the other hand, GALR1 is widely expressed throughout the human body such as in 
the brain and spinal cord, as well as in peripheral sites such as the small intestine and heart [31]. 
Because of lack of reliable antibodies for either of these receptor subtypes, definitive information 
about the subcellular location of the receptor protein is still sparse [32]. 
 
 
 
Figure 6.1: The schematic of the signal type(s) produced by GPCR dimers. Monomers that forms a dimer produce different 
signals individually, a different signal when the monomers dimerize. 
 
 
In a normal body system the functions of 5-HT (Figure 2), produced in serotonergic neurons of the 
central nervous system includes the regulation of mood, appetite, and sleep. 5HT also has some 
cognitive functions, including memory and learning. Modulation of 5-HT release and activity in the 
synapses is thought to be mode of action of several classes of pharmacological antidepressant [33-
35].  In contrast, in the nervous system galanin primarily displays predominantly an inhibitory, 
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hyperpolarizing and modulatory role and as such inhibits release of neurotransmitters [36]. 
 
                            
Figure 6.2: The chemical structure of the neurotransmitter serotonin. 
 
 
Several neurochemical and molecular studies on the in vivo effects of the neuropeptide galanin 
on central 5-HT neurotransmission and on 5-HT1A receptor-mediated responses have shown that 
galanin (Figure 3) affects noradrenalin and 5HT release in locus coeruleus and dorsal raphe nucleus 
regions [37-38], the two neurotransmitter systems known to be important in mood disorders. 
Galanin is also known to downregulate 5-HT1A since intraventricular administration of galanin was 
shown to reduce the efficacy of antidepressants [39], indicating that galanin has important inhibitory 
actions on central 5HT neurotransmission and on 5-HT1A receptor-mediated activities [37-40]. 
Furthermore, segments of galanin such as the fifteen residues of the N-terminus, are especially 
potent in antagonizing 5-HT1A receptor signaling in limbic regions and this effect is blocked by 
known GALR1 antagonists [24]. In the dorsal raphe, similar antagonistic interactions have been 
reported to exist, on the contrary here 5-HT1A is involved [41]. 
These experimental results were the first indications that heterodimers of GALR1 and 5-HT1A do 
form in which GALR1 antagonize 5-HT1A recognition and signaling via a protein-protein interactions 
postulated to involve allosteric mechanisms [24, 26-27, 42]. Indeed, FRET experiments have shown 
5-HT1A to heterodimerize with galanin, furthermore studies have also found that the 5-HT1A receptor 
can be co-immuno-precipitated with a wide range of different GPCRs, including 5-HT1B, 5-HT1D, 
EDG1, EDG3, GPR26 and GABAB2 receptors [43]. Thusly, 5-HT1A has propensity to 
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homo/heterodimerize.  
 
 
 
Figure 6.3: The structure of the 30 AA human neuropeptide galanin (WTLNSAGYLLGPHAVGNHRSFSDKNGLTS). 
 
Metal ions such as zinc are known to be physiologically relevant agonist or modulators of 
GPCRs [44-50]. For example, zinc ions specifically, has been reported to be the agonist for the GPR39 
receptor which has been linked with depressive disorders. Furthermore, in diverse types of binding 
assays reported zinc was found to interact allosterically with 5-HT1A receptors. More specifically, it 
was concluded that the zinc ion is an insurmountable antagonist of 5-HT1A receptor [46].  Finally, 
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clinical studies have shown that zinc supplementation increases the efficiency of the 5-HT1A 
receptor ligands citalopram and imipramine used in depression treatment [51-52].  
Based on these well-established links between zinc and 5-HT1A, and of 5-HT1A with GalR1, it 
was hypothesized that zinc could be involved in altering the heterodimerization process between 5-
HT1A and GALR1. Accordingly experimental studies using FRET and SPR results were conducted. The 
results of that experimental study confirmed proved the hypothesis that zinc antagonize formation 
of GALR1 and 5-HT1A heterodimer [53]. This chapter aims to provide molecular explanation to the 
conclusion reached in that study. 
 
6.2 Methodology 
In order to establish a rational explanation for the role of zinc in the molecular processes 
associated with the interaction of GALR1 and 5-HT1A heterodimer and its relationship with 
depression, diverse computational methods were employed. Homology modeling was used to 
construct atomistic models of both monomers: GALR1 and 5-HT1A that were subsequently refined 
using molecular dynamics simulation. In addition, MOE GRID program was used to scan a zinc probe 
all over the surface of the 5-Hydroxytryptamine 1A receptor to identify putative zinc binding sites. 
Finally, the protein-protein molecular docking GRAMM software was used to create initial 
heterodimers for further refinement.  
 
 
6.3 Homology modeling of GARL1 and 5-HT1A  
 
A starting model of the human GARL1 and of 5-HT1A receptor was constructed by homology 
modeling using the crystal structure of kappa –opioid receptor (PDB entry code 4DJH) and 5-HT1B 
receptor (PDB entry code 4IAR) as templates, respectively [54-55]. In each case, sequences of the 
two receptors were aligned, taking into account the conserved motifs found in all GPCRs, as well as 
the location of the disulfide bridges. These motifs, together with salt bridges are important factors in 
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constraining the conformation of the extracellular and transmembrane domains of the 5-HT1A 
receptor.  
From the aligned sequences, a starting model of each of the receptors was constructed using 
the Modeller 9 version 8 (9v8) software [56]. Model validation was carried out using the molecular 
operating environment (MOE) program. In a subsequent step, the selective antagonist Rec 15/3079 
[57], was docked into the starting model using the GLIDE software [58]. Little information is known 
on the non-peptidic, selective antagonists of GALR1, therefore no molecular docking was performed 
on the GALR1 model. 
Finally, both the GALR1 model and 5-HT1A - Rec 15/3079 complex were refined using molecular 
dynamics simulation with the individual systems embedded in a lipid bilayer. Specifically, the both 
GALR1 protein and 5-HT1A - Rec 15/3079 was each embedded in separate boxes consisting in a 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipids and water molecules generated and 
equilibrated according to a previously described procedure [59]. Each of the boxes had an initial size 
of 10.3 x 8.0 x 10.2 nm3 (XYZ), organized in such a way that the bilayer plane was oriented on the XY 
plane. Before protein insertion, the box contained 256 lipids (corresponding to an area per lipid of 
0.64 nm2) and circa 17000 water molecules. The proteins were placed in the center of the box, and 
the overlapping molecules were removed. Particularly, all water molecules with oxygen atoms closer 
than 0.40 nm to a non-hydrogen atom of the protein, as well as all lipid molecules with at least one 
atom closer than 0.25 nm to a non-hydrogen atom of the protein, were removed. This resulted in a 
5-HT1A final system containing 197 lipids and approximately 16000 water molecules and GALR1 final 
system containing 189 lipids and around 15000 water molecules. In order to obtain a neutral system 
with approximately 0.2 M NaCl concentration, randomly selected water molecules were replaced 
with sodium and chloride ions. For 5-HT1A system, 103 water molecules were replaced by 41 sodium 
and 62 chloride ions. A 0.2 M NaCl concentration is fairly similar to that found in biological 
organisms, although they exhibit different intra and extracellular ion concentrations. The molecular 
dynamic sampling was carried out for 600ns using GROMACS package 4.6 [60]. 
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6.4 Heterodimerization of GARL1 and 5-HT1A   
The GARL1 and 5-HT1A docking was performed using GRAMM-X [61]. GRAMM-X docking involves 
a simplification of the structures that are considered as a rigid body representation on a 3D 
Cartesian grid. The program then performs an exhaustive sampling of the translation or rotation 
space with a softened Lennard–Jones potential to model conformational changes. The program 
employs a Fast Fourier Transform based conformational search method and docking involves 
searching for degrees of overlap between the pairs of grid.  The use of GRAMM-X to study protein-
protein interactions has been extensively published and validated over the years [62-65].  
Model dimers resulted from the docking stage were ranked order and subject to minimization 
using a soft van der Waals interaction potential. Dimers were then rescored and refined by 
incorporating flexibility into the protein sidechains as well as the backbones. Top scoring models 
obtained showed three different interaction interfaces: TM4 -TM5, TM6 -TM7 and TM1-TM2. Finally, 
the heterodimer complex with the highest score for each of the three groups was selected for 
refinement. For this purpose a 600 ns molecular dynamics simulation of the heterodimer embedded 
in a lipid bilayer was performed on the three dimeric systems, following the procedure protocol 
explained in section 6.3. 
 
6.5 Results and discussion 
Time evolution of the root mean square deviation (rmsd) of the alpha carbons of the both 
GALR1 and 5-HT1A as well as those of their TMs bundle subset during the refinement process are 
shown in Figure 4.  In accordance to the discussion in the previous sections only the last 100ns 
segment of the molecular dynamics trajectory was used to generate an average structure that was 
subsequently minimized in a two-step process using the steepest descent method with a distance 
dependent dielectric constant of 2. The average protein structure generated for each system was 
annotated as the refined model of GARL and of 5-HT1A.   
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(a) 
Figure 6.4: The rmsd of the GALR1 (a) and 5-HT1A (b) during the refinement process. In black is the rmsd of the alpha 
carbons of the protein and in red the rmsd of the alpha carbons of the helix bundle subset.  
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Since experimental results indicate that heterodimerization is prevented by zinc and based on 
previous results, zinc can directly interact with the 5-HT1A receptor [51-52] it is likely to consider that 
binding sites coincide with the heterodimerization interface [53]. Accordingly, we investigated 
prospective sites for zinc binding. For this purpose, a zinc probe was rolled over the surface of the 
refined model of 5-HT1A using the GRID as implemented by MOE program [66]. This permits to 
identify energetically favorable sites for zinc ion binding. 
 
 
6.6 Determination of Zinc sites  
Figure 5 shows putative sites for zinc binding on the 5-HT1A receptor as green spheres that are 
also labelled. As can be seen, most of the putative binding sites are located on the extracellular and 
intracellular loops, although some sites are located on the transmembrane regions including TM1; 
on the interface TM4 -TM5; on the interface TM6-TM7 and TM7-H8. In addition, there is another 
putative binding site on the inside of TM3. This site (Figure 6i) is located beneath the orthosteric 
binding site of the 5-HT1A receptor.  
Experimental results aimed at characterizing receptor heterodimerization using SPR 
spectroscopy reported that a relative low level of receptor binding when 5-HT1A receptor was 
exposed to ZnCl2 and injected to GALR1 immobilized on SPR sensorchip, compared to the control 
sample that was not exposed to Zncl2 and furthermore, a complete receptor removal was achieved 
upon washing with buffer. Together these results suggest a transient protein-protein interaction 
much less stable than the one observed in the absence of zinc. Thus, presence of zinc ions impairs 
heterodimerization. At a structural level, this also suggests that zinc binding sites coincide with key 
protein-protein interactions sites [53].  
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Figure 6.5: Putative zinc binding sites in the 5-HT1A. 
 
It is known that amino acids such as glutamic acid, aspartic acid, histidine etc. are excellent 
coordinating ligands for metals such zinc, manganese, nickel etc. This characteristic makes them the 
prototypical metal chelators that form stable dative covalent bonds [67-68]. The capability of the 5-
HT1A receptor to bind zinc can explain the transiency of the formed dimers and the complete 
removal. In other words, the existence of multiple zinc binding sites in different receptor interfaces 
suggests that the heterodimer between 5-HT1A and GALR1 will be unable to be formed in the 
presence of zinc. Furthermore, in case that few of the sites are populated with zinc, the heterodimer 
will be formed transiently or less stable either because of the location of the site or nature of the 
binding site free to interact with GALR1. Figure 6 shows each of the 12 putative zinc binding sites in 
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detail. As it can be seen, most of residues found in these sites are aspartic acids, serine, threonine 
etc.  
 
(a) 
 
 
(b)                                                                                                                                (C) 
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 (d) 
 
 
 
 
 
(e)                                                                                                                      (f) 
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(g)                                                                                                                      (h) 
 
 
(i)                                                                                                                      (j) 
 
 
Figure 6.6: Putative zinc binding sites in the 5-HT1A. (a) Site 1 on the receptor N-terminus and site 2 on the N terminal of 
TM1, (b) site 3 and 4 both on TM1, (c) site 5 on ICL1, (d) site 6 on ECL1 and ECL2, (e) site 7 on ICL2,  (f) site 8 in the 
interface of TM3 and TM5, (g) site 9 on the ECL2, ECL3 and the N-terminal of TM6 ,(h) site 10 in the interface of TM6 and 
TM7 (i) site 11 in the TM3, and  (j) site 12 on the N-terminal of helix 8. 
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6.7 Oligomerization interfaces 
Identification of the helices involved in the ligand-ligand interaction is a very intriguing problem. 
In the case of homodimers, information provided by high-resolution crystallographic structures 
points to the existence of different dimer interfaces. However, some of the observed interfaces may 
reflect artifacts of crystal packing and the conditions employed for crystallization [69]. Moreover, 
they may also depend on the ligand-specific conformational states of receptors may adopt. With 
these considerations in mind, analysis of the available crystallographic structures reveals that TM5 
and TM6 residues constitute the main interfaces for chemokine CXCR4 [70], and μ-opioid receptors 
[71]. Apart from this interface, crystallized chemokine CXCR4 dimers also show contacts at the 
intracellular ends of TM3 and TM4 and μ-opioid dimers also show a second, less prominent 
symmetric interface, involving TM1, TM2, and H8. However, the latter interface is also found in 
crystals of κ-opioid receptor dimers [54], rhodopsin, [72-73], opsin (ligand-free rhodopsin), [74], and 
β1-adrenoceptor [75]. Moreover, an additional interface involving TM4 and TM5 can also be found 
in the β1-adrenergic and smoothened receptors [76]. 
  The use of interfering synthetic peptides and cysteine cross-linking techniques also has 
provided additional information. Thus, the use of interfering synthetic peptides pointed the 
involvement of TM6 in the formation of β2-adrenoceptor homodimers. Moreover, the involvement 
of TM5 in the homodimerization of dopamine D2, muscarinic M3, and serotonin 5-HT2C receptors has 
been suggested from cysteine cross-linking experiments [77-79]. Similar experiments support the 
two crystallographic interfaces of the β1-adrenoceptor (TM1–TM2–H8 and TM4–TM5) as 
physiologically relevant [75], and the involvement of a TM1–TM2–H8 interface in rhodopsin 
quaternary organization [80].  
The case of the heterodimers is even more intriguing. Experimental results suggest that spite 
evidence of hetero-dimers in class C of GPCRs, there is no evidence of the existence of such a 
quaternary structure in class A GPCRs. Instead, it is thought that hetero-oligomers are formed from 
two different homodimers [69]. Reported computer modelling studies designed to investigate 
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potential GPCR dimer interfaces have concluded that there is no energy barrier to the formation of a 
TM1-H8 or a TM4-TM5 interface, but predict that a symmetric TM1-H8 interface is favored 
energetically than a TM4-TM5 interface [81-83]. Similar conclusions were reached in saturation FRET 
studies of the β2 adrenergic receptors [82], and from cysteine cross-linking and FRAP studies of 
dopamine D2 receptors [22, 77], suggesting the TM1-H8 interface to be more stable than TM4-TM5 
interface, while the later potentially responsible for transient association of dimers into tetramers. 
On the contrary, similar dimerization studies on 5-HT receptors subtypes have concluded that TM4-
TM5 is the preferred dimer interface. Through FRET and computer modelling, specific residues 
Trp175, Tyr198, Arg151, and Arg152 in TM4 were identified and conformed by mutagenesis as being 
essential for maintaining the homodimer structure [83].  
An extensive computational study on the homo- and hetero-dimerization of opioid receptors 
it was found that only selected interfaces in the diverse homo- and heterodimeric systems were 
formed. Specifically, they include TM1–TM2–H8/TM1–TM2–H8; TM1–TM2/ TM4-TM5 (also TM4-
TM5/ TM1–TM2 for hetero-dimers); and TM1–TM2/TM5-TM6 (also TM5-TM6 / TM1–TM2 for 
hetero-dimers). Other interfaces scarcely were found along the simulations [84]. The results suggest 
that the dimer interface from simulations that is closest to one inferred from crystal structures is the 
TM1–TM2–H8/TM1–TM2–H8 interface. 
Although it is not complete clear that class A GPCRs do not form heterodimers, computer 
simulations of such a system provide information on the favorite interfaces that could be found 
either in heterodimers or hetero-oligomers. As mentioned in the methods section in the present 
work we have carried out three different simulations of the heterodimer GARL1 and 5-HT1A in three 
different possible arrangements: the TM4-TM5/TM4-TM5; TM6-TM7/ TM6-TM7 and TM1-TM2-H8/ 
TM1-TM2-H8 interface. 
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6.7.1. Dimer interface 1:TM4-TM5  
 
The TM4-TM5 dimer interface (Figure 7), has been reported to be the preferred interface for 
the homodimers of 5-HT1A and 5-HT receptors subtypes [85], however dimerization studies on other 
rhodopsin class GPCR [22, 81-83], interactions at this TM regions is deemed weak or unstable. 
Incorporating the experimental studies supporting this work [53], and the putative zinc binding site 
disclosed in the previous subchapter, it is very likely that at least for the heterodimer of GARL1 and 
of 5-HT1A , the interactions are transient. Consider the putative zinc binding sites, at TM4-TM5 only 
site 8, Figure 6(f) and site 11 in Figure 6 (i) will be obscured for interactions with zinc. However the 
other 10 putative sites will bind with zinc and impair heterodimerization. 
 
Figure 6.7: (a) The aerial representation of dimer 1 (TM4-TM5 interface), side view (b) and (c) molecular surface. GALR1 is 
shown in green and 5-HT1A in blue. 
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6.7.2. Dimer interface 2: TM6-TM7  
 
Unlike TM4-TM5 dimer interface, TM6-TM7 (Figure 8) offer compounding credence to 
various reported dimerization interfaces, specifically active conformation of 5-HT1B as it pertaining 
to the angle of rotation of TM6 [55, 85], dimerization studies on other rhodopsin class GPCRs [81-
83], which indicated the involvement of TM1-H8. While TM1 is not directly involved here, H8 is 
involved and the fact that the interfacing TM6 and TM7 here are parallel organized exposed the TM1 
to interfacing region and favoring it. Furthermore, the putative zinc binding sites obscured by 
dimerization at this interface includes site 2, site 3, site 4, site 9, site 10, site 12 and part of site 1. 
Figure 8(a) shows that N-terminal of TM1 of 5-HT1A is oriented towards the interfacing TMs. 
Figure 6.8: (a) The aerial representation of dimer 1 (TM6-TM7 interface), side view (b) and (c) molecular surface. GALR1 is 
shown in green and 5-HT1A in blue. 
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Thusly, in the absence of zinc, the protein-protein interaction at this interface maybe be 
more stable than at TM4-TM5 interface. This is more in accord with the suggested dimer intefaces of 
other rhodopsin class GPCRs and not with suggested homodimer interfaces of 5-HT1A and other 5-HT 
receptors subtypes. 
 
 
6.7.3. Dimer interface 3: TM1-TM2  
 
TM2 in most cases has not been considered to be a possible dimer interface, however TM1 
has been strongly implicated [81-82]. With regard to putative zinc binding sites on the 5-HT1A 
receptor, dimerization at TM1-TM2 (Figure 9) interface will obscure site 2, site 3 and site 4. 
Figure 6.9: (a) The aerial representation of dimer 1 (TM1-TM2 interface), side view (b) and (c) molecular surface. GALR1 is 
shown in green and 5-HT1A in blue.  The TM3 of 5-HT1A receptor is also seen involved in the dimerization due to the 
slanted positioning of the receptor. 
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 Furthermore, dimerization at TM1-TM2 interface present a peculiar arrangement of the 
TMs. Specifically TM3 as can be seen in figure 9(a), is skewed at an angle that allows the TM3 of 5-
HT1A receptor to be exposed to towards the interfacing region but the corresponding TM3 in GALR1 
is not involved. In most of contact dimers, there is parallel arrangement of the interfaces, such that 
as an example TM4 of monomer A, will interface with TM5 of monomer B and accordingly TM5 of 
monomer A will interface with TM4 of monomer B [22, 81-83, 85].  
 
 
6.8 The implication of GARL1 and 5-HT1A   heterodimer formation  
 
As it can be deduced from both the computer modeling results presented here, and the 
published FRET and SPR sensorchip experimental studies, zinc impairs the heterodimerization of 
GARL1 and 5-HT1A. Considering the concentration of zinc used in the FRET experiments is on par with 
the reported physiological concentration of zinc, a disease model was disclosed (Figure 10). Where 
by in a healthy cell environment where by zinc is present at a normal physiological concentration of 
50μM, there is no heterodimer formation. However in a diseased cell environment such as in 
depressed patients where there is a zinc deficiency, heterodimers will be formed predominantly, 
hence the disease phenotype [53]. 
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Figure 6.10: Scheme of zinc inhibition of heterodimer formation. Whereby under physiological zinc deficient conditions, the 
heterodimer would be the predominant form, causing a disease phenotype, while in optimal zinc condition, heterodimer 
formation is disrupted [53]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 221 
Dimerization of Serotonin receptor 1A and Galanin Receptor 1 
6.9 Conclusions to chapter 6  
 
Considering the available extensive literature on both the existence and relevance of GPCR 
dimers as the therapeutical targets, it is only natural the relevance of GPCR heterodimers are 
explored.  From the literature, the 5-HT1A receptor is known to be involved with major depressive 
disorders, moreover GARL1 receptor is known to be involved in major depressive through its 
modulation of the 5-HT1A receptor function via heterodimerization. Thusly atomistic heterodimers 
were created and disclosed in this chapter. The heterodimers interfaces are TM4-TM5, TM6- TM7, 
and TM1- TM2.  
Furthermore, zinc supplementation is known to improve treatment of major depressive disorder 
specifically by interacting with 5-HT1A receptor. Hence the 5-HT1A receptor was probed for zinc prior 
to heterodimerization and 12 sites were identified. Analysis of the zinc sites and the heterodimer 
interfaces suggests that there is a coincidence between zinc binding sites and heterodimerization 
interfaces.  Further information on the stability and propensity of the heterodimer interfaces was 
gauged. While the number of zinc sites blocked by heterodimer formation is not enough to predict 
the stability or transiency of the heterodimer formation, it provides a starting point for experimental 
studies of mutation at these putative zinc sites. 
The results presented here also establish a rational explanation for the role of zinc in the 
molecular processes associated with heterodimer interactions and its relationship with depression, 
in agreement with previously reported evidence for the positive effects of zinc in depression 
treatment, and the involvement of the heterodimer in the same disease. 
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1. The results of this work support that molecular dynamics in an adequate methodology to 
refine the structures of GPCRs constructed by homology modeling. Specifically, the rmsd of 
the transmembrane region of constructed models compared to the target receptor improves 
with the refinement process. Moreover, higher accuracy is obtained when the template 
used is closer to the target in the phylogenetic tree in the sampling times used in this work. 
  
2. The use of a ligand in the molecular dynamics refinement process makes convergence time 
to be shorter and yields more accurate models for the transmembrane region than in the 
absence of a ligand.  
 
3. The model constructed in this work of the bradykinin B1 receptor together with the docking 
studies of several selective antagonist described in the literature permitted the definition of 
a pharmacophore. This consists of five points that defined on ligand features correspond to 
a proton donor (point 1); a proton acceptor/donor (point 2); a hydrophobic ring (point 3); a 
proton acceptor/ donor (point 4) and proton donor/ acceptor (point 5). 
 
4. The pharmacophore was used to guide a virtual screening process. The results permitted to 
identify a set of compounds some of which were purchased and in vitro tested for their 
capability to antagonize the B1R. These results give support to the validity of the bradykinin 
B1 receptor pharmacophoric hypothesis described in this work. 
 
5. The model constructed in this work of the bradykinin B2 receptor together with the docking 
studies of several selective antagonist described in the literature permitted the definition of 
a pharmacophore. This consists of five points that defined on ligand features correspond to 
a proton donor (point 1); a proton acceptor/donor (point 2); a hydrophobic ring (point 3); a 
proton acceptor/ donor (point 4) and hydrophobic/aromatic moiety (point 5). 
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6. The pharmacophore was used to guide a virtual screening process. The results permitted to 
identify a set of compounds some of which were purchased and in vitro tested for their 
capability to antagonize the B2R. These results give support to the validity of the bradykinin 
B2 receptor pharmacophoric hypothesis described in this work. 
 
7. Analysis of the pharmacophores for B1R and B2R permitted to get insight on the features 
responsible for receptor selectivity. Specifically, the key difference lies on pharmacophore 
point 5 that exhibits different nature on both receptors.  
 
8. The model constructed in this work of the serotonin 5-HT1A receptor permitted the 
identification of 12 prospective sites for zinc binding. Most of the putative binding sites are 
located on the extracellular and intracellular loops, although some sites are located on the 
transmembrane regions including TM1; on the interface TM4 -TM5; on the interface TM6-
TM7 and TM7-H8. 
 
9. The models constructed in this work of the serotonin 5-HT1A and GAL1 receptors were used 
to build heterodimers with diverse possible interfaces. Analysis of the models together with 
the results of zinc binding to the serotonin 5-HT1A receptor permitted to identify the 
interface TM6-TM7 as most likely for heterodimerization. 
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8.1 Sequence Alignments 
 
8.1.1 Sequence alignments 
 
 
Figure 8.1: Sequence alignment of the target selected templates (muscarinic M2, Histamine H1 and Rhodopsin receptor), 
and the target muscarinic M3 receptor. 
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Figure 8.2: Sequence alignment between rat and human CHRM3. 
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Figure 8.3: Sequence alignment between the template, crystallographic structure of 5HT1B and the target 5HT1A showing an 
overall sequence homology of 47%. The blue blocks represent the TM residues              
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Figure 8.4: Sequence alignment between the template, crystallographic structure of κ-opioid receptor and the target GALR1 
showing an overall sequence homology of 28%. The green blocks represent the TM residues. 
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8.2 Radio-ligand binding assays 
 
8.2.1 BKRB1 radio-ligand Binding assays 
 
B1R antagonism assays were carried out following a protocol described elsewhere [1]. 
Specifically, compounds were tested on human recombinant B1R expressed in CHO cells. Saturation 
isotherms were obtained with [3H] des-Arg10- (0.35 nM) incubated for 60 minutes at room 
temperature. Nonspecific binding was evaluated by adding bradykinin at 1 mM. Antagonism was 
measured by the capacity of a specific compound to displace the radio-ligand using the scintillation 
counting method. Scintillation counting refers to the the measurement of activity of a sample of 
radioactive material which uses the technique of mixing the active material with a liquid scintillator, 
and counting the resultant photon emissions. 
 
8.2.2 BKRB2 radio-ligand Binding assays 
 
B2R antagonism assays were carried out following a protocol described elsewhere [2]. Specifically, 
compounds were tested on human recombinant B2R expressed in CHO cells. Saturation isotherms were 
obtained with [3H]-bradykinin (0.30 nM) incubated for 60 minutes at room temperature. Nonspecific 
binding was evaluated by adding bradykinin at 1 mM. Antagonism was measured by the capacity of a 
specific compound to displace the radio-ligand using the scintillation counting method. 
  
1. Jones, C., Phillips, E., Davis, C., Arbuckle, J., Yaqoob, M., Burgess, G. M., ... & McIntyre, P. (1999). 
Molecular characterisation of cloned bradykinin B 1 receptors from rat and human. European 
journal of pharmacology, 374(3), 423-433. 
2. Pruneau D, Luccarini J-M, Fouchet C, Defrene E, Franck R-M, Loillier B, Duclos H, Robert C, 
Cremers B, Belichard P, Paquet J-L. (1998) LF 16.0335, a novel potent and selective nonpeptide 
antagonist of the human bradykinin B2 receptor. British J Pharmacol 125: 365-372. 
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8.3 Analysis of the MD trajectories 
 
8.3.1 Dihedral angles 
Dihedral angle for the ECL regions of M3 models along their trajectories. The residues are identified 
according to the M3 muscarinic crystal structure, thus below pictures depict the dihedral angles of the 
residue in the models that makes up the ECL region in the M3 crystal structure. 
 ECL1 residue # 131-136 (ECL1-1: N-R-W-A, ECL1-2: R-W-A-L and ECL1-3: W-A-L-G) 
 ECL2 residue # 214-222 (ECL2-1 : T-V- P-P, ECL2-2: V- P-P-G, ECL2-3: P-P-G-E, ECL2-4: P-G-E-
C, ECL2-5: G-E-C-F, and ECL2-6: E-C-F-I) 
  ECL3 residue # 515-520 (ECL3-1: F-C-D-S, ECL3-2: C-D-S-C and ECL3-3: D-S-C-I) 
 
(a) 
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(b)   
 
(c) 
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(d)  
(e) 
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(f) 
 (g) 
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(h)  
 
(i) 
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(j)  
 
 (k) 
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(l) 
 (m) 
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(n) 
(o) 
 
Figure 8.5: (a-o), the evolution of the extracellular dihedral angle for each of the receptor model during the refinement 
process. 
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8.3.2 Root mean square fluctuations 
 
Figure 8.6: The rmsf of the B1R average structure (at 450-500ns) 
   Figure 8.7: The rmsf of the B2R average structure (at 450-500ns) 
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   Figure 8.8: The rmsf of the Dimer interfacing at TM1-TM2 average structure (at 450-500ns)                                  
Figure 8.8: The rmsf of the Dimer interfacing at TM6-TM7 average structure (at 450-500ns)                                                    
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        Figure 8.9: The rmsf of the Dimer interfacing at TM4-TM5 average structure (at 450-500ns)      
 
                   
 
